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Viral Diversity by Deep Sequencing: Approaches to Analyzing Effects of
Anti-HIV Treatments
Abstract
HIV is a deadly virus responsible for the AIDS pandemic, which has claimed countless lives since its origins in
the early 1980s. A cure for HIV is still elusive - HIV can exist as a diverse and dynamic population that adapts
quickly to immune and drug pressures, making elimination of infection difficult. Advances in antiretroviral
(ARV) therapy have resulted in effective control of HIV for some but not all patients. This dissertation reports
case studies of the response of viral populations to selection pressures exerted by emerging anti-HIV
therapies. Deep sequencing technology was used to probe viral swarms at high-resolution, which helped make
clinically relevant conclusions. Further, novel computational approaches were implemented to control
procedural noise and carefully interpret signal. In one study, we examine HIV integrase inhibitors (INIs),
which are among the latest ARV drugs. INIs act at a pre-integration level by aborting viral integration, which
would normally lead to lasting infection. Raltegravir (RAL) is the only FDA-approved INI to date.
Investigating drug resistance is crucial to informing future course of ARV therapy. We describe evolving HIV
swarms in patients exhibiting a switch in RAL-resistance profiles. To understand implications of RAL
administration, we analyzed the pre-therapy or treatment-naÃ¯ve context for the viral populations in-depth.
Our findings suggest that predominant mutations arise only in presence of RAL - in its absence, they do not
constitute fit polymorphisms. For all their effectiveness, drugs have not eradicated HIV. A recent clinical case,
however, involving transfer of HIV-resistant cells to an infected patient, resulted for the first time in possible
cure. This emphasized the importance of gene-modification and cell-based therapies to treat HIV. One such
strategy showing promise uses an antisense to target HIV. The approach has been safe although clinical
efficacy has not been fully determined. In support of one such study, we deep-sequenced viral swarms in the
presence of antisense-modified cells. Encouragingly, we observed minority strains harboring evidence of
antisense pressure in vivo, demonstrating the potential of alternative therapy. Finally, this dissertation
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ABSTRACT	  	  VIRAL	  DIVERSITY	  BY	  DEEP	  SEQUENCING:	  APPROACHES	  TO	  ANALYZING	  EFFECTS	  OF	  ANTI-­‐HIV	  TREATMENTS	  	   Rithun	  Mukherjee	  Frederic	  D	  Bushman	  	  HIV	  is	  a	  deadly	  virus	  responsible	  for	  the	  AIDS	  pandemic,	  which	  has	  claimed	  countless	  lives	  since	  its	  origins	  in	  the	  early	  1980s.	  A	  cure	  for	  HIV	  is	  still	  elusive	  –	  HIV	  can	  exist	  as	  a	  diverse	  and	  dynamic	  population	  that	  adapts	  quickly	  to	  immune	  and	  drug	  pressures,	  making	  elimination	  of	  infection	  difficult.	  Advances	  in	  antiretroviral	  (ARV)	  therapy	  have	  resulted	  in	  effective	  control	  of	  HIV	  for	  some	  but	  not	  all	  patients.	  	  This	  dissertation	  reports	  case	  studies	  of	  the	  response	  of	  viral	  populations	  to	  selection	  pressures	  exerted	  by	  emerging	  anti-­‐HIV	  therapies.	  Deep	  sequencing	  technology	  was	  used	  to	  probe	  viral	  swarms	  at	  high-­‐resolution,	  which	  helped	  make	  clinically	  relevant	  conclusions.	  Further,	  novel	  computational	  approaches	  were	  implemented	  to	  control	  procedural	  noise	  and	  carefully	  interpret	  signal.	  In	  one	  study,	  we	  examine	  HIV	  integrase	  inhibitors	  (INIs),	  which	  are	  among	  the	  latest	  ARV	  drugs.	  INIs	  act	  at	  a	  pre-­‐integration	  level	  by	  aborting	  viral	  integration,	  which	  would	  normally	  lead	  to	  lasting	  infection.	  Raltegravir	  (RAL)	  is	  the	  only	  FDA-­‐approved	  INI	  to	  date.	  Investigating	  drug	  resistance	  is	  crucial	  to	  informing	  future	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course	  of	  ARV	  therapy.	  We	  describe	  evolving	  HIV	  swarms	  in	  patients	  exhibiting	  a	  switch	  in	  RAL-­‐resistance	  profiles.	  To	  understand	  implications	  of	  RAL	  administration,	  we	  analyzed	  the	  pre-­‐therapy	  or	  treatment-­‐naïve	  context	  for	  the	  viral	  populations	  in-­‐depth.	  Our	  findings	  suggest	  that	  predominant	  mutations	  arise	  only	  in	  presence	  of	  RAL	  –	  in	  its	  absence,	  they	  do	  not	  constitute	  fit	  polymorphisms.	  For	  all	  their	  effectiveness,	  drugs	  have	  not	  eradicated	  HIV.	  A	  recent	  clinical	  case,	  however,	  involving	  transfer	  of	  HIV-­‐resistant	  cells	  to	  an	  infected	  patient,	  resulted	  for	  the	  first	  time	  in	  possible	  cure.	  This	  emphasized	  the	  importance	  of	  gene-­‐modification	  and	  cell-­‐based	  therapies	  to	  treat	  HIV.	  One	  such	  strategy	  showing	  promise	  uses	  an	  antisense	  to	  target	  HIV.	  The	  approach	  has	  been	  safe	  although	  clinical	  efficacy	  has	  not	  been	  fully	  determined.	  	  In	  support	  of	  one	  such	  study,	  we	  deep-­‐sequenced	  viral	  swarms	  in	  the	  presence	  of	  antisense-­‐modified	  cells.	  Encouragingly,	  we	  observed	  minority	  strains	  harboring	  evidence	  of	  antisense	  pressure	  in	  vivo,	  demonstrating	  the	  potential	  of	  alternative	  therapy.	  Finally,	  this	  dissertation	  underscores	  the	  significance	  of	  rare	  signatures	  in	  HIV	  populations,	  and	  outlines	  methods	  to	  investigate	  them.	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Chapter	  1 INTRODUCTION	  
	  
Background	  and	  motivation	  	  A	  goal	  of	  modern	  medicine	  is	  to	  understand	  and	  control	  infectious	  agents.	  The	  host	  immune	  system	  protects	  by	  targeting	  structures	  or	  sequences	  of	  the	  pathogen	  that	  are	  sufficiently	  distinct	  from	  those	  of	  the	  host	  for	  specific	  recognition.	  Pathogens	  that	  are	  highly	  mutable	  have	  the	  ability	  to	  withstand	  a	  variety	  of	  pressures	  –	  they	  are	  difficult	  targets	  for	  the	  host	  as	  they	  can	  readily	  escape	  the	  immune	  system.	  	  Examples	  include	  RNA	  viruses	  [1]	  and	  single	  stranded	  DNA	  viruses	  [2,	  3],	  which	  quickly	  produce	  a	  wide	  spectrum	  of	  mutants	  after	  infection	  by	  virtue	  of	  an	  error-­‐prone	  replication	  system.	  	  	  HIV	  is	  among	  the	  most	  deadly	  of	  these	  viruses.	  It	  has	  already	  claimed	  millions	  of	  lives	  in	  a	  pandemic	  that	  is	  ongoing.	  The	  virus	  is	  fascinating	  in	  that	  it	  infects	  some	  of	  the	  very	  cells	  in	  the	  body	  that	  protect	  against	  infections.	  In	  fact	  HIV	  infects	  more	  efficiently	  when	  its	  target	  cells	  are	  in	  an	  activated	  state,	  which	  ironically	  is	  their	  state	  when	  there	  is	  an	  infection	  to	  be	  cleared.	  After	  replication	  in	  a	  host,	  HIV	  is	  not	  a	  single	  viral	  strain	  but	  a	  distribution	  of	  strains,	  each	  different	  from	  the	  other,	  although	  related	  in	  sequence.	  As	  discussed	  below,	  such	  entities	  have	  unique	  properties	  and	  have	  been	  termed	  quasi-­species.	  	  Given	  the	  challenges	  posed	  by	  HIV,	  developing	  therapeutic	  strategies	  has	  been	  a	  huge	  challenge	  to	  biomedical	  research.	  HIV	  is	  the	  topic	  of	  the	  studies	  described	  in	  the	  following	  chapters.	  These	  investigations	  were	  performed	  in	  clinical	  settings,	  in	  which	  a	  particular	  therapeutic	  approach	  was	  applied	  to	  either	  human	  subjects	  or	  animal	  models.	  Outcomes	  and	  aspects	  of	  efficacy	  of	  the	  treatment	  strategies	  are	  discussed.	  The	  larger	  goal	  in	  each	  case,	  however,	  was	  highlighting	  clinically	  relevant	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observations	  on	  the	  nature	  of	  the	  HIV	  quasi-­‐species.	  In	  addition	  to	  assessing	  treatment	  efficacy,	  this	  is	  relevant	  in	  deciding	  the	  future	  course	  of	  therapy.	  	  In	  this	  dissertation,	  I	  outline	  ways	  in	  which	  we	  have	  explored	  aspects	  of	  HIV	  quasi-­‐species	  under	  selective	  pressure	  from	  therapy.	  In	  each	  case,	  a	  high-­‐resolution	  picture	  of	  circulating	  viral	  variants	  was	  obtained	  by	  high-­‐throughput	  deep	  sequencing	  technology.	  Further,	  novel	  algorithms	  were	  implemented	  to	  reduce	  procedural	  error	  whereas	  bioinformatics	  and	  statistical	  techniques	  were	  devised	  to	  robustly	  identify	  meaningful	  signals.	  Beyond	  a	  collection	  of	  methods,	  I	  hope	  the	  reader	  also	  gains	  an	  appreciation	  of	  the	  nature	  of	  the	  data	  in	  studies	  like	  these	  and	  why	  specific	  computational	  approaches	  are	  necessary.	  	  	  Multiple	  therapeutic	  strategies	  are	  available	  to	  treat	  HIV	  infection.	  Given	  the	  difficulties	  of	  controlling	  a	  complex	  quasi-­‐species,	  absolute	  eradication	  of	  virus	  is	  still	  mostly	  hypothetical	  –	  progress	  is	  often	  assessed	  by	  identifying	  treatment-­‐induced	  signatures	  in	  "pockets"	  of	  the	  quasi-­‐species	  structure.	  I	  hope	  that	  this	  dissertation	  illustrates	  approaches	  that	  can	  be	  adapted	  to	  such	  studies.	  In	  the	  following	  sections	  of	  this	  introduction,	  I	  discuss	  relevant	  concepts	  and	  provide	  background	  on	  the	  clinical	  context	  of	  the	  studies	  that	  follow	  in	  chapters	  2-­‐4.	  	  In	  parallel,	  I	  aim	  to	  inform	  the	  reader	  about	  advances	  made	  in	  sequencing	  that	  makes	  such	  studies	  feasible.	  	  Finally,	  I	  introduce	  some	  of	  the	  bioinformatics	  and	  algorithms	  used	  in	  analyzing	  the	  sequencing	  data.	  	  
The	  quasi-­species	  	  
Mutability	  	  Replication	  of	  the	  genetic	  material	  of	  all	  species	  results	  in	  error	  at	  some	  rate.	  Representative	  mutation	  rates	  per	  replication	  cycle	  per	  genome	  or	  µg	  are	  shown	  in	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Table	  1.1.	  It	  can	  be	  seen	  that	  there	  is	  a	  difference	  between	  RNA	  viruses	  and	  species	  with	  DNA	  genomes.	  For	  the	  latter,	  µg	  is	  around	  0.004	  irrespective	  of	  genome	  size.	  Higher	  eukaryotes	  such	  as	  humans	  have	  a	  bulk	  of	  DNA	  that	  is	  non-­‐functional	  –	  in	  such	  cases	  µg	  is	  estimated	  for	  the	  effective	  genome,	  which	  is	  the	  part	  where	  any	  change	  is	  likely	  to	  have	  functional	  consequences	  and	  where	  mutations	  are	  largely	  expected	  to	  be	  deleterious.	  DNA	  is	  more	  stable	  than	  RNA,	  and	  the	  replication	  machinery	  has	  robust	  proofreading	  and	  repair	  activities	  [4].	  	  	  
GENOME SIZE (in bases) µg 
RNA   
Poliovirus 7.4E+03 0.8000 
Influenza A 1.4E+04 1.0000 
MLV 8.0E+03 0.0600 
RSV 9.3E+03 0.4300 
HIV-1 9.7E+03 0.2200 
DNA   
Bacteriophage 
M13 6.4E+03 0.0046 
Bacteriophage λ 4.9E+04 0.0038 
Bacteriophage T4 1.7E+05 0.0040 
E. coli 4.6E+06 0.0025 
S. cerevisiae 1.2E+07 0.0027 
C. elegans 8.0E+07 0.0040 
H. sapiens 3.2E+09 0.0040 
   
	  
Table	  1.1	  Mutation	  rates	  for	  the	  replication	  machinery	  of	  representative	  genomes.	  Retroviruses	  are	  indicated	  in	  green	  and	  eukaryotes	  in	  red.	  Number	  of	  errors	  per	  replication	  cycle	  per	  genome	  (µg)	  is	  contrasted	  with	  genome	  size.	  For	  the	  eukaryotes,	  µg	  is	  calculated	  for	  the	  functional	  part	  of	  the	  genome	  where	  errors	  are	  likely	  to	  produce	  effects	  [92].	  	  Viruses	  with	  RNA	  genomes,	  in	  contrast,	  have	  higher	  values	  for	  µg	  (Table	  1.1).	  For	  their	  replication,	  they	  depend	  on	  RNA	  dependent	  polymerases.	  These	  include	  RNA	  dependent	  RNA	  polymerases	  (RdRPs)	  as	  in	  poliovirus	  and	  influenza	  virus.	  	  Retroviruses	  use	  reverse	  transcriptases	  (RTs).	  Both	  classes	  of	  enzymes	  are	  about	  a	  million	  times	  more	  error-­‐prone	  than	  the	  DNA	  polymerases	  that	  replicate	  DNA	  genomes	  [4].	  This	  poses	  a	  risk	  that	  the	  genomic	  information	  encoded	  as	  RNA	  could	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be	  lost	  in	  a	  few	  generations.	  This	  happens	  at	  a	  theoretical	  limit	  called	  the	  error	  
threshold	  [5]	  beyond	  which	  mutations	  accumulate	  at	  a	  rate	  faster	  than	  they	  can	  be	  selected	  against.	  However	  RNA	  being	  more	  labile	  than	  DNA,	  the	  size	  of	  genomic	  RNA	  is	  limited	  (Table	  1.1).	  This	  limits	  the	  number	  of	  mutations	  on	  any	  individual	  genome	  such	  that	  µg	  values	  are	  still	  high	  enough	  to	  produce	  diversity	  quickly	  but	  low	  enough	  to	  avoid	  surpassing	  the	  error	  threshold.	  	  
Complex	  distribution	  of	  mutants	  	  Many	  viruses	  with	  RNA	  genomes	  have	  large	  burst	  sizes	  and	  short	  generation	  times.	  The	  rapid	  exponential	  growth	  and	  high	  µg	  combine	  to	  continuously	  generate	  mutants	  at	  a	  brisk	  pace.	  This	  results	  in	  a	  large	  number	  of	  non-­‐functional	  genomes.	  The	  huge	  number	  of	  progeny	  produced,	  however,	  ensures	  that	  there	  is	  still	  a	  large	  arsenal	  of	  diverse	  functional	  forms	  in	  the	  viral	  population.	  Manfred	  Eigen	  in	  the	  1980s	  proposed	  a	  theoretical	  framework	  to	  describe	  such	  dynamic	  populations	  featuring	  a	  spectrum	  of	  variants	  –	  the	  concept	  of	  quasi-­species	  [6].	  	  The	  term	  quasi-­‐species	  defines	  distributions	  of	  variants	  of	  a	  replicating	  system	  such	  that	  the	  density	  of	  variants	  is	  proportional	  to	  their	  fitness	  [7,	  8].	  The	  fitness	  coefficients	  are	  in	  turn	  dependent	  on	  selection	  differentials	  characteristic	  of	  the	  environment.	  For	  a	  replicating	  system	  in	  equilibrium	  with	  its	  environment,	  the	  quasi-­‐species,	  described	  in	  terms	  of	  variants	  and	  their	  densities,	  is	  a	  stable	  distribution.	  Existence	  as	  quasi-­‐species	  helps	  RNA	  viruses	  survive	  the	  often	  rapidly	  changing	  pressures	  exerted	  by	  the	  host	  environment.	  The	  unit	  of	  replication	  and	  evolution	  is	  no	  longer	  the	  individual	  genome	  but	  a	  population	  of	  related	  but	  different	  genomes,	  posing	  a	  substantial	  challenge	  for	  controlling	  such	  pathogens.	  	  
Nature	  of	  the	  quasi-­species	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The	  typical	  size	  of	  a	  RNA	  genome	  such	  as	  for	  HIV-­‐1	  is	  of	  the	  order	  of	  10kb.	  Theoretically,	  there	  can	  be	  410,000	  different	  sequences	  for	  such	  a	  genome.	  This	  astronomical	  number	  represents	  the	  entire	  sequence	  space	  available	  for	  exploration	  to	  the	  HIV-­‐1	  replication	  system.	  Of	  all	  possible	  sequences,	  most	  do	  not	  code	  for	  meaningful	  genomes.	  Only	  a	  fraction	  does,	  and	  under	  given	  selection	  pressure	  that	  fraction	  defines	  a	  quasi-­‐species.	  	  	  The	  nature	  of	  the	  quasi-­‐species	  is	  illustrated	  in	  the	  context	  of	  dynamics	  of	  the	  replication	  system	  in	  Figure	  1.1	  [7].	  Consider	  the	  cubes	  in	  this	  panel	  to	  represent	  available	  sequence	  space.	  Assuming	  a	  viral	  population	  is	  centered	  on	  a	  wild-­‐type	  genome,	  three	  situations	  can	  arise.	  A	  high-­‐fidelity	  replication	  system	  results	  in	  a	  population	  that	  remains	  centered	  around	  the	  wild-­‐type	  (Fig.	  1.1a).	  This	  preserves	  the	  original	  genomic	  information	  but	  generates	  little	  diversity	  resulting	  in	  populations	  susceptible	  to	  immune	  eradication	  or	  antiviral	  agents.	  In	  contrast,	  an	  extremely	  error-­‐prone	  system	  ends	  up	  exploring	  all	  available	  space	  (Fig.	  1.1b).	  Although	  this	  yields	  a	  rich	  spectrum	  of	  variants,	  there	  is	  rapid	  and	  continual	  dissipation	  of	  genomic	  information	  as	  error	  rates	  exceed	  the	  error	  threshold,	  yielding	  replication	  incompetent	  genomes.	  
a.	  Perfect	  replication	  does	  not	  produce	  diversity.	  b.	  Imperfect	  replication	  generates	  high	  diversity	  at	  the	  cost	  of	  disintegrating	  genomic	  information	  c.	  Systems	  that	  balance	  creation	  of	  variation	  with	  preservation	  of	  information	  exists	  as	  diverse	  yet	  structured	  entities	  called	  quasi-­‐species.	  Available	  
Figure	  1.1	  Replication	  system	  dynamics	  govern	  population	  distributions.	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space	  for	  genome	  diversity	  is	  represented	  by	  a	  cube.	  Founder	  strain	  or	  population	  is	  shown	  as	  a	  sphere	  in	  the	  center	  of	  the	  cube.	  Area	  shaded	  in	  blue	  depicts	  space	  explored	  by	  replicating	  system	  over	  time.	  Permission	  to	  reuse	  this	  figure	  was	  granted	  by	  the	  publisher,	  ©	  1993	  JSDinfographics,	  New	  York,	  NY.	  	  Just	  below	  the	  error	  threshold,	  however,	  the	  viral	  population	  explores	  the	  sequence	  space	  more	  optimally	  [9].	  First-­‐generation	  mutants	  accumulate	  around	  the	  original	  wild-­‐type	  in	  numbers	  that	  depend	  on	  their	  relative	  fitness.	  These	  in	  turn	  lead	  to	  newer	  mutants	  that	  arise	  especially	  from	  well-­‐adapted	  existing	  mutants.	  In	  time,	  the	  distribution	  of	  sequences	  represents	  a	  cloud	  centered	  on	  the	  wild-­‐type	  but	  asymmetrically	  exploring	  pockets	  of	  the	  sequence	  space	  dictated	  by	  fitness	  and	  selection	  considerations	  (Fig.	  1.1c).	  In	  Eigen’s	  words,	  this	  cloud	  is	  a	  quasi-­‐species.	  Beyond	  the	  error	  threshold	  the	  cloud	  loses	  form	  (Fig.	  1.1b)	  whereas	  much	  below	  it	  the	  cloud	  contracts	  to	  a	  single	  point	  (Fig.	  1.1a).	  Successful	  viruses	  such	  as	  HIV-­‐1	  therefore	  function	  just	  below	  the	  error	  threshold	  in	  order	  to	  achieve	  high	  evolutionary	  flexibility	  while	  maintaining	  integrity	  of	  information.	  	  
The	  HIV-­1	  quasi-­species	  	  In	  HIV-­‐1,	  mutations	  occur	  across	  all	  codon	  positions	  and	  non-­‐coding	  regions.	  This	  is	  ideal	  for	  generating	  diversity	  and	  facilitates	  escape	  of	  the	  quasi-­‐species	  under	  selection	  pressures.	  How	  does	  the	  virus	  cope	  with	  preserving	  essential	  structural	  motifs?	  The	  virus	  does	  indeed	  have	  conserved	  positions	  that	  preserve	  a	  structural	  backbone.	  These	  could	  be	  targets	  for	  the	  host	  immune	  system	  or	  therapy,	  except	  features	  having	  less	  functional	  constraints	  and	  therefore	  high	  variability	  conceal	  them.	  In	  HIV	  env,	  which	  is	  the	  viral	  surface	  protein	  and	  thus	  a	  target	  for	  both	  antibodies	  and	  vaccines,	  only	  about	  20%	  of	  positions	  are	  constant	  whereas	  70%	  are	  variable	  and	  10%	  are	  hyper-­‐variable	  [9].	  It	  has	  been	  proposed	  that	  such	  flexibility	  in	  sequence	  space	  afforded	  to	  the	  quasi-­‐species	  helps	  in	  outlasting	  the	  diversity	  generating	  capacity	  of	  the	  immune	  system	  [10].	  This	  is	  a	  candidate	  explanation	  for	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The	  HIV	  replication	  cycle	  	  It	  is	  necessary	  to	  study	  the	  replication	  cycle	  of	  the	  pathogen	  to	  identify	  treatment	  opportunities.	  A	  virus	  like	  HIV-­‐1	  needs	  both	  viral	  and	  host	  proteins	  to	  replicate.	  Careful	  characterization	  of	  the	  steps	  involved	  helps	  in	  determining	  processes	  that	  are	  sufficiently	  distinct	  from	  those	  in	  the	  host,	  which	  are	  good	  choices	  for	  therapy.	  The	  HIV	  replication	  cycle	  outlining	  the	  various	  steps	  is	  illustrated	  in	  Figure	  1.2.	  	  HIV-­‐1	  infects	  cells	  that	  bear	  the	  molecules	  CD4	  and	  either	  CCR5	  or	  CXCR4	  on	  their	  surface	  [16].	  Target	  cells	  are	  constituents	  of	  the	  immune	  system,	  including	  CD4	  T-­‐cells	  and	  macrophages.	  Both	  CD4,	  which	  is	  the	  primary	  receptor,	  and	  one	  of	  the	  two	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co-­‐receptors,	  CCR5	  or	  CXCR4,	  are	  required	  for	  viral	  entry	  and	  fusion	  with	  the	  host	  cell,	  steps	  that	  have	  been	  targeted	  by	  drugs.	  The	  transmitted	  founder	  virus	  is	  also	  a	  focus	  of	  therapy	  –	  it	  has	  been	  proposed	  that	  only	  one	  or	  a	  few	  particles	  typically	  establish	  initial	  infection	  [11].	  The	  founder	  virus	  is	  mainly	  the	  CCR5	  utilizing	  kind	  [17]	  whereas	  CXCR4	  utilizing	  variants	  usually	  appear	  late	  in	  pathogenesis	  near	  the	  onset	  of	  AIDS	  [18].	  Accordingly,	  much	  research	  has	  been	  undertaken	  to	  inhibit	  or	  reduce	  the	  CCR5	  interaction.	  	  The	  envelope	  protein	  of	  HIV-­‐1	  (Env)	  is	  a	  key	  player	  in	  the	  entry	  process	  [19].	  The	  surface	  gp120	  subunit	  first	  engages	  CD4.	  This	  promotes	  interaction	  of	  the	  V3	  loop	  of	  gp120	  with	  co-­‐receptor.	  Subsequently,	  conformational	  changes	  in	  the	  trans-­‐membrane	  gp41	  subunit	  of	  Env	  result	  in	  formation	  of	  a	  six-­‐helix	  bundle	  that	  mediates	  fusion	  of	  the	  viral	  and	  target	  cell	  membranes.	  This	  releases	  the	  viral	  core	  into	  the	  cytoplasm	  where	  it	  is	  uncoated.	  Next	  the	  viral	  RNA	  genome	  is	  reverse	  transcribed	  into	  DNA.	  This	  crucial	  step,	  which	  is	  a	  hallmark	  of	  retroviruses,	  is	  catalyzed	  by	  the	  viral	  enzyme	  reverse	  transcriptase	  (RT)	  [20].	  RT	  was	  the	  target	  of	  the	  earliest	  antiretroviral	  drugs,	  and	  RT	  inhibitors	  continue	  to	  be	  a	  mainstay	  of	  modern	  HIV	  combination	  therapies.	  	  Reverse	  transcription	  leads	  to	  the	  second	  characteristic	  feature	  of	  the	  retroviral	  replication	  cycle,	  which	  is	  integration	  of	  the	  viral	  DNA	  into	  the	  host	  genome.	  The	  viral	  enzyme	  involved	  is	  integrase	  (IN)	  [21].	  Together	  with	  several	  host	  factors,	  IN	  associates	  with	  the	  viral	  DNA	  to	  form	  the	  pre-­‐integration	  complex	  (PIC),	  which	  enters	  the	  nucleus.	  There	  IN	  catalyzes	  the	  joining	  of	  the	  viral	  and	  host	  DNA.	  This	  too	  has	  been	  a	  target	  of	  anti-­‐HIV	  therapy.	  Upon	  integration,	  HIV-­‐1	  is	  stably	  incorporated	  as	  a	  part	  of	  the	  host	  genome.	  	  
	  The	  integrated	  viral	  DNA	  or	  provirus	  co-­‐opts	  the	  cellular	  machinery	  to	  transcribe	  and	  translate	  all	  viral	  proteins	  and	  as	  well	  as	  produce	  genomic	  viral	  RNA	  [22].	  The	  latter	  is	  packaged	  with	  the	  viral	  Gag	  and	  Gag-­‐Pol	  poly-­‐proteins	  at	  the	  cell	  surface.	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Finally	  nascent	  viral	  particles	  bud	  off	  the	  host	  cell.	  Before	  they	  are	  ready	  to	  infect	  new	  cells,	  however,	  they	  need	  to	  undergo	  maturation,	  involving	  cleavage	  of	  Gag	  and	  Gag-­‐Pol	  into	  its	  structural	  and	  enzymatic	  components	  by	  the	  third	  viral	  enzyme,	  protease	  (PR)	  [23].	  Drugs	  have	  also	  been	  developed	  to	  inhibit	  PR,	  thereby	  preventing	  the	  formation	  of	  infectious	  virus.	  
	  	  	  	  	  	  	  	  Courtesy:	  National	  Institute	  of	  Allergy	  and	  Infectious	  Diseases	  	  
Figure	  1.2	  The	  HIV	  replication	  cycle	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Highly	  active	  anti-­retroviral	  therapy	  or	  HAART	  
	  Developing	  drugs	  against	  HIV-­‐1	  has	  been	  challenging	  due	  to	  the	  complex	  and	  dynamic	  nature	  of	  the	  quasi-­‐species.	  For	  the	  early	  part	  of	  the	  HIV	  pandemic,	  until	  the	  mid-­‐1990s,	  only	  a	  handful	  of	  antiretroviral	  drugs	  received	  FDA	  approval.	  All	  of	  them	  were	  nucleoside	  analogs	  lacking	  a	  3’	  hydroxyl	  group	  such	  that	  their	  incorporation	  terminated	  DNA	  synthesis	  [24,	  25].	  They	  were	  designed	  to	  interfere	  with	  reverse	  transcription	  by	  aborting	  production	  of	  viral	  DNA.	  Such	  compounds	  were	  called	  nucleoside	  RT	  inhibitors	  (NRTIs)	  and	  the	  earliest	  ones	  included	  zidovudine	  (AZT),	  lamivudine	  (3TC)	  and	  stavudine	  (d4T).	  	  
	  There	  is	  always	  ongoing	  DNA	  synthesis	  in	  the	  host	  cell,	  so	  any	  NRTIs	  that	  can	  be	  incorporated	  into	  host	  cell	  DNA	  have	  the	  potential	  for	  high	  toxicity.	  Also	  mutant	  forms	  of	  RT	  arise	  that	  overcome	  NRTIs	  by	  either	  removing	  them	  or	  precluding	  their	  incorporation	  [25].	  Around	  the	  mid-­‐1990s	  non-­‐nucleoside	  RT	  inhibitors,	  or	  NNRTIs,	  were	  developed	  that	  targeted	  HIV-­‐1	  RT	  specifically	  instead	  of	  the	  process	  or	  synthesis	  that	  the	  enzyme	  catalyzes.	  Nevirapine	  and	  delavirdine	  were	  the	  earliest	  NNRTIs.	  These	  inhibited	  by	  binding	  to	  RT	  and	  changing	  the	  conformation	  of	  its	  active	  site	  [25].	  NNRTIs	  suffered,	  however	  from	  low	  fitness	  costs	  of	  resistant	  RT,	  which	  meant	  that	  HIV-­‐1	  readily	  escaped	  from	  drug	  pressure	  [26].	  	  PR	  was	  the	  second	  viral	  enzyme	  that	  was	  targeted	  by	  FDA-­‐approved	  inhibitors.	  PR	  inhibitors	  or	  PIs	  inhibited	  the	  cleavage	  activity	  of	  PR	  [24].	  As	  a	  consequence	  resistance	  mutations	  emerged	  both	  on	  PR	  as	  well	  as	  around	  cleavage	  sites	  of	  the	  Gag	  and	  Gag-­‐Pol	  polyproteins,	  which	  are	  the	  substrates	  for	  PR	  [26,	  27].	  Nelfinavir,	  ritonavir	  and	  saquinavir	  were	  among	  the	  first	  PIs	  that	  received	  approval,	  also	  in	  the	  mid-­‐90s.	  Thus	  around	  1995-­‐6,	  there	  was	  not	  only	  a	  proliferation	  in	  the	  number	  of	  antiretroviral	  drugs	  but	  also	  availability	  of	  drugs	  that	  had	  different	  targets	  and	  mechanisms	  of	  inhibition.	  This	  prompted	  the	  initiation	  of	  combination	  therapy	  with	  three	  or	  more	  drugs	  under	  the	  premise	  that	  even	  with	  its	  high	  µg	  HIV-­‐1	  would	  find	  it	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difficult	  to	  escape	  them	  simultaneously	  [28-­‐30].	  Additionally,	  the	  cumulative	  reduction	  of	  ongoing	  viral	  replication	  by	  multiple	  drugs	  would	  be	  sufficient	  to	  control	  viral	  loads	  in	  patients	  at	  levels	  where	  few	  healthy	  cells	  would	  be	  infected	  [31].	  Optimization	  of	  such	  cocktails	  of	  drugs	  led	  to	  establishment	  of	  well-­‐defined	  HAART	  regimens	  [32-­‐34].	  
	  Poor	  adherence	  and/or	  tolerance	  of	  drug	  regimens	  lead	  to	  breakthrough	  resistance	  in	  virus.	  Resistant	  strains	  emerging	  in	  individuals	  can	  also	  be	  transmitted	  resulting	  in	  their	  wider	  circulation	  in	  the	  host	  population.	  This	  demands	  continuously	  finding	  new	  ways	  of	  targeting	  the	  virus.	  Such	  efforts	  have	  led	  to	  drugs	  inhibiting	  the	  entry	  step.	  Enfuvirtide,	  or	  T20,	  is	  an	  FDA-­‐approved	  drug	  that	  limits	  viral	  fusion	  –	  it	  is	  a	  peptide	  mimic	  of	  the	  six-­‐helix	  bundle	  of	  gp41	  that	  interferes	  with	  the	  inter-­‐helix	  interactions	  [35].	  Maraviroc,	  another	  recent	  drug	  in	  the	  market,	  acts	  by	  antagonizing	  CCR5	  and	  is	  unique	  in	  targeting	  an	  essential	  host	  factor	  for	  HIV	  [36].	  	  	  
Integrase	  inhibitors	  	  Success	  has	  also	  been	  achieved	  in	  targeting	  IN,	  the	  third	  enzyme	  of	  HIV-­‐1.	  Researchers	  at	  Imperial	  College	  London	  recently	  described	  the	  structure	  of	  full-­‐length	  retroviral	  IN	  in	  complex	  with	  viral	  and	  target	  DNA	  providing	  insights	  into	  the	  integration	  reaction	  [37,	  38].	  It	  was	  proposed	  that	  the	  active	  complex	  or	  intasome	  has	  an	  IN	  tetramer	  bound	  to	  viral	  DNA.	  The	  intasome	  causes	  bending	  of	  the	  target	  DNA,	  which	  facilitates	  the	  joining	  of	  viral	  and	  host	  DNA	  strands.	  The	  structure	  of	  the	  intasome	  is	  depicted	  in	  Figure	  1.3	  [38].	  Thus	  far	  all	  integrase	  inhibitors	  inhibit	  the	  strand	  transfer	  reaction	  of	  IN,	  so	  they	  are	  called	  INSTIs	  [39].	  The	  only	  drug	  that	  has	  so	  far	  received	  FDA	  approval	  is	  Raltegravir	  (RAL).	  Studies	  of	  INSTIs	  have	  focused	  on	  investigating	  drug	  efficacies	  and	  characterizing	  resistance.	  In	  chapter	  2	  of	  this	  dissertation	  we	  describe	  an	  analysis	  of	  patients	  undergoing	  RAL	  therapy	  who	  exhibited	  a	  switch	  in	  RAL-­‐resistance	  profiles.	  
	   12	  
The	  strand	  transfer	  complex	  consists	  of	  integrase	  tetramer,	  viral	  DNA	  and	  target	  or	  host	  DNA.	  The	  spatial	  arrangement	  of	  the	  catalytic	  core	  domains	  (CCD)	  of	  the	  four	  IN	  molecules	  around	  the	  viral	  and	  target	  DNA	  is	  shown.	  The	  active	  site	  (red	  circles)	  is	  part	  of	  the	  CCD	  juxtaposing	  on	  the	  junctions	  between	  the	  viral	  and	  target	  DNA	  molecules.	  The	  N-­‐terminal	  extension	  domains	  (NED)	  are	  also	  displayed.	  Figure	  adapted	  from	  Maertens	  et	  al	  [38].	  	  IN	  requires	  two	  bivalent	  metal	  ions	  such	  as	  magnesium	  (Mg2+)	  or	  manganese	  (Mn2+)	  at	  its	  active	  site	  to	  catalyze	  strand	  transfer.	  INSTIs	  inhibit	  IN	  by	  binding	  to	  the	  active	  site,	  chelating	  the	  two	  metal	  cations	  and	  displacing	  the	  terminal	  3’	  nucleotide	  of	  the	  viral	  DNA	  in	  the	  PIC	  [37,	  40].	  IN	  counteracts	  this	  by	  acquiring	  mutations	  in	  the	  active	  site.	  Against	  RAL,	  the	  primary	  mutations	  are	  Y143H/R/C,	  Q148H/R/K	  and	  	  
   T arget DNA
   CCD
   CCD   CCD
   NED    NED
   CCD
   Viral DNA   Viral DNA
Figure	  1.3	  The	  intasome	  of	  prototype	  foamy	  virus	  (PFV)	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N155H	  [41].	  These	  primarily	  alter	  the	  native	  conformation	  of	  IN	  such	  as	  to	  make	  INSTI	  binding	  energetically	  unfavorable	  [42].	  	  	  Of	  all	  major	  IN	  resistance	  forms,	  Q148H	  in	  conjunction	  with	  its	  accessory	  mutation	  G140S/A	  results	  in	  the	  largest	  reduction	  in	  RAL	  susceptibility	  [42,	  43].	  This	  configuration	  also	  exhibits	  the	  most	  cross-­‐resistance	  to	  other	  INSTIs	  currently	  evaluated	  in	  clinical	  trials,	  namely	  Elvitegravir	  (EVG	  or	  GS9137)	  and	  Dolutegravir	  (S/GSK	  1349572)	  [44].	  The	  study	  in	  chapter	  2	  describes	  patients	  presenting	  a	  switch	  from	  N155H	  to	  Q148H+G140S.	  Investigating	  fine	  details	  of	  the	  genotypic	  spectrum	  of	  the	  viral	  populations	  that	  underlies	  this	  transition	  could	  be	  crucial	  for	  both	  understanding	  resistance	  evolution	  and	  informing	  therapy.	  Also	  it	  is	  important	  to	  interrogate	  levels	  of	  natural	  polymorphisms	  for	  these	  mutations.	  This	  would	  relate	  to	  their	  fitness	  in	  the	  wild-­‐type	  quasi-­‐species	  for	  IN,	  that	  is	  in	  absence	  of	  INSTI.	  It	  could	  also	  explain	  the	  propensity	  of	  their	  outgrowth	  following	  drug	  treatment	  and	  help	  in	  understanding	  the	  genetic	  barrier	  to	  INSTIs.	  Accordingly,	  in	  the	  context	  of	  the	  patients	  studied,	  pre-­‐RAL	  occurrence	  of	  resistance	  polymorphisms	  is	  analyzed	  in	  detail	  in	  chapter	  2.	  
	  
The	  Berlin	  patient	  –	  curing	  HIV?	  	  In	  2008	  an	  HIV-­‐infected	  person	  presented	  with	  symptoms	  of	  acute	  myeloid	  leukemia	  (AML)	  in	  Berlin,	  Germany.	  He	  underwent	  chemotherapy,	  however	  AML	  relapsed	  and	  stem	  cell	  transplantation	  (SCT)	  from	  a	  healthy	  HLA-­‐matched	  donor	  was	  performed.	  Keeping	  in	  mind	  the	  HIV	  status	  of	  the	  patient,	  the	  donor	  was	  selected	  to	  be	  of	  homozygous	  CCR5Δ32	  genotype	  [45].	  CCR5Δ32	  is	  a	  32	  bp	  deletion	  in	  the	  CCR5	  gene	  that	  is	  found	  in	  roughly	  1-­‐3%	  of	  the	  Caucasian	  population.	  It	  results	  in	  a	  truncated	  gene	  product	  that	  abrogates	  cell	  surface	  expression	  of	  CCR5	  [46,	  47].	  This	  is	  restrictive	  for	  cellular	  entry	  of	  CCR5-­‐utilizing	  HIV	  –	  crucially	  the	  transmitted	  virus	  as	  well	  as	  those	  dominating	  until	  the	  later	  stages	  of	  pathogenesis	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are	  CCR5-­‐tropic.	  The	  objective	  behind	  sourcing	  SCT	  from	  a	  CCR5Δ32	  donor	  by	  design	  was	  repopulating	  the	  immune	  system	  with	  progenitor	  cells	  that	  would	  also	  be	  restrictive	  to	  CCR5-­‐tropic	  virus.	  	  The	  Berlin	  patient	  underwent	  a	  conditioning	  therapy	  pre-­‐SCT	  intended	  to	  eradicate	  leukemic	  cells	  as	  well	  as	  suppress	  immune	  response	  to	  donor	  cells	  [45].	  For	  the	  former,	  myelo-­‐ablative	  chemotherapy	  and	  total	  body	  irradiation	  (TBI)	  was	  performed	  –	  in	  the	  process	  potentially	  also	  eliminating	  infected	  cells	  with	  actively	  replicating	  or	  latent	  virus.	  SCT	  resulted	  in	  successful	  engraftment	  of	  donor	  cells	  and	  both	  peripheral	  and	  mucosal	  CD4	  T	  cell	  populations	  were	  reconstituted	  at	  levels	  comparable	  to	  HIV-­‐uninfected	  SCT	  recipients	  as	  well	  as	  healthy	  control	  patients	  [48].	  Over	  the	  long-­‐term	  both	  HIV	  target	  cell	  populations	  –	  T	  cells	  and	  macrophages	  –	  showed	  a	  transition	  to	  the	  donor	  CCR5Δ32	  genotype.	  In	  addition	  to	  the	  peripheral	  circulation,	  this	  was	  also	  true	  of	  the	  mucosal	  circulation,	  which	  is	  where	  HIV	  infection	  is	  first	  initiated.	  Finally,	  post-­‐SCT	  for	  over	  40	  months	  now,	  there	  is	  no	  detectable	  virus	  in	  the	  patient	  either	  in	  the	  plasma	  or	  in	  tissues	  –	  all	  in	  the	  absence	  of	  HAART	  that	  was	  discontinued	  to	  reduce	  drug	  toxicity	  following	  SCT-­‐conditioning.	  Consistent	  with	  this,	  researchers	  reported	  a	  decreasing	  trend	  in	  the	  titers	  of	  anti-­‐HIV	  antibodies	  [48].	  	  Although	  the	  CCRΔ32	  genotype	  is	  resistant	  to	  CCR5-­‐tropic	  HIV,	  it	  does	  not	  protect	  against	  CXCR4-­‐tropic	  or	  dual	  tropic	  virus.	  Indeed	  researchers	  demonstrated	  that	  engrafted	  donor	  cells	  in	  the	  Berlin	  patient	  were	  prone	  to	  infection	  by	  CXCR4-­‐tropic	  HIV	  [48].	  Deep	  sequencing	  of	  the	  pre-­‐SCT	  viral	  population	  had	  revealed	  a	  minority	  of	  CXCR4-­‐tropic	  strains	  [45].	  Thus	  the	  possibility	  remained	  of	  ensuing	  viral	  infection	  post-­‐SCT.	  Undetectable	  virus	  for	  almost	  4	  years,	  however,	  suggests	  that	  post-­‐SCT	  levels	  of	  circulating	  or	  latent	  CXCR4-­‐tropic	  HIV	  were	  insufficient	  for	  reinitiating	  HIV	  infection.	  	  	  
	   15	  
The	  Berlin	  patient	  is	  a	  striking	  example	  of	  possible	  cure	  from	  HIV.	  Potentially	  conditioning	  therapy	  contributed	  to	  cure	  by	  expunging	  long-­‐lived	  cells	  and	  viral	  reservoirs	  therein	  [48].	  Nevertheless	  reconstituting	  the	  patient	  immune	  system	  with	  HIV-­‐resistant	  cells	  was	  a	  significant	  factor,	  emphasizing	  the	  promise	  of	  cell	  therapy	  to	  control	  HIV.	  An	  important	  consideration	  is	  cure	  from	  HIV	  in	  the	  absence	  of	  HAART.	  This	  overcomes	  several	  challenges	  of	  long-­‐term	  drug	  use:	  persistent	  costs,	  toxicities,	  and	  tolerance	  issues	  that	  often	  lead	  to	  poor	  adherence	  and	  breakthrough	  of	  resistance.	  Furthermore	  HAART	  controls	  HIV	  but	  never	  ‘cures’	  –	  cessation	  of	  drugs	  is	  accompanied	  by	  breakthrough	  of	  virus.	  This	  happens	  due	  to	  eventual	  activation	  of	  latent	  HIV	  existing	  as	  provirus	  in	  long-­‐lived	  cells.	  Such	  viral	  reservoirs	  are	  a	  formidable	  hurdle	  for	  cure	  and	  beyond	  the	  reach	  of	  HAART	  [49].	  	  
Cell	  and	  gene	  therapy	  targeted	  to	  HIV	  
	  Cell	  and	  gene	  therapy	  strategies	  are	  directed	  at	  long-­‐term	  modification	  of	  HIV	  target	  cell	  populations	  in	  the	  host	  such	  as	  to	  reduce	  susceptibility	  to	  the	  virus	  in	  the	  absence	  of	  drugs.	  Approaches	  have	  been	  directed	  against	  either	  viral	  targets	  or	  cellular	  factors	  that	  are	  essential	  for	  viral	  replication,	  and	  either	  proteins	  or	  nucleic	  acids.	  Although	  therapeutic	  benefit	  has	  not	  been	  conclusively	  established	  thus	  far,	  researchers	  have	  reported	  survival	  advantage	  of	  gene-­‐modified	  cells	  in	  the	  presence	  of	  virus.	  Also,	  trials	  have	  successfully	  addressed	  safety	  considerations	  related	  to	  genotoxicity.	  Transient	  lowering	  of	  viral	  loads	  were	  observed	  in	  some	  cases.	  There	  is	  hope	  that	  improvements	  can	  made	  with	  better	  in	  vivo	  engraftment,	  persistence	  and	  expression	  of	  gene-­‐modified	  cells	  and	  their	  products.	  Certainly	  given	  the	  example	  of	  the	  Berlin	  patient,	  this	  is	  an	  area	  with	  much	  promise.	  	  
Gene	  therapy	  at	  the	  level	  of	  proteins	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The	  first	  gene	  therapy	  clinical	  trial	  was	  conducted	  in	  the	  mid-­‐1990s	  in	  the	  early	  days	  of	  HAART.	  HIV	  patients	  were	  infused	  with	  autologous	  (or	  self)	  CD4	  T	  cells	  modified	  with	  an	  antiviral	  protein	  called	  RevM10	  [50].	  This	  is	  a	  form	  of	  HIV	  Rev	  with	  mutations	  in	  a	  conserved	  domain	  that	  interacts	  with	  host	  factors.	  RevM10	  binds	  to	  the	  Rev-­‐response	  element	  or	  RRE	  on	  viral	  transcripts	  but	  does	  not	  promote	  their	  nuclear	  export.	  Thus	  it	  interferes	  with	  Rev	  function	  and	  inhibits	  viral	  replication	  by	  exerting	  a	  dominant	  negative	  effect.	  As	  opposed	  to	  control	  cells	  transduced	  with	  ΔRevM10,	  which	  does	  not	  produce	  a	  protein,	  RevM10	  transduced	  cells	  survived	  longer	  in	  HIV	  patients	  [50,	  51].	  The	  latter	  also	  inhibited	  HIV	  replication	  in	  vitro	  although	  in	  vivo	  there	  was	  no	  pronounced	  effect	  on	  viral	  load	  [50,	  51].	  Persistence	  of	  modified	  cells	  was	  a	  limitation	  –	  when	  a	  RevM10	  plasmid	  was	  delivered	  by	  microgold	  particles,	  the	  half-­‐life	  was	  1-­‐2	  weeks	  [50].	  This	  was	  improved	  upon	  to	  a	  few	  months	  with	  a	  murine	  retrovirus	  (MoMuLV)	  based	  delivery	  vector,	  which	  presumably	  led	  to	  stable	  integrated	  forms	  of	  RevM10	  [51].	  Trials	  were	  assessed	  for	  safety	  –	  no	  adverse	  biochemical	  or	  physiological	  events	  were	  reported	  and	  no	  replication	  competent	  MoMuLV	  or	  undesirable	  immune	  responses	  to	  RevM10	  detected.	  	  A	  more	  recent	  clinical	  trial	  involved	  the	  membrane	  anchored	  antiviral	  peptide	  C46	  (maC46),	  a	  mimic	  of	  a	  gp41	  heptad	  helix	  [52].	  It	  is	  similar	  to	  the	  fusion	  inhibitor	  T-­‐20	  and	  inhibits	  HIV	  replication	  in	  vitro	  by	  blocking	  entry.	  The	  trial	  was	  a	  first	  in	  using	  a	  pre-­‐integration	  step	  target	  in	  a	  gene	  therapy	  setting.	  This	  can	  afford	  protection	  to	  modified	  cells	  without	  the	  requirement	  of	  HIV	  integration.	  HIV	  patients	  that	  received	  autologous	  T	  cells	  modified	  with	  a	  retroviral	  vector	  encoding	  maC46	  exhibited	  no	  adverse	  effects,	  insertional	  mutagenesis	  or	  attenuating	  immune	  responses	  to	  maC46.	  In	  vivo	  levels	  of	  modified	  cells	  correlated	  with	  the	  reinfusion	  doses	  and	  in	  some	  patients	  maC46-­‐marked	  cells	  persisted	  for	  a	  year.	  Although	  modified	  cell	  numbers	  were	  not	  high	  enough	  to	  reduce	  viral	  load,	  they	  possibly	  stimulated	  T	  cell	  growth	  such	  that	  infusions	  led	  to	  transient	  increases	  in	  total	  CD4	  cell	  counts.	  
	   17	  
	  Host	  proteins	  essential	  to	  HIV	  have	  also	  been	  targeted.	  Such	  strategies	  have	  fewer	  concerns	  with	  viral	  escape.	  However,	  they	  have	  to	  contend	  with	  possible	  toxic	  effects	  on	  the	  host,	  especially	  if	  targeted	  protein	  has	  important	  roles	  in	  the	  body.	  Given	  the	  success	  story	  of	  the	  Berlin	  patient,	  and	  the	  HIV-­‐resistance	  afforded	  by	  the	  CCR5Δ32	  genotype,	  much	  effort	  has	  been	  invested	  in	  reducing	  or	  abolishing	  CCR5	  expression	  on	  cell	  surfaces.	  In	  addition	  CXCR4	  has	  also	  been	  targeted.	  To	  knockdown	  host	  gene	  expression,	  investigators	  have	  adopted	  RNAi	  techniques	  [53].	  Ribozymes,	  which	  are	  catalytic	  RNA	  that	  bind	  and	  degrade	  complementary	  target	  RNA,	  have	  also	  been	  used	  [54].	  Alternative	  approaches	  have	  focused	  on	  knocking	  out	  host	  genes	  [55,	  56].	  Advances	  in	  design	  of	  recombinant	  endonucleases	  called	  zinc	  finger	  nucleases	  or	  ZFNs	  have	  facilitated	  this	  [57].	  ZFNs	  can	  be	  engineered	  to	  cleave	  genomic	  DNA	  at	  a	  unique	  locus.	  Although	  off-­‐target	  effects	  are	  a	  concern,	  there	  are	  several	  advantages.	  Even	  transient	  expression	  of	  ZFNs	  can	  result	  in	  a	  permanent	  disruption	  of	  a	  gene	  –	  this	  also	  obviates	  the	  need	  for	  using	  integrating	  vectors	  as	  delivery	  vehicles.	  Clinical	  trials	  are	  ongoing	  to	  study	  effects	  of	  T	  cells	  modified	  with	  CCR5-­‐targeting	  ZFN	  (clinicaltrials.gov	  Id	  NCT00842634,	  NCT01252641).	  	  	  
RNA	  based	  strategies	  	  Gene	  therapy	  at	  the	  level	  of	  nucleic	  acid	  overcomes	  problems	  with	  immunogenicity	  that	  a	  modified	  cell	  expressing	  an	  antiviral	  protein	  could	  experience.	  RNAi	  and	  ribozyme	  based	  techniques	  have	  been	  popular	  although	  avoiding	  off-­‐target	  effects	  is	  challenging.	  Results	  of	  the	  largest	  gene	  therapy	  trial	  till	  date,	  involving	  74	  HIV-­‐1	  patients,	  were	  reported	  in	  2009	  –	  a	  ribozyme	  that	  targeted	  the	  overlapping	  region	  of	  HIV-­‐1	  vpr	  and	  tat	  was	  used.	  This	  antiviral	  payload	  was	  delivered	  by	  a	  MoMuLV	  vector	  and	  was	  called	  OZ1	  [58].	  The	  study	  was	  also	  the	  first	  phase	  II	  clinical	  trial	  that	  tested	  anti-­‐HIV	  gene-­‐modified	  hematopoetic	  stem	  cells	  (HSCs).	  Compared	  to	  T	  cells,	  ex	  vivo	  transduction	  and	  expansion	  of	  HSCs	  has	  been	  difficult	  and	  associated	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genotoxicity	  has	  been	  documented	  [59-­‐61].	  Still	  it	  is	  attractive	  to	  modify	  HSCs	  as	  antiviral	  resistance	  can	  then	  be	  transferred	  on	  a	  long-­‐term	  basis	  to	  descendent	  immune	  cells	  of	  both	  myeloid	  and	  lymphoid	  lineages	  that	  HIV	  targets.	  	  	  In	  the	  OZ1	  trial,	  participants	  were	  infused	  with	  modified	  or	  control	  autologous	  HSCs.	  Importantly	  patient	  groupings	  into	  treated	  and	  control	  cohorts	  was	  randomized	  and	  the	  study	  double-­‐blinded.	  OZ1-­‐modified	  cells	  persisted	  in	  some	  patients	  at	  least	  for	  100	  weeks	  –	  OZ1	  RNA	  was	  also	  detectable	  till	  that	  time	  in	  a	  few	  cases	  indicating	  the	  potential	  for	  durable	  in	  vivo	  expression.	  Although	  viral	  replication	  was	  not	  controlled	  following	  post-­‐infusion	  interruption	  of	  HAART,	  viral	  loads	  over	  the	  long-­‐term	  were	  lower	  in	  the	  treated	  group.	  Significantly,	  viral	  loads	  were	  even	  lower	  in	  patients	  with	  long-­‐lasting	  OZ1	  expression.	  Also,	  CD4	  counts	  were	  higher	  in	  treated	  patients.	  Finally	  no	  serious	  adverse	  events	  were	  reported.	  Integration	  site	  analysis	  of	  OZ1	  did	  not	  detect	  proliferation	  of	  any	  single	  clone	  and	  viral	  sequencing	  did	  not	  establish	  any	  OZ1	  resistance.	  	  Yet	  another	  RNA-­‐based	  gene	  therapy	  procedure	  employs	  RNA	  decoys	  to	  divert	  HIV	  proteins.	  Good	  targets	  are	  HIV	  Tat	  and	  Rev:	  Tat	  binds	  to	  a	  trans-­‐acting	  responsive	  or	  TAR	  element	  on	  the	  5’	  UTR	  of	  viral	  mRNAs	  to	  promote	  transcription,	  whereas	  Rev	  recognizes	  RRE	  also	  on	  viral	  mRNAs	  –	  other	  than	  the	  completely	  spliced	  forms	  –	  to	  promote	  nuclear	  export.	  	  A	  phase	  I	  clinical	  trial	  conducted	  in	  1999	  transduced	  autologous	  HSCs	  with	  an	  RRE	  decoy	  delivered	  by	  a	  MoMuLV	  vector	  [62].	  Gene-­‐modified	  HSCs	  were	  detectable	  until	  almost	  a	  year	  post-­‐infusion	  in	  some	  samples.	  Also	  they	  survived	  much	  longer	  than	  control	  HSCs	  that	  contained	  vector	  but	  not	  RRE	  decoy.	  Participants	  did	  not	  exhibit	  any	  complications	  and	  did	  not	  present	  with	  evidence	  for	  replication	  competent	  MoMuLV.	  	  	  
The	  story	  of	  anti-­HIV	  env	  antisense	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A	  possible	  first	  therapeutic	  benefit	  in	  HIV	  patients	  due	  to	  gene	  therapy	  in	  a	  clinical	  setting	  was	  reported	  in	  2006	  by	  investigators	  at	  University	  of	  Pennsylvania.	  The	  study	  enrolled	  5	  HIV	  patients	  who	  were	  failing	  HAART	  and	  involved	  the	  use	  of	  a	  ~1kb	  long	  anti-­‐HIV	  antisense	  directed	  to	  HIV	  env	  [63].	  Autologous	  CD4	  T	  cells	  were	  modified	  with	  this	  antiviral	  RNA	  delivered	  as	  part	  of	  a	  lentiviral	  vector	  called	  VRX496.	  Remarkably,	  3	  patients	  showed	  at	  least	  0.5	  log	  reductions	  in	  viral	  loads	  over	  a	  period	  of	  3-­‐6	  months	  post-­‐infusion	  of	  gene-­‐modified	  cells.	  In	  one	  patient,	  this	  reduction	  continued	  until	  at	  least	  a	  year,	  when	  a	  sharp	  drop	  of	  ~2	  log	  was	  registered.	  After	  a	  year	  CD4	  T	  cell	  counts	  had	  improved	  in	  4	  of	  5	  patients	  and	  no	  adverse	  events	  were	  reported.	  	  	  The	  premise	  of	  antisense	  treatment	  was	  that	  antisense	  RNA	  would	  form	  duplexes	  with	  HIV	  messages	  rendering	  them	  impotent.	  In	  addition,	  the	  duplexes	  would	  be	  long	  double-­‐stranded	  RNA	  (dsRNA)	  molecules	  that	  belong	  to	  the	  category	  of	  pathogen-­‐associated	  molecular	  patterns	  (PAMPs)	  –	  these	  could	  then	  be	  recognized	  and	  degraded	  by	  mechanisms	  of	  cellular	  immunity	  [64].	  Compared	  to	  ribozyme	  or	  RNAi,	  a	  long	  antisense	  is	  likely	  to	  make	  viral	  escape	  more	  difficult.	  As	  a	  corollary	  multiple	  mutations	  would	  be	  needed	  to	  evade	  antisense	  pressure,	  which	  might	  debilitate	  any	  escape	  variant.	  	  The	  VRX496	  study	  was	  also	  the	  first	  clinical	  trial	  for	  lentiviral	  vectors.	  Use	  of	  other	  retroviral	  vectors	  that	  integrate	  in	  the	  promoter	  regions	  of	  genes	  had	  led	  to	  incidences	  of	  insertional	  mutagenesis	  [60,	  61].	  In	  contrast,	  lentiviruses	  tend	  to	  integrate	  within	  transcriptional	  units	  away	  from	  promoters	  –	  vectors	  based	  on	  lentiviruses	  were	  thus	  developed	  as	  safer	  alternatives.	  Consistent	  with	  this,	  long-­‐term	  follow-­‐up	  analysis	  of	  VRX496	  integration	  sites	  in	  patients	  did	  not	  detect	  evidence	  of	  genotoxicity	  [65].	  Employing	  a	  lentivirus	  vector	  like	  VRX496	  that	  contains	  elements	  of	  HIV	  also	  confers	  the	  benefit	  of	  conditional	  vector	  mobilization.	  By	  relying	  on	  HIV	  Tat	  and	  Rev	  for	  transcription	  and	  expression,	  integrated	  VRX496	  is	  only	  activated	  upon	  HIV	  infection.	  Also,	  in	  the	  presence	  of	  HIV,	  VRX496	  RNA	  can	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potentially	  co-­‐package	  with	  HIV	  Env	  forming	  antiviral	  particles	  that	  could	  spread	  HIV	  resistance	  from	  cell-­‐to-­‐cell.	  There	  was	  possible	  short-­‐term	  VRX496	  mobilization	  in	  patients	  but	  importantly	  there	  was	  no	  indication	  of	  a	  replication-­‐competent	  VRX496	  [63].	  	  Taken	  together,	  this	  phase	  I	  antisense-­‐mediated	  anti-­‐HIV	  trial	  was	  promising	  in	  many	  respects.	  Most	  significantly,	  there	  was	  suggestion	  of	  HIV	  control	  in	  some	  patients	  beyond	  that	  achieved	  by	  HAART.	  This	  called	  for	  a	  deeper	  investigation	  of	  clinical	  efficacy.	  Researchers	  had	  already	  reported	  that	  VRX	  antisense	  pressure	  in	  
vitro	  produced	  mutant	  virus	  –	  these	  were	  sufficiently	  impaired	  so	  that	  they	  were	  not	  true	  escape	  forms	  [64].	  It	  remained	  to	  be	  seen	  if	  similar	  observations	  could	  be	  recapitulated	  in	  vivo.	  To	  answer	  this,	  and	  to	  get	  a	  better	  understanding	  of	  the	  mechanism	  of	  antisense	  inhibition	  of	  HIV,	  the	  clinical	  trial	  was	  simulated	  in	  a	  mouse	  model.	  This	  is	  discussed	  in	  detail	  in	  chapter	  3.	  Subsequent	  experiments	  illustrating	  measurable	  effects	  of	  antisense	  on	  HIV	  populations	  are	  also	  described.	  This	  is	  also	  the	  first	  report	  of	  viral	  signatures	  bearing	  evidence	  of	  anti-­‐HIV	  pressure	  in	  vivo	  in	  a	  gene	  therapy	  setting.	  	  	  In	  a	  second	  VRX496	  clinical	  trial,	  the	  majority	  of	  patients	  exhibited	  lowering	  of	  viral	  loads	  with	  one	  patient	  suppressing	  virus	  for	  about	  15	  weeks	  in	  the	  absence	  of	  HAART	  (clinicaltrials.gov	  Id	  NCT00295477).	  Given	  the	  results	  presented	  in	  chapter	  3,	  molecular	  effects	  of	  antisense,	  if	  any,	  were	  investigated	  within	  patient	  virus.	  Longitudinal	  samples	  corresponding	  to	  the	  HAART-­‐interrupted	  period	  in	  patients	  following	  VRX496	  infusion	  were	  studied.	  Data	  and	  analysis	  are	  presented	  in	  chapter	  4	  –	  antisense	  effects	  were	  detectable	  at	  low	  levels.	  Interestingly,	  effects	  could	  be	  observed	  only	  for	  the	  initial	  time-­‐points	  sampled,	  which	  is	  also	  when	  more	  antisense-­‐modified	  cells	  are	  present.	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Advances	  in	  sequencing	  and	  bioinformatics	  applications	  for	  HIV	  
research	  	  
Early	  developments	  leading	  to	  sequencing	  of	  single	  genomes	  
	  Until	  the	  advent	  of	  high-­‐throughput	  platforms	  onwards	  of	  2005,	  capillary-­‐based	  Sanger	  sequencing	  [66]	  was	  the	  main	  tool	  to	  read	  DNA.	  The	  basic	  chemistry	  in	  this	  process	  relies	  on	  sequencing	  by	  synthesis.	  The	  sequence	  is	  read	  using	  fluorescently	  labeled	  dideoxy-­‐nucleotides,	  which	  terminate	  DNA	  polymerization.	  These	  incorporate	  at	  every	  base	  position	  in	  a	  fraction	  of	  the	  clonal	  DNA	  population	  being	  polymerized	  –	  this	  helps	  decipher	  the	  sequence.	  Sanger	  sequencing	  is	  still	  the	  choice	  for	  many	  low-­‐scale	  applications	  today,	  although	  costs	  per	  sequenced	  base	  are	  unattractive	  for	  large-­‐scale	  projects.	  	  However	  read	  lengths	  up	  to	  ~1kb	  and	  errors	  in	  the	  order	  of	  0.001%	  are	  still	  among	  the	  best	  [67].	  	  Initial	  efforts	  to	  genotype	  HIV	  populations	  from	  clinical	  samples	  used	  sequencing	  based	  on	  Sanger	  chemistry	  or	  hybridization	  to	  high-­‐density	  oligonucleotide	  arrays,	  such	  as	  Affymetrix	  GeneChips	  [68,	  69].	  Sanger	  sequencing	  of	  HIV	  populations	  generates	  a	  composite	  sequence	  for	  the	  bulk	  of	  the	  viral	  swarm	  –	  termed	  population	  sequencing.	  This	  carries	  limited	  information	  on	  polymorphisms.	  GeneChip-­‐sequencing	  using	  probes	  that	  differ	  at	  given	  positions	  can	  address	  this	  deficiency.	  Synthesizing	  probes,	  however,	  relies	  on	  knowledge	  of	  sequence	  thereby	  limiting	  its	  use	  for	  de	  novo	  applications.	  Neither	  approach	  allows	  the	  sequence	  estimation	  of	  individual	  variants.	  Thus	  linkage	  information	  is	  also	  lost.	  Furthermore	  they	  are	  unsuited	  to	  quantification	  of	  minority	  variants	  that	  can	  be	  clinically	  relevant.	  	  In	  1990,	  researchers	  at	  University	  of	  Edinburgh,	  Scotland,	  reported	  amplification	  of	  single	  molecules	  of	  provirus	  isolated	  by	  limiting	  dilution	  [70,	  71]	  .	  Based	  on	  this	  approach,	  John	  Coffin	  and	  colleagues	  described	  an	  assay	  to	  perform	  single	  genome	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sequencing	  [72].	  They	  progressively	  diluted	  HIV	  cDNA,	  obtained	  by	  reverse-­‐transcribing	  viral	  RNA,	  until	  only	  about	  30%	  of	  real-­‐time	  PCR	  reactions	  set	  up	  for	  a	  sample	  yielded	  amplified	  product.	  At	  these	  levels,	  according	  to	  the	  Poisson	  distribution,	  sample	  dilutions	  would	  correspond	  to	  on	  average	  1	  viral	  cDNA	  per	  positive	  reaction.	  In	  this	  way,	  individual	  genomes	  could	  be	  amplified	  and	  studied.	  The	  approach	  was	  appropriately	  named	  single	  genome	  amplification	  or	  SGA.	  Multiple	  independent	  viral	  genomes	  from	  a	  given	  sample	  were	  analyzed	  by	  setting	  up	  appropriate	  number	  of	  PCR	  reactions.	  Linkage	  information	  for	  viral	  variants	  was	  preserved.	  Additionally,	  since	  single	  genomes	  were	  amplified	  within	  any	  given	  reaction,	  PCR	  errors	  –	  such	  as	  due	  to	  nucleotide	  mis-­‐incorporation	  or	  inter-­‐template	  recombination	  –	  were	  suppressed.	  Also	  a	  single	  sequence	  was	  determined	  per	  positive	  reaction	  avoiding	  re-­‐sampling	  of	  the	  same	  original	  template,	  which	  is	  a	  problem	  with	  bulk	  PCR	  of	  viral	  populations.	  In	  the	  report	  by	  Coffin	  and	  colleagues,	  no	  recombination-­‐related	  error	  was	  detected	  whereas	  base	  substitution	  error	  was	  0.01%.	  	  Importantly,	  SGA	  detected	  drug-­‐resistance	  mutations	  (DRMs)	  missed	  by	  population	  sequencing.	  DRMs	  identified	  by	  SGA	  at	  levels	  of	  10-­‐35%	  in	  samples	  were	  detected	  only	  1	  in	  4	  times	  by	  population	  sequencing	  while	  DRMs	  below	  10%	  were	  rarely	  detected	  [72].	  Investigators	  have	  since	  used	  SGA	  to	  study	  HIV	  transmission	  and	  establish	  founder	  virus	  genotypes	  [11,	  73].	  SGA	  has	  also	  been	  employed	  to	  demonstrate	  the	  contribution	  of	  HIV	  latency	  to	  residual	  viremia	  in	  patients	  displaying	  HIV	  control	  by	  HAART	  [74].	  For	  all	  its	  merits,	  SGA	  is	  extremely	  resource-­‐intensive	  due	  to	  requirement	  for	  huge	  number	  of	  PCR	  reactions	  and	  individual	  determination	  of	  sequences	  in	  the	  positive	  reactions.	  Throughput	  in	  SGA	  studies	  has	  been	  in	  the	  order	  of	  hundred	  to	  a	  few	  thousand	  sequences	  with	  an	  average	  of	  less	  than	  100	  sequences	  per	  sample.	  Such	  numbers	  could	  still	  miss	  rare	  signatures	  in	  HIV	  populations	  important	  in	  a	  clinical	  setting,	  prompting	  the	  need	  for	  high-­‐throughput	  single	  molecule	  sequencing	  approaches.	  	  
	   23	  
Deep	  sequencing	  and	  associated	  computational	  techniques	  
	  The	  ability	  to	  perform	  numerous	  sequencing	  reactions	  in	  parallel	  on	  arrays	  has	  led	  to	  the	  rise	  of	  high-­‐throughput	  sequencing	  platforms	  [67].	  This	  involves	  several	  steps.	  From	  a	  sample	  of	  interest	  a	  library	  is	  prepared.	  This	  has	  fragmented	  whole	  genomes	  or	  amplified	  products	  from	  targeted	  regions	  with	  oligonucleotide	  adaptors	  attached	  at	  the	  ends	  of	  molecules.	  Next,	  clonal	  copies	  of	  DNA	  molecules	  sampled	  from	  the	  library	  are	  generated,	  either	  by	  emulsion	  PCR	  or	  bridge	  PCR	  with	  the	  oligonucleotide	  adaptors	  [67].	  Resulting	  clonal	  clusters	  are	  spatially	  distributed	  on	  an	  array	  and	  subjected	  simultaneously	  to	  cyclic	  flows	  of	  enzymes,	  nucleotides	  and	  other	  reagents.	  Sequencing	  by	  synthesis	  iteratively	  adds	  the	  appropriate	  nucleotide	  for	  each	  clone	  accompanied	  by	  a	  light	  signal.	  This	  information	  is	  captured	  over	  the	  entire	  array	  and	  across	  all	  flows.	  The	  imaging	  technology	  precisely	  resolves	  all	  clones	  on	  the	  array	  –	  in	  this	  way	  massively	  parallel	  sequencing	  determines	  a	  single	  sequence	  read	  per	  clone.	  
	  Illumina	  is	  currently	  the	  market	  leader	  among	  next	  generation	  sequencing	  (NGS)	  technologies	  [75].	  Per	  run	  100-­‐200	  Gb	  can	  be	  generated	  with	  yields	  up	  to	  1	  billion	  read	  clusters,	  each	  100-­‐150	  bases	  long	  (for	  paired	  ends,	  the	  numbers	  are	  2	  billion	  and	  2	  X	  100-­‐150	  bases	  respectively).	  Error	  rates	  are	  in	  the	  order	  of	  0.1%.	  The	  SOLiD	  platform	  offered	  by	  Life	  Technologies	  is	  a	  competitor	  in	  terms	  of	  information	  yield	  per	  run.	  Sequencing	  is	  performed	  by	  ligation	  of	  oligomer	  probes	  and	  is	  mediated	  by	  a	  DNA	  ligase,	  rather	  than	  polymerase	  [76].	  The	  same	  template	  is	  read	  multiple	  times	  beginning	  at	  positions	  frame-­‐shifted	  with	  respect	  to	  each	  other.	  This	  scheme	  ensures	  low	  error	  rates,	  however	  read	  lengths	  are	  shorter	  at	  ~60	  bases.	  Whereas	  Illumina	  uses	  bridge	  PCR,	  SOLiD	  relies	  on	  emulsion	  PCR	  to	  achieve	  clonal	  amplification.	  	  	  The	  third	  popular	  NGS	  platform	  is	  the	  454/Roche	  system	  [77].	  It	  employs	  emulsion	  PCR	  followed	  by	  a	  sequencing	  process	  based	  on	  pyrosequencing	  [78].	  Compared	  to	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the	  Illumina	  or	  SOLiD	  systems,	  a	  454	  run	  generates	  only	  around	  1	  million	  reads	  and	  it	  is	  also	  15-­‐30	  times	  costlier	  per	  base	  [79].	  Nevertheless	  454/Roche	  has	  its	  advantages	  such	  as	  faster	  run	  times	  and	  longer	  read	  lengths	  [79,	  80].	  It	  should	  be	  noted	  that	  numbers	  and	  figures	  quoted	  here	  for	  all	  NGS	  systems	  are	  current	  estimates	  (http://knowledgebank.blueseq.com/sequencing-­‐platforms/)	  and	  are	  subject	  to	  changes	  with	  continuous	  progress	  in	  technologies.	  	  454	  pyrosequencing	  was	  introduced	  in	  2005	  as	  the	  first	  commercially	  available	  NGS	  platform	  [77].	  Within	  a	  short	  time,	  researchers	  started	  using	  it	  for	  deep	  sequencing	  HIV	  populations	  [81,	  82].	  Longer	  read	  lengths	  help	  analyze	  polymorphism	  linkages	  on	  viral	  variants.	  Costs	  can	  be	  reduced	  by	  multiplexing	  samples	  by	  bar-­‐coding	  [82,	  83],	  which	  is	  easily	  done	  during	  library	  preparation.	  Also,	  the	  depth	  afforded	  by	  454/Roche	  is	  adequate	  to	  sample	  clinical	  samples	  of	  HIV.	  For	  these	  reasons	  454/Roche	  is	  a	  good	  NGS	  platform	  of	  choice	  for	  studying	  HIV	  diversity.	  All	  deep	  sequencing	  studies	  described	  in	  this	  dissertation	  have	  used	  it	  to	  gain	  valuable	  insights	  into	  existence	  of	  rare	  signatures	  in	  HIV	  swarms.	  	  With	  benefits	  of	  454/Roche	  comes	  the	  cost	  of	  sequencing	  errors	  [84].	  Homopolymers,	  or	  a	  succession	  of	  identical	  nucleotides,	  are	  a	  significant	  source	  of	  errors	  and	  arise	  due	  to	  non-­‐linearity	  of	  signal	  for	  a	  sequencing	  reaction	  flow	  cycle	  to	  number	  of	  nucleotides	  incorporated.	  Errors	  can	  inflate	  sample	  diversity	  and	  is	  crucial	  to	  correct	  interpretation	  of	  rare	  variants.	  Sophisticated	  algorithms	  have	  been	  developed	  for	  de-­‐noising	  pyrosequence	  data	  [85-­‐90].	  Of	  these	  the	  PyroNoise	  method	  developed	  by	  Quince	  et	  al	  is	  preferable	  as	  it	  uses	  raw	  flow	  data,	  which	  is	  the	  source	  of	  error,	  to	  interpret	  base	  calls.	  Other	  methods	  use	  sequence	  data,	  by	  which	  stage	  error	  may	  already	  be	  fixed.	  Reeder’s	  method	  utilizes	  flow	  data,	  however	  assignment	  of	  reads	  to	  solution	  haplotypes	  is	  based	  on	  a	  simplistic	  greedy	  clustering	  algorithm.	  Although	  this	  improves	  computational	  efficiency,	  there	  is	  a	  cost	  of	  mis-­‐assigning	  reads.	  PyroNoise	  has	  already	  been	  used	  to	  study	  viral	  populations	  in	  a	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report	  describing	  HCV	  transmission.	  In	  following	  chapters	  it	  has	  now	  been	  applied	  extensively	  in	  the	  analysis	  HIV	  populations.	  	  The	  need	  for	  multiple	  alignments	  of	  high-­‐throughput	  454	  data	  has	  been	  addressed	  with	  development	  of	  efficient	  multiple	  sequence	  alignment	  (MSA)	  tools	  such	  as	  Mosaik	  (http://bioinformatics.bc.edu/marthlab/Mosaik)	  and	  MUSCLE	  [91].	  In	  chapter	  2,	  a	  pipeline	  with	  PyroNoise	  followed	  by	  MSA	  based	  on	  a	  pair-­‐wise	  alignment	  strategy	  is	  presented.	  This	  reduces	  error	  to	  levels	  comparable	  to	  SGA.	  In	  contrast	  to	  SGA,	  PCR	  re-­‐sampling	  is	  another	  challenge	  inherent	  of	  the	  454/Roche	  process	  as	  library	  preparation	  involves	  bulk	  PCR	  amplification	  of	  samples.	  This	  issue	  is	  also	  addressed	  in	  Chapter	  2.	  Finally	  in	  all	  chapters,	  studies	  highlight	  the	  use	  of	  appropriate	  deeply	  sequenced	  control	  data	  to	  help	  in	  interpretation	  of	  rare	  biological	  signatures.	  Thus	  this	  dissertation	  illustrates	  that	  with	  careful	  experimental	  design	  and	  application	  of	  computational	  techniques,	  the	  power	  of	  deep	  sequencing	  can	  be	  reliably	  harnessed	  to	  gain	  significant	  insights	  into	  the	  nature	  of	  dynamic	  and	  diverse	  HIV	  swarms.	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Abstract	  
	  In	  this	  study	  we	  analyzed	  the	  pathways	  leading	  to	  resistance	  of	  HIV	  to	  the	  integrase	  (IN)	  inhibitor	  raltegravir	  (RAL).	  Three	  HIV-­‐infected	  individuals	  exhibiting	  RAL	  resistance	  pathway	  switching	  were	  characterized	  using	  longitudinal	  analysis	  of	  viral	  samples	  from	  plasma.	  454/Roche	  pyrosequencing	  was	  used	  to	  generate	  ~74,000	  sequence	  reads	  from	  the	  IN	  coding	  region.	  	  Effects	  of	  error	  were	  controlled	  by	  denoising	  with	  Pyronoise,	  and	  by	  comparison	  to	  ~142,000	  control	  reads	  from	  HIVNL4-­‐3.	  	  Viral	  lineages	  were	  modeled	  quantitatively	  using	  viral	  serial	  pathway	  analysis	  (vSPA).	  All	  three	  patients	  showed	  transitions	  from	  the	  N155H	  pathway	  to	  the	  Q148H/G140S	  pathway.	  	  Analysis	  with	  vSPA	  revealed	  complex	  pathways	  to	  the	  final	  genotype,	  probably	  involving	  both	  de	  novo	  mutation	  and	  recombination.	  	  No	  reads	  contained	  both	  the	  N155H	  and	  Q148H	  drug	  resistance	  mutations	  (DRMs),	  indicating	  that	  the	  double	  mutant	  is	  not	  a	  prominent	  intermediate,	  consistent	  with	  low	  fitness.	  	  To	  characterize	  possible	  drug	  resistant	  variants	  circulating	  prior	  to	  therapy,	  we	  sequenced	  ~70,000	  reads	  from	  samples	  collected	  prior	  to	  initiating	  treatment.	  	  Although	  some	  pre-­‐existing	  drug	  resistant	  variants	  were	  detected,	  N155H,	  the	  first	  major	  DRM	  present	  after	  initiating	  RAL	  therapy,	  was	  not	  detected.	  We	  conclude	  that	  the	  main	  DRMs	  are	  present	  at	  very	  low	  levels	  if	  at	  all	  prior	  to	  initiating	  therapy.	  We	  also	  outline	  general	  methods	  for	  deep	  sequence	  analysis	  of	  DRMs	  in	  longitudinal	  HIV	  samples.	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Introduction	  
	  The	  high	  mutation	  rate	  of	  HIV	  can	  result	  in	  rapid	  development	  of	  drug	  resistance	  [1,	  2].	  	  For	  raltegravir	  (RAL),	  which	  inhibits	  DNA	  strand	  transfer	  by	  integrase	  (IN)	  [3-­‐5],	  resistance	  mutations	  typically	  arise	  in	  the	  part	  of	  the	  IN	  gene	  encoding	  the	  catalytic	  domain	  [6-­‐8].	  Three	  codons	  can	  mutate	  to	  generate	  primary	  resistance	  mutations,	  which	  encode	  Y143R/C/H,	  Q148H/R/K	  and	  N155H.	  	  Each	  primary	  DRM	  is	  associated	  with	  a	  preferred	  set	  of	  accessory	  mutations	  [9,	  10].	  	  	  	   	  Patients	  who	  exhibited	  virologic	  failure	  following	  RAL	  treatment	  often	  switch	  from	  one	  resistance	  pathway	  to	  another	  [10,	  11].	  	  Specifically,	  the	  N155H	  pathway	  is	  commonly	  replaced	  by	  the	  Q148H/R/K	  pathway,	  resulting	  in	  reduced	  susceptibility	  to	  RAL	  and	  improved	  viral	  replication	  capacity	  [9,	  10].	  However,	  questions	  remain	  regarding	  the	  nature	  of	  the	  switch,	  such	  as	  whether	  resistance	  mutations	  were	  present	  before	  treatment,	  and	  the	  nature	  of	  intermediates	  during	  pathway	  switching.	  	  Here	  we	  investigated	  three	  patients	  for	  whom	  conventional	  viral	  population	  genotyping	  identified	  an	  N155H	  to	  Q148H	  pathway	  switch.	  Longitudinal	  analysis	  of	  viral	  population	  evolution	  under	  RAL	  pressure	  was	  performed	  using	  454/Roche	  pyrosequencing	  [12],	  which	  is	  well	  suited	  to	  tracking	  viral	  variants	  in	  complex	  populations	  [13-­‐20].	  	  We	  used	  the	  Pyronoise	  pre-­‐clustering	  method	  for	  controlling	  error	  [21]	  and	  performed	  longitudinal	  analysis	  of	  serially	  sampled	  viral	  populations	  using	  vSPA	  [22]	  for	  rigorous	  lineage	  analysis.	  	  	  Particularly	  deep	  sequencing	  was	  also	  carried	  out	  on	  pre-­‐treatment	  samples	  and	  controls	  to	  investigate	  the	  abundance	  of	  possible	  pre-­‐existing	  resistance	  mutations.	  	  
Results	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Participants	  studied	  	  The	  three	  patients	  studied	  were	  failing	  their	  existing	  HAART	  regimen	  and	  were	  administered	  RAL	  as	  salvage	  therapy.	  All	  of	  them	  exhibited	  a	  drop	  in	  the	  viral	  load	  in	  the	  first	  few	  weeks	  of	  RAL	  treatment,	  followed	  by	  a	  rebound	  with	  development	  of	  resistance.	  	  Population	  genotyping	  with	  Sanger	  sequencing	  identified	  N155H	  as	  one	  of	  the	  first	  IN	  DRMs	  to	  appear,	  but	  later	  the	  Q148H	  mutant	  predominated.	  For	  each	  patient	  we	  studied	  a	  baseline	  sample,	  obtained	  just	  prior	  to	  RAL	  initiation,	  and	  several	  time	  points	  after	  initiating	  therapy	  (Tables	  2.1	  and	  2.2).	  	  
# 454 reads # Pyronoise OTUs Patient Visit date 
Viral load 
(copies/ml) Month Total Fwd Rev Total Fwd Rev 
1 04/04/06 34300 0 293 162 131 22 13 9 
  07/05/06 8500 3 450 234 216 22 4 18 
  08/02/06 48100 4 305 193 112 11 9 2 
                    
2 07/11/06 40700 0 410 251 159 28 21 7 
  09/05/06 3630 2 28 14 14 12 6 6 
  10/03/06 16700 3 168 93 75 16 9 7 
  10/31/06 11400 4 489 250 239 13 9 4 
  11/28/06 31300 5 304 190 114 11 9 2 
  03/20/07 66600 8 1012 562 450 23 17 6 
  07/05/07 31100 12 550 307 243 16 13 3 
                    
3 05/30/06 36800 0 32 16 16 14 5 9 
  08/29/06 11000 3 19 12 7 9 4 5 
  10/24/06 31700 5 29 16 13 2 1 1 
  12/27/06 50000 7 5 3 2 3 2 1 
  05/22/07 95100 12 103 50 53 6 3 3 
Controls              
RNA - 50000 - 179 87 92 2 1 1 
DNA - - - 264 143 121 3 1 2 
                    
	  
Table	  2.1	  Plasma	  samples	  and	  controls	  studied	  in	  the	  low	  depth	  first	  pass	  experiment	  using	  
454/Roche	  GS	  FLX	  pyrosequencing.	  Sequencing	  was	  performed	  in	  both	  directions	  –	  forward	  (Fwd)	  and	  reverse	  (Rev).	  	  
Longitudinal	  samples	  assayed	  using	  pyrosequencing	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HIV	  RNA	  was	  extracted	  from	  each	  plasma	  sample,	  reverse-­‐transcribed,	  and	  PCR	  amplified	  to	  examine	  bases	  3906	  through	  4288	  (numbering	  of	  the	  HIV-­‐1NL4-­‐3	  genome).	  	  This	  corresponds	  to	  IN	  codons	  45-­‐171,	  which	  span	  the	  reported	  major	  DRM	  sites.	  	  PCR	  products	  were	  purified	  and	  sequenced	  using	  454/Roche	  pyrosequencing.	  	  RNA	  and	  DNA	  controls	  from	  HIV-­‐1NL4-­‐3	  were	  also	  included	  in	  this	  experiment.	  	  	  All	  samples	  analyzed	  are	  summarized	  in	  Table	  2.1.	  	  	  Control	  of	  error	  is	  central	  to	  studies	  of	  the	  low	  abundance	  resistance	  mutations.	  	  Error	  in	  this	  study	  could	  originate	  from	  the	  reverse	  transcription	  step,	  the	  PCR	  step,	  or	  the	  sequence	  determination	  step.	  	  We	  used	  Pyronoise	  for	  control	  of	  sequencing	  error	  [21].	  	  Pyronoise	  operates	  in	  a	  Bayesian	  framework	  to	  cluster	  sequence	  reads	  as	  light	  intensity	  values	  (flowgrams)	  prior	  to	  interpretation	  as	  base	  calls.	  	  	  The	  resulting	  clusters	  are	  termed	  operational	  taxonomic	  units	  or	  OTUs.	  	  The	  number	  of	  Pyronoise	  OTUs	  was	  then	  interpreted	  as	  the	  number	  of	  unique	  variants	  at	  each	  time	  point	  (Table	  2.1).	  	  No	  single	  OTU	  occurred	  in	  more	  than	  one	  patient	  and	  no	  HIV-­‐1NL4-­‐3	  control	  OTU	  was	  detected	  in	  any	  patient.	  Thus	  there	  was	  no	  detectable	  contamination	  between	  samples.	  	   	  To	  determine	  the	  optimal	  parameters	  for	  use	  in	  the	  Pyronoise	  analysis,	  we	  generated	  a	  first	  set	  of	  parallel	  HIV-­‐1NL4-­‐3	  controls	  (443	  reads;	  Table	  2.1),	  wherein	  the	  correct	  number	  of	  OTUs	  is	  known	  to	  be	  one	  (Figure	  2.1a,b).	  	  Under	  the	  parameters	  used,	  the	  two	  HIV-­‐1NL4-­‐3	  RNA	  read	  sets	  (one	  each	  for	  forward	  and	  reverse	  direction	  sequencing)	  each	  yielded	  one	  OTU,	  whereas	  the	  HIV-­‐1NL4-­‐3	  DNA	  sets	  yielded	  one	  and	  two	  OTUs.	  	  Examination	  of	  the	  output	  showed	  that	  an	  artifact	  at	  the	  extreme	  edge	  of	  the	  sequence	  reads	  led	  to	  the	  formation	  of	  two	  OTUs	  in	  one	  DNA	  control	  set.	  	  Thus	  we	  conclude	  that	  Pyronoise	  processing	  resulted	  in	  effective	  though	  not	  perfect	  control	  of	  inflation	  of	  OTU	  numbers	  due	  to	  sequencing	  error.	  	  A	  much	  larger	  set	  of	  141,582	  HIV-­‐1NL4-­‐3	  reads	  was	  generated	  for	  comparison	  to	  deep	  analysis	  of	  pretreatment	  time	  points	  and	  is	  discussed	  below.	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RNA	  from	  HIV-­‐1NL4-­‐3	  particles	  was	  purified,	  amplified	  by	  RT-­‐PCR,	  and	  analyzed	  by	  454/Roche	  pyrosequencing.	  	  After	  filtering	  for	  error-­‐prone	  reads,	  sequences	  were	  denoised	  using	  Pyronoise,	  which	  pre-­‐clusters	  reads	  based	  on	  light	  intensity	  values	  for	  each	  flow	  prior	  to	  interpretation	  as	  base	  calls.	  	  Alignments	  of	  a	  subset	  of	  reads	  are	  shown	  before	  denoising	  (a)	  and	  after	  denoising	  (b).	  	  	  The	  effects	  of	  denoising	  were	  also	  compared	  at	  each	  position	  in	  the	  HIV-­‐1NL4-­‐3	  sequences	  studied	  (c	  and	  
d).	  	  Shown	  are	  sequences	  from	  the	  forward	  reads.	  	  The	  base	  position	  is	  shown	  on	  the	  x-­‐axis	  and	  the	  error	  rate	  is	  shown	  on	  the	  y-­‐axis.	  Positions	  are	  assigned	  a	  homopolymer	  index	  of	  1-­‐5	  (refer	  key)	  based	  on	  their	  location	  on	  a	  homopolymer.	  For	  example,	  a	  position	  with	  index	  3	  carries	  a	  base	  that	  occupies	  the	  3rd	  place	  on	  a	  homopolymer	  with	  a	  minimum	  length	  of	  3.	  Results	  are	  compared	  before	  denoising	  (c)	  and	  after	  denoising	  (d).	  The	  error	  rates	  in	  the	  high	  quality	  parts	  of	  the	  reads	  were	  1.2e-­‐3	  before	  denoising	  and	  5e-­‐4	  after	  denoising.	  
Figure	  2.1	  Results	  of	  denoising	  control	  data	  using	  Pyronoise.	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We	  estimated	  the	  error	  for	  the	  reverse	  transcription	  step	  to	  be	  2e-­‐4	  base	  substitutions	  per	  nucleotide	  by	  comparing	  the	  HIV-­‐1NL4-­‐3	  DNA	  and	  RNA	  sets.	  	  For	  PCR,	  the	  error	  rate	  (estimated	  by	  the	  manufacturer)	  is	  1e-­‐5	  base	  substitutions	  per	  nucleotide	  per	  replication	  cycle,	  which	  results	  in	  1.75e-­‐4	  base	  substitutions	  per	  nucleotide	  over	  35	  cycles	  of	  PCR.	  Thus	  pre-­‐sequencing	  misincorporations	  add	  up	  to	  3.75e-­‐4	  per	  nucleotide.	  	  Comparison	  to	  the	  measured	  overall	  rate	  leaves	  ~	  8e-­‐4	  base	  substitutions	  per	  nucleotide	  resulting	  from	  the	  pyrosequencing	  procedure.	  This	  is	  applicable	  to	  the	  highest	  quality	  portion	  of	  the	  reads	  over	  which	  such	  errors	  are	  uniform.	  	  In	  the	  3'	  part	  of	  the	  reads,	  the	  error	  rate	  rises	  sharply,	  as	  illustrated	  in	  Figure	  2.1c,d	  with	  data	  generated	  from	  re-­‐sequencing	  of	  HIVNL4-­‐3.	  	  The	  presence	  of	  homopolymers	  had	  no	  influence	  on	  base	  substitution	  frequency	  with	  our	  alignment	  protocol.	  Our	  pyrosequencing	  error	  is	  slightly	  lower	  than	  that	  in	  previous	  studies,	  which	  used	  full	  reads	  and	  not	  just	  high	  quality	  regions	  [14,	  15,	  23].	  	  A	  multiple	  sequence	  alignment	  (MSA)	  was	  constructed	  with	  denoised	  OTUs.	  	  Positions	  of	  codon	  polymorphisms	  within	  each	  patient	  over	  time	  are	  shown	  in	  Figure	  2.2.	  	  The	  sequence	  reads	  were	  then	  translated	  in	  silico,	  and	  the	  known	  IN	  DRM	  sites	  were	  abstracted	  to	  create	  an	  IN	  resistance	  amino	  acid	  profile	  for	  each	  patient	  (Figure	  2.3).	  	  	  	  
Longitudinal	  analysis	  of	  drug	  resistance	  pathways	  	   	  In	  the	  pyrosequence	  data,	  the	  majority	  of	  early	  primary	  mutations	  encoded	  N155H	  in	  all	  three	  patients,	  whereas	  the	  majority	  of	  later	  primary	  mutations	  encoded	  Q148H,	  confirming	  the	  pathway	  switch	  inferred	  from	  population	  genotyping.	  	  There	  was	  no	  evidence	  of	  any	  double	  mutant	  variants	  harboring	  both	  155	  and	  148	  pathway	  primary	  mutations.	  All	  DRMs	  detected	  by	  population	  genotyping	  (Table	  2.1)	  were	  also	  detected	  by	  deep	  sequencing.	  A	  methodological	  concern	  is	  that	  recombination	  during	  RT-­‐PCR	  in	  vitro	  may	  link	  DRMs	  artifactually,	  but	  no	  recombinants	  encoding	  both	  substitutions	  were	  observed.	  	  We	  did	  not	  find	  evidence	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of	  pre-­‐existing	  IN	  inhibitor-­‐related	  primary	  mutations	  (positions	  143,	  148	  and	  155)	  prior	  to	  initiating	  therapy	  in	  this	  first	  pass	  analysis.	  	  
Nucleic	  acid	  sequences	  are	  shown	  for	  the	  three	  participants:	  (a)	  patient	  1;	  (b)	  patient	  2;	  (c)	  patient	  3.	  For	  economy	  of	  display,	  only	  codons	  with	  polymorphisms	  over	  the	  time-­‐course	  studied	  are	  shown.	  The	  display	  shows	  the	  sequence	  of	  each	  OTU	  detected	  without	  reference	  to	  their	  abundance.	  	  The	  
Figure	  2.2	  Sequence	  analysis	  of	  HIV	  populations	  in	  three	  patients	  treated	  with	  RAL	  and	  
undergoing	  pathway	  switches	  from	  N155H	  to	  Q148	  +	  G140S.	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numbers	  to	  the	  left	  of	  each	  panel	  show	  the	  cumulative	  number	  of	  OTUs,	  the	  numbers	  to	  the	  right	  indicate	  the	  number	  of	  months	  since	  initiating	  therapy.	  	  A	  key	  to	  nucleic	  acid	  designations	  is	  shown	  at	  the	  bottom.	  
	  
Amino	  acid	  profiles	  of	  OTUs	  for	  each	  subject	  were	  generated	  by	  conceptual	  translation:	  (a)	  patient	  1;	  Figure	  2.3	  Inferred	  amino	  acid	  substitutions	  for	  each	  patient	  at	  DRM	  positions.	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(b)	  patient	  2;	  (c)	  patient	  3.	  	  For	  economy	  of	  display,	  only	  those	  codons	  encoding	  amino	  acid	  residues	  implicated	  in	  drug	  resistance	  are	  shown.	  	  IN	  DRM	  positions	  are	  listed	  along	  the	  x-­‐axis.	  The	  profiles	  are	  grouped	  horizontally	  by	  time-­‐point.	  The	  width	  of	  each	  horizontal	  bar	  indicates	  the	  total	  number	  of	  sequences	  recovered	  with	  each	  amino	  acid	  profile.	  	  To	  track	  the	  evolution	  of	  drug-­‐resistance	  lineages	  in	  a	  rigorous	  fashion,	  we	  used	  the	  vSPA	  algorithm	  [22].	  	  For	  each	  sequence,	  a	  normalized	  distance	  vector	  over	  all	  other	  sequences	  is	  used	  to	  construct	  a	  correlation	  matrix.	  	  	  Sequences	  with	  more	  than	  a	  threshold	  correlation	  coefficient	  are	  clustered	  together	  based	  on	  a	  distribution	  of	  such	  matrices	  obtained	  from	  permuted	  datasets,	  and	  clusters	  across	  serial	  samples	  are	  linked	  based	  on	  average	  genetic	  distance	  to	  yield	  a	  longitudinal	  phylogenetic	  network	  (Figure	  2.4).	  	  	  In	  patient	  1	  at	  month	  3	  after	  initiating	  treatment,	  N155H	  predominated,	  though	  there	  were	  rare	  variants	  with	  Q148R	  and	  Q148H	  present	  (Figures	  2.2a	  and	  2.4a).	  	  Some	  but	  not	  all	  of	  the	  Q148H	  codons	  were	  associated	  with	  G140S	  (middle	  of	  Month	  3	  panel	  in	  Figures	  2.2a	  and	  2.4a).	  	  Even	  though	  the	  most	  common	  substitution	  at	  position	  148	  at	  month	  3	  encodes	  Q148R,	  it	  does	  not	  occur	  together	  with	  any	  accessory	  mutations	  at	  codons	  138	  or	  140.	  	  Two	  separate	  lineages	  were	  detected	  at	  all	  three	  time-­‐points,	  distinguished	  by	  polymorphisms	  at	  codons	  encoding	  amino	  acids	  124,	  125,	  129,	  130,	  and	  139	  (Figures	  2.2a	  and	  2.4a).	  	  Each	  of	  the	  collections	  of	  DRMs	  (N155H,	  Q148R,	  and	  Q148H	  +	  G140S)	  was	  found	  on	  both	  backgrounds.	  	  For	  most	  of	  the	  mutations,	  it	  is	  simplest	  to	  assume	  that	  the	  mutations	  arose	  once	  and	  recombined	  onto	  the	  different	  backgrounds.	  	  However,	  for	  the	  G140S	  mutation,	  the	  codon	  is	  directly	  adjacent	  to	  the	  polymorphic	  codon	  139,	  so	  in	  this	  case	  recombination	  would	  need	  to	  break	  exactly	  between	  the	  two	  codons	  to	  generate	  the	  observed	  genotypes.	  	  Thus,	  independent	  mutations	  to	  generate	  the	  G140S	  substitution	  on	  the	  two	  backgrounds	  seem	  more	  likely.	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  (a)	  patient	  1;	  (b)	  patient	  2;	  (c)	  patient	  3.	  The	  color	  of	  the	  cluster	  corresponds	  to	  the	  frequency	  of	  its	  membership	  from	  among	  sequences	  in	  that	  time-­‐point	  (see	  color	  code).	  vSPA	  reports	  all	  mutations	  relative	  to	  a	  baseline	  (in	  this	  case	  month	  0)	  ancestral	  cluster	  that	  arise	  at	  a	  level	  2x	  or	  more	  in	  a	  descendent	  cluster.	  Primary	  mutations	  are	  in	  red,	  accessory	  ones	  in	  black	  and	  others	  in	  green	  (shown	  as	  the	  encoded	  amino	  acids).	  Mutations	  marked	  with	  an	  asterisk	  are	  not	  known	  to	  be	  associated	  with	  any	  primary	  DRM.	  	  Clusters	  can	  contain	  one	  or	  many	  OTUs.	  The	  proportion	  of	  OTUs	  within	  a	  cluster	  carrying	  a	  particular	  mutation	  is	  indicated	  in	  parenthesis.	  	  Patient	  2	  also	  showed	  N155H	  switching	  to	  Q148H	  +	  G140S,	  but	  N155H	  was	  still	  detected	  at	  low	  abundance	  even	  after	  8	  months	  of	  therapy,	  and	  a	  complex	  collection	  of	  intermediates	  were	  detected	  over	  the	  period	  sampled.	  	  After	  three	  months	  of	  therapy,	  N155H,	  Q148K	  and	  Q148R	  all	  coexisted	  (Figures	  2.2b	  and	  2.4b).	  	  The	  Q148K	  +	  E138K	  combination	  was	  evident	  at	  month	  3,	  and	  though	  this	  combination	  is	  reported	  to	  be	  a	  potent	  RAL	  escape	  variant	  [8]	  ,	  it	  was	  not	  detected	  subsequently.	  	  By	  month	  4,	  only	  the	  N155H	  variants	  were	  detected,	  whereas	  by	  month	  8	  Y143R,	  Q148H	  and	  N155H	  all	  were	  detected.	  At	  month	  12,	  Q148H	  was	  the	  majority	  but	  N155H	  was	  still	  detectable,	  whereas	  Y143R	  was	  not.	  Patient	  2	  was	  the	  only	  subject	  where	  Y143R	  and	  N155H	  were	  detectable	  at	  later	  time-­‐points.	  Tracking	  the	  origin	  of	  drug	  resistance	  lineages	  using	  vSPA	  indicated	  that	  all	  primary	  DRMs	  derived	  from	  a	  single	  ancestral	  cluster	  present	  before	  initiation	  of	  therapy.	  We	  also	  detected	  T97A,	  an	  accessory	  mutation	  for	  Y143R,	  and	  L74M	  and	  E92Q,	  accessory	  mutations	  for	  N155H,	  from	  the	  forward	  read	  sets	  (data	  not	  shown).	  	  	  	  In	  Patient	  3,	  three	  clusters	  were	  detected	  at	  time	  0,	  one	  of	  which	  went	  on	  to	  give	  rise	  to	  the	  N155H	  drug	  resistant	  lineages	  by	  month	  3.	  	  A	  different	  lineage	  derived	  from	  the	  same	  ancestral	  group	  emerged	  at	  month	  5	  and	  acquired	  the	  Q148H	  +	  G140S	  mutations,	  which	  persisted	  thereafter.	  	  Q148H	  replaced	  N155H	  after	  5	  months.	  	  
Figure	  2.4	  Evolutionary	  network	  of	  mutations	  following	  RAL	  treatment	  inferred	  using	  
vSPA	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In	  depth	  analysis	  of	  pre-­treatment	  time	  points	  	   	  An	  important	  question	  in	  understanding	  the	  origin	  of	  RAL	  resistance	  is	  whether	  resistance	  mutations	  were	  present	  in	  the	  viral	  population	  prior	  to	  initiation	  of	  therapy.	  	  We	  thus	  carried	  out	  deeper	  sequencing	  analysis	  of	  the	  pre-­‐treatment	  time-­‐point.	  	  RT-­‐PCR	  products	  were	  sequenced	  in	  both	  directions,	  yielding	  69,862	  sequence	  reads,	  ranging	  from	  ~18,000	  to	  ~26,000	  for	  each	  of	  the	  three	  participants.	  	  	  	  
Patient Viral load Pre-RT-PCR Read # 454  Denoised Sampling statistics 
# copies/ml # genomes direction reads # OTUs Prop independent Variance 
    "n"  "s"  E(Y/s) Var(Y)/s2 
           Simulations Formula Simulations Formula 
Forward 19483 3374 0.7162 0.7160 4.21E-06 5.66E-06 1 34300 27440 
Reverse 6666 1249 0.8879 0.8878 1.33E-05 1.22E-05 
Forward 12824 2574 0.8267 0.8266 7.37E-06 8.00E-06 2 40700 32560 
Reverse 4815 1413 0.9301 0.9296 8.92E-06 1.20E-05 
Forward 18558 2512 0.7422 0.7418 4.73E-06 6.01E-06 3 36800 29440 
Reverse 7516 1223 0.8828 0.8826 1.24E-05 1.11E-05 
	  
Table	  2.2	  Pre-­treatment	  plasma	  samples	  studied	  in	  depth	  by	  454/Roche	  Titanium	  
pyrosequencing.	  Viral	  load	  values	  for	  the	  baseline	  time-­‐point	  for	  each	  patient	  are	  indicated.	  “n”	  gives	  the	  estimate	  of	  the	  number	  of	  starting	  templates	  in	  the	  RT-­‐PCR	  reaction.	  “s”	  represents	  the	  sampling	  size	  –	  sample	  is	  drawn	  from	  a	  pool	  of	  amplified	  templates	  (here	  35	  cycles	  of	  PCR).	  Sampling	  statistics	  provides	  an	  estimate	  of	  numbers	  of	  starting	  templates	  actually	  sampled.	  The	  mean	  proportion	  of	  independent	  templates	  assayed	  (‘Prop	  Independent’)	  is	  indicated	  along	  with	  its	  variance.	  Estimates	  from	  both	  simulation	  studies	  and	  formulae	  described	  to	  assess	  re-­‐sampling	  are	  tallied	  (see	  text	  for	  details	  of	  simulation	  and	  formulae).	  	  In	  designing	  such	  a	  study,	  it	  is	  desirable	  to	  avoid	  sequencing	  multiple	  PCR	  products	  derived	  from	  a	  single	  viral	  genome,	  as	  this	  would	  waste	  sequencing	  effort	  and	  potentially	  confuse	  the	  analysis.	  	  To	  minimize	  this	  potential	  problem,	  the	  number	  of	  viral	  RNA	  templates	  in	  each	  RT-­‐PCR	  reaction	  was	  arranged	  to	  be	  greater	  than	  the	  number	  of	  pyrosequence	  reads	  ultimately	  determined	  (Table	  2.2).	  	  	  For	  each	  sample,	  800µl	  of	  plasma	  was	  used	  for	  RNA	  purification,	  and	  all	  was	  used	  for	  RT-­‐PCR,	  so	  the	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predicted	  numbers	  of	  templates	  (assuming	  full	  recovery	  of	  RNA)	  were	  27440,	  32560,	  and	  29440	  for	  patients	  1-­‐3	  respectively.	  	  The	  numbers	  of	  sequences	  for	  each	  sample	  were	  lower,	  24937,	  16461,	  and	  24943	  respectively,	  and	  distributed	  between	  the	  forward	  and	  reverse	  directions	  (Table	  2.2).	  	  	  	   	  	  An	  important	  question	  centers	  on	  how	  many	  of	  our	  sequence	  reads	  corresponded	  to	  different	  viral	  genomes	  present	  in	  the	  initial	  pre-­‐amplification	  sample,	  and	  how	  many	  were	  duplicates	  generated	  during	  PCR.	  We	  devised	  a	  general	  formula	  relating	  the	  number	  of	  viral	  genomes	  in	  the	  starting	  sample	  to	  the	  number	  observed	  in	  the	  sequence	  output	  (Methods	  section).	  	  	  For	  the	  three	  pre-­‐treatment	  samples,	  we	  calculated	  72-­‐93%	  of	  the	  sequence	  reads	  corresponded	  to	  independent	  viral	  genomes	  from	  the	  starting	  RNA	  sample	  (Table	  2.2).	  	  	  
Figure	  2.5	  Reproducibility	  of	  OTU	  recoveries	  in	  duplicate	  analyses	  of	  the	  pre-­treatment	  
samples.	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In	  this	  study,	  the	  pre-­‐treatment	  time-­‐points	  were	  analyzed	  twice,	  once	  in	  the	  low	  depth	  first	  pass	  analysis,	  then	  again	  in	  our	  deeper	  re-­‐sequencing	  study,	  allowing	  a	  comparison	  of	  the	  OTUs	  recovered.	  	  The	  x-­‐	  and	  y-­‐axes	  show	  the	  relative	  proportion	  of	  each	  OTU	  in	  the	  two	  experiments.	  	  The	  red	  lines	  indicate	  the	  5%	  abundance	  cut-­‐off.	  	  To	  compare	  consistency,	  we	  asked	  for	  how	  many	  OTUs	  did	  the	  placement	  in	  <5%	  or	  >5%	  abundance	  cut-­‐off	  groups	  agree	  (that	  is,	  in	  how	  many	  cases	  were	  samples	  in	  the	  lower	  left	  or	  upper	  right	  quadrants,	  indicating	  concordance).	  	  4,050	  OTUs	  showed	  concordance,	  or	  99.7%	  of	  the	  total.	  	  We	  next	  investigated	  the	  numbers	  of	  variants	  present	  in	  the	  pre-­‐treatment	  samples.	  To	  assess	  reproducibility,	  the	  results	  from	  the	  first	  pass	  low	  coverage	  analysis	  of	  the	  pre-­‐treatment	  samples	  were	  compared	  to	  the	  second	  much	  deeper	  analysis.	  OTU	  sets	  were	  reconstructed	  and	  analyzed	  for	  the	  high	  accuracy	  5'	  part	  of	  the	  reads	  for	  both	  experiments.	  We	  plotted	  the	  proportion	  of	  reads	  contributed	  by	  each	  OTU	  within	  each	  participant	  in	  the	  two	  experiments	  (Figure	  2.5).	  	  	  OTUs	  mostly	  fell	  near	  a	  line	  from	  lower	  left	  to	  upper	  right,	  indicating	  rough	  reproducibility	  between	  experiments.	  	  To	  assess	  concordance,	  we	  divided	  OTUs	  into	  those	  in	  the	  upper	  95%	  of	  abundance	  or	  lower	  5%	  in	  each	  experiment	  (Figure	  2.5,	  indicated	  by	  red	  lines),	  and	  asked	  how	  many	  OTUs	  were	  concordant	  between	  experiments	  (that	  is	  present,	  in	  the	  lower	  left	  and	  upper	  right	  quadrants).	  	  We	  found	  that	  4,050	  out	  of	  4,062	  or	  99.7%	  of	  OTUs	  were	  concordant	  between	  experiments	  by	  this	  measure.	  	  	   	  454/Roche	  pyrosequence	  determination	  is	  error	  prone,	  making	  identification	  of	  low-­‐level	  DRMs	  challenging.	  	  We	  used	  two	  strategies	  to	  distinguish	  low-­‐level	  authentic	  DRMs	  in	  patient	  samples	  from	  spurious	  DRMs	  arising	  from	  error.	  	  In	  the	  first,	  we	  determined	  an	  additional	  141,582	  reads	  for	  the	  same	  IN	  amplicon	  on	  a	  homogeneous	  HIVNL4-­‐3	  template,	  calculated	  the	  frequency	  of	  false	  calls	  of	  DRMs	  on	  HIVNL4-­‐3,	  and	  then	  compared	  these	  frequencies	  to	  those	  observed	  in	  patient	  baseline	  samples.	  	  In	  the	  second	  strategy,	  we	  measured	  the	  error	  frequencies	  in	  the	  HIVNL4-­‐3	  data,	  and	  used	  them	  to	  model	  the	  expected	  frequency	  of	  spurious	  DRMs	  in	  the	  patient	  samples.	  	  The	  first	  approach	  has	  the	  advantage	  of	  modeling	  all	  aspects	  of	  the	  sequence	  acquisition	  process,	  whereas	  the	  second	  method	  allows	  larger	  numbers	  of	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in	  silico	  generated	  control	  sequences	  to	  be	  compared	  to	  the	  patient	  sequences.	  For	  both,	  only	  the	  reverse	  reads	  were	  used	  because	  these	  had	  the	  highest	  quality	  bases	  over	  the	  relevant	  143-­‐155	  coding	  positions.	  
(a)	   	  
Patient   Y143C Y143H Y143R Q148H Q148K Q148R N155H 
Raw Reads 0.5481 0.0808 1.0000 1.0000 0.1602 0.6102 0.1602 1 
PyroNoised 0.9277 0.0110 1.0000 1.0000 0.1647 1.0000 1.0000 
Raw Reads 0.4480 0.1477 1.0000 0.1937 1.0000 0.7862 1.0000 2 
PyroNoised 0.7480 0.0221 1.0000 0.1234 1.0000 0.1234 1.0000 
Raw Reads 0.5135 0.0010 1.0000 0.6915 0.1780 0.4659 1.0000 3 
PyroNoised 0.9958 0.0001 1.0000 0.1828 1.0000 0.0259 1.0000 
  Significance based on Fisher's exact test 
  Significance maintained after Bonferroni correction for multiple testing 	  
(b)	  
Patient   Y143C Y143H Y143R Q148H Q148K Q148R N155H 
Prop 
DRM 0.0009 0.0016 0.0000 0.0000 0.0002 0.0011 0.0002 
Expt OBS 6 10 0 0 1 7 1 
Sim Av 3 3 0 5 3 3 3 
Sim MAX 10 12 1 16 11 10 11 
1 
P Value 0.0488 0.0005 1.0000 1.0000 0.9280 0.0194 0.9273 
Prop 
DRM 0.0011 0.0015 0.0000 0.0004 0.0000 0.0008 0.0000 
Expt OBS 5 7 0 2 0 4 0 
Sim Av 2 2 0 4 2 2 2 
Sim MAX 10 10 1 14 10 9 9 
2 
P Value 0.0487 0.0030 1.0000 0.8952 1.0000 0.1355 1.0000 
Prop 
DRM 0.0010 0.0023 0.0000 0.0001 0.0001 0.0012 0.0000 
Expt OBS 7 17 0 1 1 9 0 
Sim Av 3 3 0 6 3 3 3 
Sim MAX 11 11 1 18 11 12 11 
3 
P Value 0.0312 0.0000 1.0000 0.9974 0.9506 0.0045 1.0000 
Prop DRM Experimentally observed proportion of DRM codons of the indicated type  
Expt OBS Experimentally observed number of DRM codons of the indicated type 
Sim Av Average #DRM substitutions due to error from 10,000 simulations 
Sim MAX Highest #DRM substitutions in any of the 10,000 simulations  
  Significance based on ranking P values from 10,000 simulations 
  Significance maintained after Bonferroni correction for multiple testing 
	  
Table	  2.3	  Analysis	  of	  possible	  DRM	  substitutions	  present	  in	  subjects	  prior	  to	  initiation	  of	  RAL	  
therapy.	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(a)	  P	  values	  for	  the	  comparison	  of	  DRMs	  at	  codons	  143,	  148,	  and	  155	  in	  the	  pre-­‐treatment	  samples	  to	  error	  rate	  measured	  with	  the	  HIV-­‐1NL4-­‐3	  sequence	  controls.	  	  Analysis	  was	  carried	  out	  both	  before	  and	  after	  denoising	  with	  Pyronoise.	  (b)	  DRMs	  called	  as	  significantly	  enriched	  based	  on	  simulated	  frequencies	  of	  false	  calls.	  	  Simulations	  were	  carried	  out	  on	  pre-­‐denoised	  data	  using	  a	  model	  error	  rate	  as	  described	  in	  the	  methods	  section.	  	  Table	  2.3a	  shows	  the	  P	  values	  for	  detection	  of	  the	  major	  DRMs	  at	  amino	  acids	  143,	  148,	  and	  155	  in	  pre-­‐treatment	  patient	  samples	  when	  compared	  to	  the	  HIVNL4-­‐3	  empirical	  control.	  The	  results	  are	  compared	  for	  both	  the	  raw	  sequence	  data	  and	  denoised	  data.	  	  A	  few	  substitutions	  show	  potential	  significance,	  including	  Y143H	  in	  all	  patients	  and	  Q148R	  in	  patient	  3	  (Table	  2.3a,	  pink	  and	  red	  shading).	  	  However,	  after	  correction	  for	  multiple	  comparisons,	  only	  Y143H	  in	  patient	  3	  maintained	  significance	  (Table	  2.3a,	  red	  shading).	  	  	  	   	  A	  similar	  analysis	  was	  carried	  out	  comparing	  the	  pre-­‐treatment	  patient	  sequencing	  data	  to	  simulations	  of	  DRM	  accumulation	  due	  to	  error	  (Table	  2.3b).	  	  For	  this,	  the	  error	  rate	  of	  1.2e-­‐3	  was	  used	  to	  generate	  a	  set	  of	  codons	  equal	  to	  the	  number	  sampled	  for	  each	  patient	  at	  each	  codon.	  	  A	  total	  of	  10,000	  such	  simulations	  were	  carried	  out,	  and	  the	  relationship	  of	  the	  observed	  data	  to	  simulated	  data	  assessed.	  	  Following	  correction	  for	  multiple	  comparisons,	  Y143H	  attained	  significance	  in	  both	  patient	  1	  and	  3,	  but	  no	  other	  positions	  survived	  the	  test	  for	  multiple	  comparisons.	  	   	  In	  all	  three	  patients,	  N155H,	  which	  was	  the	  first	  DRM	  to	  arise	  after	  RAL	  therapy,	  as	  well	  as	  Q148H,	  which	  was	  the	  majority	  primary	  DRM	  after	  pathway	  switch,	  were	  not	  significantly	  enriched	  in	  the	  pre-­‐treatment	  samples.	  	  Thus	  pre-­‐existing	  mutations	  did	  not	  contribute	  detectably	  to	  treatment	  failure.	  	   	   	  
Discussion	  	   	  
	   51	  
We	  analyzed	  the	  evolutionary	  dynamics	  of	  RAL	  DRMs	  for	  three	  patients	  who	  showed	  a	  switch	  from	  the	  N155H	  to	  the	  Q148H	  pathway.	  We	  describe	  an	  analytical	  pipeline	  based	  on	  Pyronoise	  and	  vSPA	  that	  may	  be	  useful	  for	  longitudinal	  tracking	  of	  DRMs	  in	  the	  future,	  though	  we	  note	  that	  computational	  feasibility	  becomes	  an	  issue	  with	  larger	  data	  sets.	  	  The	  pathways	  leading	  to	  the	  final	  states	  were	  complex,	  probably	  involving	  multiple	  rounds	  of	  point	  mutation	  to	  generate	  new	  variants	  and	  recombination	  to	  assemble	  variants	  on	  a	  single	  genome.	  	  	  	   	  Following	  our	  initial	  survey,	  we	  sequenced	  deeply	  into	  the	  pre-­‐treatment	  time-­‐point	  to	  assess	  whether	  genomes	  containing	  DRMs	  that	  became	  abundant	  after	  treatment	  were	  detectable	  before	  treatment.	  Comparisons	  to	  control	  sequences	  from	  HIVNL4-­‐3	  or	  to	  results	  of	  simulations	  showed	  that	  most	  DRMs	  were	  not	  convincingly	  detectable	  above	  the	  error	  background.	  	  We	  did	  find	  significant	  enrichment	  for	  Y143H	  in	  one	  patient	  by	  all	  measures,	  and	  possible	  enrichment	  in	  a	  second	  patient	  (marginally	  significant	  relative	  to	  HIVNL4-­‐3	  and	  significant	  relative	  to	  simulated	  data).	  	  The	  Y143C	  and	  Q148R	  substitutions	  were	  marginally	  significant	  by	  some	  measures	  but	  did	  not	  survive	  correction	  for	  multiple	  comparisons.	  	  Codoner	  et	  al.	  [23]	  also	  investigated	  RAL	  resistance	  using	  454	  sequencing,	  and	  reported	  detection	  of	  Y143H,	  Y143C	  and	  Q148R	  prior	  to	  initiation	  of	  therapy.	  	  Our	  findings	  taken	  together	  support	  the	  idea	  that	  Y143H,	  and	  possibly	  Y143C	  and	  Q148R,	  are	  authentic	  replication-­‐competent	  polymorphisms	  that	  are	  present	  in	  viral	  populations	  in	  the	  absence	  of	  RAL.	  	   	  One	  of	  the	  main	  questions	  in	  initiating	  this	  analysis	  was	  whether	  the	  first	  resistance	  mutation	  to	  arise,	  N155H,	  was	  present	  prior	  to	  initiating	  therapy.	  	  We	  found	  a	  single	  read	  for	  this	  DRM	  over	  all	  patients,	  which	  is	  readily	  attributable	  to	  error.	  	  Thus,	  the	  primary	  DRM	  that	  appeared	  immediately	  after	  treatment	  initiation	  was	  not	  detectable	  before	  treatment	  initiation,	  despite	  sequencing	  to	  a	  depth	  of	  ~19,000	  reads	  in	  the	  reverse	  direction,	  wherein	  the	  DRM	  positions	  are	  of	  highest	  quality.	  	  Similarly	  for	  Q148H,	  the	  major	  form	  at	  the	  last	  time-­‐point,	  only	  3	  reads	  were	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detected,	  a	  number	  also	  attributable	  to	  error.	  This	  is	  consistent	  with	  the	  idea	  that	  viruses	  with	  N155H	  or	  Q148H	  substitutions	  are	  considerably	  less	  fit	  than	  wild-­‐type,	  and	  so	  are	  very	  low	  in	  abundance	  in	  the	  absence	  of	  pressure	  from	  RAL.	  	  
Materials	  and	  Methods	  
	  
Deep	  sequencing	  of	  viral	  populations	  	  Plasma	  samples	  were	  obtained	  from	  patients	  at	  multiple	  time-­‐points	  and	  sequenced	  (Tables	  2.1	  and	  2.2).	  RNA	  was	  purified	  from	  200	  µl	  plasma	  using	  the	  MagNA	  Pure	  LC	  extraction	  system	  (Roche	  Applied	  Science,	  Indianapolis,	  IN).	  	  A	  plasmid	  clone	  encoding	  HIV-­‐1NL4-­‐3	  was	  used	  as	  a	  control	  DNA,	  and	  particles	  were	  generated	  by	  transfection	  and	  used	  as	  control	  viral	  RNA.	  	  Composite	  primers	  (Table	  2.4)	  made	  of	  454	  sequencing	  adapters,	  barcodes	  and	  HIVint	  primers	  were	  used	  to	  amplify	  patient	  RNA	  and	  controls	  by	  One-­step	  Reverse	  Transcriptase-­‐PCR	  (Qiagen,	  Valencia,	  CA)	  using	  RNasin	  RNase	  inhibitor	  (Promega,	  Madison,	  WI)	  over	  35	  cycles	  as	  follows:	  1	  ×	  (30	  min	  at	  50°C),	  1	  ×	  (15	  min	  at	  95°C),	  35	  ×	  (1	  min	  at	  94°C;	  1	  min	  at	  60°C;	  1	  min	  at	  72°C),	  1×	  (10	  min	  at	  72°C;	  maintained	  at	  4°C).	  	  Amplified	  products	  were	  gel-­‐purified	  with	  the	  QIAquick	  Gel	  Extraction	  Kit	  (Qiagen,	  Valencia,	  CA)	  using	  a	  vacuum	  manifold.	  Purified	  DNA	  was	  quantified	  using	  the	  Quant-­iT	  PicoGreen	  dsDNA	  Assay	  kit	  (Molecular	  Probes,	  Invitrogen,	  Eugene,	  OR).	  	  Pooled	  amplicons	  were	  pyrosequenced	  using	  the	  454/Roche	  platform	  at	  the	  University	  of	  Pennsylvania.	  	  	  	  
(a)	  
Sequence int 
Primer 454 Adapter Barcode int Primer 
      
IntF3880 GCCTCCCTCGCGCCATCAG Listed AATAGTAGCCAGCTGTGATAAATGTC 
IntR4312 GCCTTGCCAGCCCGCTCAG in (b) TGCCATTTGTACTGCTGTYTTAAG 
	  
	   53	  
(b)	  
Barcode 
Sequence Patient Month 
     
ACACACTG 1 0 
CAGTCAGT 1 3 
ACGACATC 1 4 
TGAGTCAC 2 0 
ATCGATGC 2 2 
AGACACTC 2 3 
CACTACAG 2 4 
CGATATGC 2 5 
CGTACGAT 2 8 
ATATCGCG 2 12 
GACACTCA 3 0 
CTACGATG 3 3 
GAGTACAG 3 5 
GCATATCG 3 7 
GCTACGTA 3 12 
ACAGACTC Control RNA 
ACTGCTGA Control DNA 
      
	  
Table	  2.4	  Oligonucleotides	  and	  barcodes	  used	  in	  this	  study.	  
(a)	  Composite	  primers	  used	  to	  amplify	  IN	  codons	  45-­‐171.	  For	  the	  HIVint	  primers,	  ‘IntF’	  and	  ‘IntR’	  refer	  to	  the	  forward	  and	  reverse	  primers	  respectively	  whereas	  the	  following	  numbers	  refer	  to	  the	  starting	  genomic	  coordinates	  on	  the	  HIVNL4-­‐3	  template.	  The	  composite	  primer	  sequence	  is	  made	  up	  of	  454	  adapter,	  barcode	  and	  the	  actual	  envAS	  primer	  (from	  5’	  to	  3’).	  (b)	  List	  of	  unique	  barcodes	  with	  their	  8	  bp	  sequence	  and	  tagged	  patient/time-­‐point	  combination.	  	  Three	  sequencing	  experiments	  were	  carried	  out.	  	  One	  used	  the	  454/Roche	  GS	  FLX	  platform	  to	  generate	  relatively	  shallow	  data	  over	  all	  samples	  (4,640	  total	  reads).	  	  The	  second	  used	  the	  454/Roche	  Titanium	  Junior	  platform	  to	  acquire	  deep	  data	  on	  the	  three	  pre-­‐treatment	  time	  points	  (69,862	  total	  reads).	  For	  this,	  approximately	  800µl	  of	  plasma	  per	  sample	  was	  ultra-­‐centrifuged	  at	  45,000	  rpm	  for	  75	  min	  at	  7°C	  to	  pellet	  virus,	  and	  the	  pellet	  was	  re-­‐suspended	  in	  100µl	  of	  phosphate	  buffered	  saline	  (PBS)	  for	  RNA	  purification	  using	  the	  Illustra	  RNAspin	  kit	  (GE	  Healthcare,	  Buckinghamshire,	  UK)	  with	  RNA	  carrier.	  RT-­‐PCR	  was	  performed	  in	  quadruplicate	  and	  amplified	  products	  purified	  and	  concentrated	  using	  Agencourt	  AMPure	  XP	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(Beckman	  Coulter,	  Brea,	  CA)	  prior	  to	  gel-­‐purification.	  In	  the	  third	  experiment,	  the	  control	  RNA	  sample	  obtained	  from	  HIV-­‐1NL4-­‐3	  was	  sequenced	  using	  the	  454/Roche	  Titanium	  Junior	  platform	  (141,582	  reads).	  	  	  	  	  For	  the	  analysis	  below,	  we	  assume	  that	  losses	  during	  the	  viral	  isolation	  and	  cDNA	  synthesis	  steps	  are	  negligible	  (personal	  communication	  from	  manufacturer).	  All	  pyrosequence	  reads	  are	  available	  from	  our	  laboratory.	  	  
	  
Bioinformatic	  analysis	  	  We	  required	  that	  the	  first	  320	  flows	  have	  fewer	  than	  four	  low	  quality	  flows	  as	  defined	  by	  the	  454/Roche	  criteria	  (note	  that	  this	  is	  not	  the	  default	  filtering).	  All	  pyrosequence	  reads	  were	  filtered	  for	  exact	  matches	  to	  barcodes	  and	  primers,	  and	  to	  remove	  shorter	  reads	  (<200	  bases	  long)	  and	  reads	  with	  >2	  ambiguous	  base	  calls,	  which	  are	  often	  error-­‐prone	  [24].	  	  Output	  sequences	  were	  assigned	  to	  each	  patient/time-­‐point	  combination	  using	  DNA	  bar	  codes	  embedded	  in	  the	  amplification	  primers.	  	  Pyrosequence	  reads	  were	  denoised	  using	  Pyronoise	  with	  default	  settings,	  except	  for	  the	  parameter	  ‘c’	  set	  to	  0.02,	  which	  pre-­‐clusters	  454/Roche	  flowgrams	  at	  ~95%	  similarity	  prior	  to	  interpretation	  as	  base	  calls	  [21],	  here	  termed	  operational	  taxonomic	  units	  (OTUs).	  	  	  Sequences	  were	  then	  aligned	  to	  the	  reference	  HIV-­‐1NL4-­‐3	  genome	  (GenBank	  accession:	  M19921)	  using	  the	  Needleman-­‐Wunsch	  pair-­‐wise	  global	  alignment	  (PWA)	  algorithm	  with	  a	  match	  score	  of	  5,	  and	  gap	  opening	  and	  extension	  penalties	  of	  20	  and	  0.5.	  	  A	  multiple	  sequence	  alignment	  (MSA)	  was	  created	  by	  parsing	  the	  individual	  PWAs.	  	  In	  the	  MSA,	  positions	  that	  carried	  a	  reference	  genome	  base	  also	  had	  high	  read	  coverage	  (>95%),	  indicative	  of	  correct	  alignment.	  	  Positions	  that	  did	  not	  harbor	  a	  reference	  base,	  and	  had	  low	  read	  coverage	  (<2%)	  were	  removed,	  reasoning	  that	  they	  were	  alignment	  artifacts.	  The	  final	  MSA	  thus	  consisted	  of	  the	  383	  base	  positions	  of	  HIV-­‐1NL4-­‐3	  from	  the	  region	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encoding	  IN	  amino	  acids	  45-­‐171.	  	  Comparison	  to	  MSAs	  constructed	  using	  MUSCLE	  [25]	  for	  the	  control	  reads	  showed	  that	  our	  alignment	  method	  described	  above	  yielded	  fewer	  substitution	  errors	  (data	  not	  shown).	  	  For	  the	  first	  sequencing	  experiment,	  reads	  with	  inferred	  amino	  acid	  sequences	  with	  any	  indeterminate	  amino	  acid	  in	  the	  region	  of	  high	  coverage	  were	  discarded.	  For	  the	  second,	  sequences	  were	  instead	  truncated	  at	  a	  point	  where	  scanning	  5’-­‐3’	  along	  the	  read	  direction	  yielded	  a	  pair	  of	  indeterminate	  amino	  acids,	  if	  any.	  	  For	  both	  experiments,	  sequences	  with	  stop	  codons	  were	  removed,	  reasoning	  that	  these	  were	  either	  sequencing	  errors	  or	  mutant	  genomes	  that	  would	  not	  yield	  replication-­‐competent	  descendents.	  None	  of	  this	  filtering	  was	  performed	  on	  the	  control	  sequences	  in	  the	  third	  experiment	  because	  this	  set	  was	  used	  for	  error	  control.	  	  Of	  237	  OTUs	  in	  the	  first	  experiment,	  213	  survived	  and	  were	  considered	  for	  in-­‐depth	  analysis	  (Table	  2.1).	  	  In	  the	  second,	  of	  14,908	  OTUs	  12,345	  remained	  and	  were	  analyzed	  for	  pre-­‐treatment	  levels	  of	  mutations	  (Table	  2.2).	  Of	  the	  12,345	  OTUs	  1,928	  were	  truncated.	  OTUs	  removed	  or	  truncated	  were	  either	  singletons	  or	  contained	  relatively	  few	  reads.	  	  IN	  amino	  acid	  positions	  classified	  as	  locations	  of	  DRMs	  were	  identified	  using	  the	  HIV	  Drug	  Resistance	  Database	  (http://hivdb.stanford.edu/cgi-­‐bin/INIResiNote.cgi)	  and	  [6].	  	  The	  amplified	  region	  studied	  here	  had	  28	  such	  positions.	  	  	  For	  each	  patient,	  OTUs	  over	  all	  time-­‐points	  (first	  experiment)	  were	  used	  to	  generate	  an	  evolutionary	  network	  of	  resistance	  pathways	  by	  vSPA	  using	  default	  settings	  [22]	  except	  that	  polymorphisms	  accumulating	  in	  descendant	  lineages	  at	  a	  level	  of	  twice	  or	  more	  that	  found	  at	  ancestral	  time	  points	  were	  reported.	  	  We	  found	  that	  vSPA	  does	  not	  operate	  on	  sequence	  sets	  less	  than	  5	  in	  size,	  so	  for	  time-­‐points	  with	  OTU	  numbers	  <5,	  the	  sequence	  dataset	  was	  replicated	  to	  facilitate	  analysis	  while	  maintaining	  the	  proportions	  of	  variants	  in	  the	  population.	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Simulation-­based	  framework	  for	  reporting	  drug-­resistance	  mutations	  	   	  For	  the	  computational	  simulation	  of	  accumulation	  of	  incorrect	  DRM	  calls	  due	  to	  error,	  it	  was	  necessary	  to	  first	  estimate	  the	  base	  substitution	  rate	  from	  control	  data.	  	  For	  this,	  an	  MSA	  was	  obtained	  for	  control	  HIV-­‐1NL4-­‐3	  RNA	  reads.	  The	  MSA	  was	  constructed	  as	  previously	  by	  removing	  positions	  of	  low	  sequence	  coverage	  that	  are	  error-­‐prone	  and	  typically	  correspond	  to	  indels	  at	  homopolymers	  (defined	  as	  any	  sequence	  with	  sequential	  identical	  bases).	  Error	  rates	  were	  determined	  for	  the	  5'	  proximal	  bases	  where	  the	  sequence	  is	  most	  accurate,	  yielding	  an	  error	  rate	  of	  1.2e-­‐3	  base	  misincorporations	  per	  position.	  	  For	  comparison,	  the	  error	  rate	  for	  the	  DNA	  control,	  which	  does	  not	  involve	  the	  RT	  step,	  was	  measured	  at	  1e-­‐3	  over	  the	  same	  region.	  	  	  	  To	  assess	  whether	  the	  frequencies	  of	  DRMs	  in	  the	  pre-­‐treatment	  samples	  were	  higher	  than	  expected	  by	  chance,	  we	  used	  a	  simulation	  approach	  in	  addition	  to	  comparison	  to	  empirical	  data.	  	  For	  each	  sample	  we	  carried	  out	  10,000	  simulations	  per	  primary	  DRM	  position.	  For	  each	  simulation,	  a	  distribution	  of	  codons	  was	  generated	  of	  the	  size	  of	  the	  total	  number	  of	  codons	  at	  that	  position	  by	  binomially	  modeling	  an	  error	  rate	  of	  1.2e-­‐3	  per	  base	  of	  the	  consensus	  codon.	  The	  numbers	  of	  resulting	  DRMs	  by	  in	  silico	  translation	  were	  then	  tabulated	  and	  compared	  to	  the	  observed	  frequencies	  of	  DRMs	  in	  the	  patient	  samples.	  P	  values	  were	  assigned	  by	  determining	  the	  proportion	  of	  simulated	  values	  that	  were	  equal	  or	  more	  extreme	  in	  the	  direction	  of	  the	  alternative	  hypothesis.	  Because	  there	  were	  seven	  primary	  DRMs	  queried,	  and	  three	  patients	  studied,	  we	  required	  that	  P	  values	  be	  below	  0.05/21=0.0023	  to	  qualify	  as	  significant	  after	  Bonferroni	  correction	  for	  multiple	  comparisons.	  	  Results	  of	  the	  simulation-­‐based	  analysis	  are	  in	  Table	  2.3b.	  	  Computation	  was	  carried	  out	  on	  a	  Dell	  Power	  Edge	  Cluster	  with	  32	  cores.	  	  Simulations	  and	  statistical	  tests	  were	  carried	  out	  using	  R.	  	  
	   57	  
Re-­sampling	  statistics	  for	  numbers	  of	  starting	  genomes	  assayed	  in	  
sequencing	  experiments	  after	  PCR	  amplification	  	   	  Given	  an	  initial	  sample	  of	  n	  viral	  genomes,	  amplified	  by	  f	  PCR	  cycles	  for	  an	  amplification	  factor	   ,	  and	  sequenced	  to	  yield	  s	  sequences,	  how	  many	  of	  the	  n	  original	  genomes	  will	  be	  detected	  among	  the	  s	  sequences?	  	  Let	  this	  quantity	  be	  defined	  by	  a	  random	  variable .	  	  It	  can	  be	  shown	  that 	  has	  a	  mean,	   ,	  	  	  
and	  variance,	   	  
These	  formulae	  assume	  sampling	  with	  replacement,	  which	  is	  reasonable	  given	  the	  large	  number	  of	  amplified	  genomes	  from	  which	  we	  are	  sampling.	  This	  approximation	  is	  validated	  by	  comparisons	  in	  each	  case	  with	  100	  sampling	  simulations	  without	  replacement	  for	  35	  PCR	  cycles	  (Table	  2.2;	  values	  labeled	  ‘Simulations’	  and	  ‘Formula’).	  Further,	  the	  equations	  are	  independent	  of	  f	  in	  the	  limit	  of	   	  which	  too	  was	  validated	  with	  simulations	  in	  the	  ranges	  of	  n	  and	  f	  studied	  (data	  not	  shown).	  These	  equations	  thus	  provide	  a	  concrete	  measure	  of	  the	  completeness	  of	  sampling	  and	  the	  extent	  of	  possible	  over-­‐sampling	  due	  to	  over-­‐sequencing.	  To	  calculate	  the	  proportion	  of	  sequence	  reads	  corresponding	  to	  independent	  viral	  templates	  in	  the	  starting	  plasma	  sample,	  we	  used	   ,	  which	  has	  
mean	   	  and	  variance	   .	  Oversampling	  is	  then	  simply	   .	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Chapter	  3 HIV	  SEQUENCE	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Abstract	  
	  The	  first	  use	  of	  lentiviral	  vectors	  in	  humans	  involved	  transduction	  of	  mature	  T	  cells	  with	  an	  HIV-­‐derived	  env	  antisense	  (envAS)	  vector	  to	  protect	  cells	  from	  HIV	  infection.	  	  In	  that	  study,	  only	  a	  minority	  of	  the	  patient	  T	  cell	  population	  could	  be	  gene-­‐modified,	  raising	  the	  question	  of	  whether	  the	  altered	  cells	  could	  affect	  replicating	  HIV	  populations.	  We	  investigated	  this	  using	  humanized	  NOD/SCID	  IL-­‐2Rγnull	  (hNSG)	  mice	  reconstituted	  with	  ~4-­‐11%	  envAS-­‐modified	  human	  T	  cells.	  	  Mice	  were	  challenged	  with	  HIV-­‐1NL4-­‐3,	  which	  has	  an	  env	  perfectly	  complementary	  to	  envAS,	  or	  with	  HIV-­‐1BaL,	  which	  has	  a	  divergent	  env.	  	  No	  differences	  were	  seen	  in	  viral	  titer	  between	  mice	  that	  received	  envAS-­‐modified	  cells	  and	  control	  mice	  that	  did	  not.	  	  Using	  454/Roche	  pyrosequencing	  we	  analyzed	  the	  mutational	  spectrum	  in	  HIV	  populations	  in	  serum-­‐-­‐from	  33	  mice	  we	  recovered	  84,074	  total	  reads	  comprising	  31,290	  unique	  sequence	  variants.	  	  We	  found	  enrichment	  of	  A-­‐to-­‐G	  transitions	  and	  deletions	  in	  envAS-­‐treated	  mice,	  paralleling	  a	  previous	  tissue	  culture	  study	  where	  most	  target	  cells	  contained	  envAS,	  even	  though	  minority	  of	  cells	  were	  envAS-­‐modified	  here.	  Unexpectedly,	  this	  enrichment	  was	  only	  detected	  following	  challenge	  with	  HIV-­‐1BaL,	  where	  the	  viral	  genome	  would	  form	  an	  imperfect	  duplex	  with	  envAS,	  and	  not	  HIV-­‐1NL4-­‐3,	  where	  a	  perfectly	  matched	  duplex	  would	  form.	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Introduction	  	  Highly	  active	  anti-­‐retroviral	  therapy	  (HAART)	  fails	  to	  eliminate	  HIV	  completely	  from	  patients	  and	  often	  elicits	  drug	  resistant	  variants,	  leading	  to	  interest	  in	  additional	  forms	  of	  therapy.	  Adoptive	  T	  cell	  therapy	  using	  gene-­‐modified	  T	  cells	  is	  one	  such	  approach,	  in	  which	  T	  cells	  are	  harvested	  from	  HIV-­‐infected	  subjects,	  transduced	  ex	  
vivo	  with	  genes	  that	  obstruct	  HIV	  replication,	  then	  re-­‐infused	  back	  into	  patients.	  	  One	  type	  of	  anti-­‐HIV	  gene	  encodes	  antisense	  RNA,	  which	  in	  several	  studies	  has	  been	  shown	  to	  inhibit	  HIV	  replication	  efficiently	  in	  tissue	  culture	  [1-­‐4].	  	  In	  a	  phase	  I	  clinical	  trial	  preceding	  our	  study,	  an	  HIV-­‐derived	  lentiviral	  vector	  encoding	  env	  antisense	  (envAS),	  called	  VRX496,	  was	  used	  to	  treat	  patients	  that	  failed	  two	  or	  more	  anti-­‐retroviral	  regimens	  [5].	  The	  trial	  was	  a	  success	  in	  that	  no	  adverse	  events	  were	  reported	  in	  this	  first-­‐in-­‐human	  use	  of	  lentiviral	  vectors	  [5,	  6].	  There	  was	  also	  significant	  reduction	  in	  viral	  loads	  and	  improvement	  of	  immune	  function	  in	  a	  subset	  of	  patients,	  even	  though	  only	  a	  fraction	  of	  autologous	  T	  cells	  were	  modified	  with	  VRX496.	  	  This	  then	  raised	  the	  question	  of	  whether	  envAS	  modification	  of	  a	  minority	  of	  cells	  could	  influence	  HIV	  infection.	  	  In	  this	  study,	  we	  have	  investigated	  the	  effect	  of	  envAS	  on	  HIV-­‐1	  populations	  in	  a	  setting	  where	  only	  a	  minority	  of	  cells	  was	  vector-­‐modified.	  	  The	  vector	  VRX494	  used	  here	  is	  the	  research	  counterpart	  of	  the	  clinically	  used	  VRX496,	  the	  only	  difference	  being	  that	  VRX494	  has	  a	  GFP	  gene	  that	  allows	  convenient	  quantification	  of	  transduction	  (Figure	  3.1a).	  	  Similar	  to	  the	  clinical	  vector,	  VRX494	  is	  derived	  from	  HIV	  and	  directs	  envAS	  expression	  from	  the	  HIV	  long	  terminal	  repeat	  (LTR),	  so	  that	  following	  HIV	  infection	  of	  a	  vector-­‐modified	  cell	  and	  expression	  of	  HIV	  tat,	  the	  anti-­‐sense	  payload	  is	  expressed.	  	  In	  addition,	  cis	  signals	  are	  present	  in	  the	  vector	  to	  allow	  mobilization	  by	  HIV	  proteins	  provided	  in	  trans	  during	  infection,	  so	  that	  the	  vector	  can	  potentially	  spread	  from	  cell	  to	  cell.	  	  In	  a	  computational	  simulation,	  formation	  of	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such	  defective	  interfering	  particles,	  combined	  with	  antisense	  inhibition,	  inhibited	  HIV	  replication	  effectively	  [7].	  	  	  The	  anti-­‐sense	  RNA	  encoded	  by	  VRX494	  can	  bind	  the	  HIV	  RNA	  genome,	  forming	  double-­‐stranded	  RNA.	  	  In	  previous	  work,	  HIV	  infection	  of	  VRX494-­‐modified	  cells	  in	  culture,	  followed	  by	  recovery	  of	  challenge	  virus	  sequences,	  showed	  1)	  large	  deletions	  in	  most	  HIV	  genomes	  and	  2)	  a	  high	  frequency	  of	  A-­‐G	  transitions	  in	  the	  
envAS	  targeted	  region,	  potentially	  the	  result	  of	  A-­‐I	  editing	  by	  cellular	  double-­‐stranded	  RNA	  adenosine	  deaminase	  (dsRAD;	  a	  member	  of	  the	  Adenosine	  Deaminase	  Acting	  on	  RNA,	  or	  ADAR,	  family	  of	  enzymes)	  [4].	  	  Such	  modifications	  may	  help	  the	  virus	  evade	  anti-­‐sense	  pressure	  by	  reducing	  the	  complementarity	  of	  the	  viral	  genome	  and	  the	  envAS.	  	  However,	  most	  of	  these	  deleted	  genomes	  would	  be	  replication	  defective,	  and	  a	  few	  A-­‐to-­‐G	  changes	  would	  be	  unlikely	  to	  significantly	  destabilize	  pairing	  in	  the	  ~900	  bp	  anti-­‐sense	  RNA	  used.	  	  Thus,	  it	  may	  be	  more	  likely	  that	  the	  accumulation	  of	  these	  sequences	  reports	  the	  action	  of	  cellular	  systems	  acting	  on	  the	  double-­‐stranded	  sense-­‐antisense	  RNA,	  but	  that	  these	  mutations	  do	  not	  confer	  reduced	  sensitivity	  to	  the	  anti-­‐sense	  [4].	  	  	  	  Here	  we	  report	  an	  analysis	  of	  HIV-­‐1	  populations	  following	  growth	  in	  the	  presence	  of	  
envAS	  using	  a	  humanized	  NOD/SCID	  IL-­‐2Rγnull	  	  (or	  hNSG)	  mouse	  model.	  	  Cohorts	  of	  mice	  were	  compared	  that	  were	  reconstituted	  with	  ~4-­‐11%	  vector-­‐modified	  T	  cells	  or	  with	  unmodified	  T	  cells	  to	  model	  the	  frequency	  of	  vector	  marking	  in	  the	  human	  phase	  I	  trial.	  We	  found	  no	  reduction	  in	  viral	  load,	  but	  we	  did	  detect	  a	  significant	  excess	  of	  challenge	  virus	  variants	  with	  enriched	  A-­‐to-­‐G	  transitions	  and	  deletions,	  documenting	  antisense	  pressure	  on	  HIV-­‐1	  populations	  even	  with	  VRX494-­‐modification	  of	  only	  a	  minority	  of	  cells.	  	  Unexpectedly,	  the	  variants	  with	  enriched	  A-­‐G	  transitions	  and	  deletions	  only	  accumulated	  significantly	  when	  the	  antisense	  was	  imperfectly	  matched	  to	  its	  target.	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Results	  
	  
A	  mouse	  model	  for	  envAS	  pressure	  on	  HIV-­1	  	  Previous	  studies	  measuring	  the	  effect	  of	  HIV-­‐1	  antisense	  therapy	  have	  used	  T	  cell	  populations	  in	  which	  the	  vast	  majority	  of	  viral	  target	  cells	  expressed	  the	  antisense	  RNA.	  	  However,	  in	  the	  therapeutic	  setting,	  although	  most	  of	  the	  cells	  that	  are	  infused	  express	  the	  antisense	  message,	  they	  are	  quickly	  diluted	  and	  persist	  as	  only	  a	  small	  percentage	  of	  the	  total	  [5].	  	  To	  study	  how	  T	  cells	  transduced	  with	  the	  VRX494	  envAS	  vector	  (Figure	  3.1a)	  might	  alter	  viral	  populations	  in	  patients,	  we	  established	  an	  in	  
vivo	  model	  that	  would	  mirror	  the	  published	  clinical	  trial	  [5],	  but	  allow	  infection	  with	  defined	  HIV	  challenge	  stocks.	  This	  was	  done	  in	  collaboration	  with	  the	  laboratory	  of	  James	  L	  Riley	  at	  University	  of	  Pennsylvania.	  We	  took	  advantage	  of	  the	  ability	  of	  NOD/SCID	  IL-­‐2Rγnull	  (NSG)	  mice	  to	  stably	  engraft	  human	  T	  cells	  [8]	  to	  model	  HIV-­‐1	  infection	  and	  therapy.	  	  We	  established	  4	  cohorts	  of	  10	  mice	  each	  as	  diagrammed	  in	  Figure	  3.1b.	  	  Two	  control	  cohorts	  were	  engrafted	  with	  untransduced	  T	  cells	  and	  challenged	  with	  either	  of	  two	  HIV-­‐1	  derivatives,	  HIVNL4-­‐3	  or	  an	  HIVNL4-­‐3	  derivative	  engineered	  to	  express	  the	  BaL	  envelope	  (henceforth	  "HIVBaL").	  	  The	  other	  two	  cohorts	  were	  engrafted	  with	  untransduced	  T	  cells	  spiked	  with	  ~4-­‐11%	  of	  VRX494-­‐transduced	  T	  cells	  and	  challenged	  similarly	  (termed	  "vector-­‐treated	  cohort"	  below).	  	  The	  VRX494-­‐transduced	  T	  cells	  used	  in	  this	  study	  were	  generated	  in	  a	  manner	  that	  replicated	  the	  clinical	  trial.	  	  Freshly	  isolated	  primary	  human	  CD4+	  T	  cells	  were	  activated,	  transduced	  with	  a	  lentiviral	  vector	  expressing	  envAS	  and	  GFP	  (VRX494),	  expanded	  for	  10	  days,	  frozen,	  and	  stored	  in	  liquid	  nitrogen	  for	  several	  weeks.	  After	  thawing,	  GFP	  expression	  was	  measured	  by	  flow	  cytometry	  and	  these	  cells	  were	  found	  to	  be	  highly	  transduced	  (Figure	  3.1c),	  as	  with	  the	  cells	  used	  for	  treating	  patients	  in	  the	  clinical	  trial	  [5].	  Mice	  in	  the	  control	  cohorts	  were	  injected	  with	  10	  million	  untransduced	  T	  cells,	  whereas	  mice	  in	  the	  vector-­‐treated	  cohorts	  were	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injected	  with	  9	  million	  untransduced	  T	  cells	  and	  1	  million	  of	  VRX494-­‐transduced	  cells	  (thus	  the	  target	  frequency	  of	  transduced	  cells	  was	  10%).	  	  	  
	  
	  
(a)	  The	  VRX494	  vector.	  	  (b)	  Time	  line	  of	  mouse	  transplantation	  and	  infection.	  	  The	  hNSG	  mice	  were	  transplanted	  on	  day	  0,	  then	  challenged	  with	  HIVNL4-­‐3	  or	  HIVBaL	  on	  day	  30.	  	  (c)	  Flow	  cytometry	  analysis	  of	  transduction	  of	  CD4	  T	  cells	  with	  envAS.	  Cells	  with	  high	  transduction	  levels	  were	  obtained	  as	  evidenced	  by	  GFP	  detection.	  (d)	  Analysis	  of	  the	  levels	  of	  T	  cell	  engraftment.	  	  (e)	  Analysis	  of	  the	  levels	  of	  engraftment	  of	  VRX494-­‐transduced	  cells,	  analyzed	  by	  sorting	  GFP-­‐positive	  cells.	  	  (f)	  Analysis	  of	  the	  level	  of	  HIV	  p24	  antigen	  in	  serum	  at	  48	  days	  after	  infection.	  	  
Figure	  3.1	  Analysis	  of	  hNSG	  mice	  with	  ~4-­11%	  VRX494	  envAS-­vector	  modified	  T	  cells	  and	  
challenged	  with	  HIVNL4-­3	  or	  HIVBaL.	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After	  27	  days,	  we	  measured	  the	  engraftment	  for	  each	  of	  the	  40	  animals.	  	  One	  animal	  failed	  to	  engraft	  T	  cells	  and	  was	  excluded	  from	  further	  analysis.	  	  For	  the	  remaining	  animals,	  similar	  levels	  of	  engraftment	  of	  total	  CD4+	  T	  cells	  were	  seen	  for	  all	  cohorts	  (Figure	  3.1d).	  The	  two	  cohorts	  that	  received	  VRX494-­‐transduced	  cells	  showed	  similar	  distributions	  for	  the	  proportion	  of	  engrafted	  cells	  transduced	  with	  GFP-­‐positive	  VRX494	  (4-­‐11%,	  Figure	  3.1e).	  	  Three	  days	  later	  (day	  30	  post-­‐infusion	  of	  T	  cells)	  we	  challenged	  each	  mouse	  with	  supernatants	  collected	  from	  293	  T	  cells	  transfected	  with	  HIVBaL	  or	  HIVNL4-­‐3.	  	  We	  note	  that	  this	  differs	  from	  the	  clinical	  trial	  in	  that	  the	  human	  subjects	  were	  HIV-­‐infected	  before	  infusion	  of	  gene-­‐modified	  cells,	  whereas	  here	  gene-­‐modified	  cells	  were	  introduced	  into	  mice	  prior	  to	  HIV	  infection.	  After	  an	  additional	  18	  days	  (day	  48	  post-­‐infusion),	  we	  measured	  viral	  replication	  by	  assaying	  p24	  in	  the	  mouse	  serum	  (Figure	  3.1f	  and	  Table	  3.1a).	  	  We	  did	  not	  observe	  a	  significant	  difference	  in	  the	  viral	  titers	  between	  the	  vector-­‐treated	  and	  control	  cohorts.	  	  This	  is	  consistent	  with	  the	  fact	  that	  it	  took	  ≥6	  months	  to	  see	  substantial	  differences	  in	  the	  viral	  load	  of	  patients	  treated	  with	  the	  clinical	  envAS	  vector	  (VRX496).	  	  After	  an	  additional	  7	  days	  (day	  55	  post-­‐infusion),	  some	  of	  the	  mice	  (across	  all	  four	  cohorts)	  began	  to	  display	  the	  early	  stages	  of	  graft	  versus	  host	  disease	  (GVHD)	  and	  the	  experiment	  was	  terminated.	  	  Serum	  obtained	  from	  the	  peripheral	  blood	  at	  the	  time	  of	  sacrifice	  was	  used	  for	  all	  subsequent	  analysis.	  	  Two	  mice	  died	  during	  the	  study,	  and	  four	  mice	  had	  undetectable	  viral	  loads	  by	  serum	  p24	  assay,	  so	  a	  total	  of	  33	  mice	  were	  available	  for	  analysis.	  All	  work	  described	  in	  this	  section	  was	  conducted	  by	  members	  of	  the	  Riley	  lab.	  	  
Amplification	  and	  sequencing	  of	  viral	  quasi-­species	  from	  mouse	  plasma	  	  To	  investigate	  possible	  pressure	  on	  viral	  populations	  exerted	  by	  envAS,	  we	  studied	  the	  structure	  of	  viral	  populations	  using	  the	  454/Roche	  pyrosequencing	  technology	  [9].	  	  HIV	  RNA	  was	  extracted	  from	  serum	  of	  each	  mouse,	  reverse	  transcribed,	  and	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PCR	  amplified	  according	  to	  the	  scheme	  in	  Figure	  3.2.	  	  Three	  amplicons	  were	  designed	  covering	  the	  envAS	  targeted	  region	  of	  the	  challenge	  viruses	  –	  two	  covering	  each	  side	  of	  the	  envAS	  target	  region,	  and	  a	  third	  spanning	  the	  two.	  	  The	  outermost	  primers	  annealed	  slightly	  outside	  each	  edge	  of	  the	  envAS	  targeted	  region.	  The	  smaller	  two	  amplicons	  permit	  detection	  of	  A-­‐G	  transitions	  and	  smaller	  deletions.	  The	  longer	  amplicon,	  at	  1037	  bases	  in	  length,	  is	  too	  long	  for	  use	  in	  the	  454/Roche	  sequencing	  procedure,	  which	  accommodates	  molecules	  of	  a	  maximum	  ~500	  bases	  in	  length.	  	  Thus	  the	  longer	  amplicon	  could	  only	  yield	  sequences	  with	  large	  deletions.	  
	  The	  numbering	  in	  the	  env	  gene	  refers	  to	  the	  HIVNL4-­‐3	  genome.	  	  The	  envAS	  targeted	  region	  extends	  from	  6,601-­‐7,538	  (see	  blow-­‐up).	  Three	  amplicons	  were	  designed	  to	  recover	  potential	  deletions	  and	  A-­‐G	  changes.	  The	  relative	  positions	  and	  length	  of	  the	  amplicons	  (including	  454	  adapters	  and	  barcodes)	  are	  shown.	  Three	  amplicons	  were	  similarly	  designed	  in	  the	  homologous	  region	  of	  the	  HIVBaL	  genome.	  	  RNA	  from	  each	  serum	  sample	  was	  separately	  amplified	  and	  products	  gel-­‐purified	  for	  each	  of	  the	  three	  amplicons.	  Gel	  regions	  corresponding	  both	  to	  full-­‐length	  and	  shorter	  sequences	  were	  isolated	  to	  avoid	  selecting	  against	  potential	  deletions.	  To	  allow	  determination	  of	  sequences	  from	  many	  samples	  in	  pools,	  unique	  8-­‐nucleotide	  error-­‐correcting	  barcodes	  [10]	  were	  incorporated	  into	  each	  primer	  to	  index	  PCR	  products	  from	  each	  mouse	  [6,	  11-­‐13].	  Following	  pyrosequencing,	  sequence	  reads	  were	  assigned	  to	  the	  source	  mouse	  by	  decoding	  the	  barcode.	  	  
Figure	  3.2	  The	  HIVNL4-­3	  genome,	  showing	  the	  regions	  targeted	  by	  the	  VRX494	  envAS,	  and	  the	  
HIV	  env	  amplicons	  used	  in	  this	  study.	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1042 BaL 2775 151 947 BaL 1055 987 
1045 BaL 22500 1248 985 BaL 89000 1517 
1047 BaL 18050 1272 1037 BaL 3710 1318 
1052 BaL 4008 1347 1089 BaL 15525 1701 
1053 BaL 30900 899 1091 BaL 17250 1230 
1085 BaL 30650 919 1095 BaL 51400 1292 
1044 NL4-3 700 1312 1138 BaL 6120 151 
1046 NL4-3 2200 1218 1140 BaL 6215 315 
1048 NL4-3 13200 1171 946 NL4-3 2759 871 
1050 NL4-3 3365 955 948 NL4-3 1700 880 
1051 NL4-3 2142 531 1038 NL4-3 780 701 
1055 NL4-3 1850 1489 1040 NL4-3 900 638 
1086 NL4-3 642 668 1090 NL4-3 3675 888 
1087 NL4-3 1735 1060 1094 NL4-3 2510 289 
1092 NL4-3 2335 1188 1136 NL4-3 11450 793 
1093 NL4-3 2050 1128 1137 NL4-3 2450 566 
      1139 NL4-3 3380 597 
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(b)	  
Challenge Vector-treated Control 
  # Mice # 454 Reads # Mice # 454 Reads 
BaL 8 8511 6 5836 
NL4-3 9 6223 10 10720 
	  
Table	  3.1	  Samples	  studied	  and	  numbers	  of	  pyrosequence	  reads.	  
(a)	  Samples	  with	  viral	  load	  (serum	  p24	  assay)	  and	  number	  of	  unique	  pyrosequence	  reads.	  (b)	  Summary	  of	  distribution	  of	  unique	  pyrosequence	  reads	  across	  4	  study	  cohorts.	  
	  
Analysis	  of	  nucleotide	  changes	  in	  VRX494-­transduced	  mice	  	  HIV	  sequences	  were	  then	  analyzed	  for	  enrichment	  for	  A-­‐G	  transitions	  and	  deletions,	  which	  were	  previously	  found	  to	  be	  associated	  with	  replication	  in	  the	  presence	  of	  the	  
envAS	  [4].	  	  Each	  sequence	  was	  aligned	  to	  the	  reference	  HIV	  genome	  using	  pair-­‐wise	  global	  alignment	  (PWA).	  	  A	  stringent	  gap	  opening	  penalty	  was	  selected	  to	  allow	  detection	  of	  deletions	  of	  up	  to	  ~900	  bases.	  	  Use	  of	  a	  stringent	  gap	  opening	  penalty	  also	  allowed	  detection	  of	  multiple	  nearby	  mismatches,	  as	  can	  occur	  if	  envAS	  elicits	  clustered	  mutations.	  Two	  parsed	  multiple	  sequence	  alignments	  (MSAs),	  one	  for	  HIVBaL	  and	  one	  for	  HIVNL4-­‐3,	  were	  constructed	  from	  the	  individual	  PWAs.	  	  	  	  To	  investigate	  A-­‐G	  transition	  rates,	  we	  trimmed	  off	  primer	  sequences,	  then	  calculated	  the	  proportion	  of	  nucleotide	  positions	  that	  changed	  from	  A-­‐to-­‐G	  for	  each	  sequence,	  yielding	  a	  value	  between	  0	  and	  1.	  	  As	  controls,	  all	  other	  base	  change	  proportions	  per	  sequence	  were	  also	  calculated.	  For	  each	  base	  change,	  the	  distribution	  of	  proportions	  for	  the	  vector-­‐treated	  and	  control	  groups	  were	  plotted	  (Figure	  3.3).	  The	  boxes	  in	  the	  figure	  indicate	  the	  middle	  two	  quartiles	  (inter-­‐quartile	  range;	  in	  most	  cases	  the	  intervals	  are	  so	  close	  that	  the	  box	  appears	  to	  be	  a	  line	  at	  0.0).	  Outliers,	  defined	  as	  sequences	  with	  base	  change	  proportions	  beyond	  1.5	  times	  the	  inter-­‐quartile	  range	  from	  the	  box	  edges,	  are	  plotted	  as	  open	  black	  circles.	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(a)	  Base	  substitutions	  that	  accumulate	  during	  growth	  of	  HIVBaL	  in	  the	  vector-­‐treated	  and	  control	  mice.	  	  (b)	  Base	  substitutions	  that	  accumulated	  during	  growth	  of	  HIVNL4-­‐3	  in	  the	  vector-­‐treated	  and	  control	  mice.	  The	  boxes	  comprise	  all	  sequences	  with	  proportion	  changes	  in	  the	  middle	  two	  quartiles.	  Outliers,	  defined	  as	  sequences	  beyond	  1.5	  times	  the	  inter-­‐quartile	  range,	  are	  plotted	  as	  open	  black	  circles.	  	  As	  can	  be	  seen	  from	  the	  plots	  in	  Figure	  3.3a,	  following	  challenge	  with	  HIVBaL,	  there	  were	  substantially	  more	  sequences	  with	  high	  proportions	  of	  A-­‐G	  transitions	  in	  the	  vector-­‐treated	  group	  compared	  to	  the	  control	  group.	  	  Multiple	  sequences	  in	  the	  vector-­‐treated	  group	  had	  A-­‐G	  change	  proportions	  of	  0.1	  or	  more	  (i.e.,	  at	  least	  10%	  of	  A	  changed	  to	  G),	  although	  the	  control	  group	  had	  none.	  	  No	  such	  effect	  was	  seen	  for	  any	  other	  base	  change.	  	  	  In	  contrast,	  we	  found	  that	  the	  A-­‐G	  effect	  was	  not	  pronounced	  for	  HIVNL4-­‐3	  challenge	  (Figure	  3.3b).	  	  The	  envAS	  was	  derived	  from	  the	  NL4-­‐3	  strain,	  so	  it	  is	  perfectly	  complementary	  to	  HIVNL4-­‐3	  but	  not	  to	  HIVBaL	  –	  thus	  one	  conjecture	  is	  that	  mismatches	  in	  the	  RNA/RNA	  hybrid	  altered	  the	  processing	  of	  the	  duplex.	  	  We	  return	  to	  this	  point	  in	  the	  discussion.	  	  We	  also	  found	  that	  viral	  sequences	  enriched	  in	  G-­‐A	  transitions	  were	  present	  at	  a	  relatively	  high	  frequency	  following	  both	  HIVNL4-­‐3	  and	  HIVBaLinfections,	  though	  independently	  of	  whether	  or	  not	  envAS	  was	  present	  (Figure	  3.3).	  	  High	  rates	  of	  G-­‐A	  transitions	  are	  well	  documented	  during	  HIV	  infection,	  and	  are	  due	  to	  reverse	  transcriptase	  errors	  [16]	  and	  the	  C-­‐to-­‐T	  deamination	  activity	  of	  APOBEC	  family	  enzymes	  [17-­‐19].	  	  We	  next	  investigated	  whether	  the	  enrichment	  for	  A-­‐G	  transitions	  in	  vector-­‐treated	  samples	  was	  statistically	  significant.	  We	  defined	  informative	  sequences	  as	  those	  that	  had	  at	  least	  one	  A-­‐G	  transition.	  	  We	  then	  calculated	  the	  probability	  of	  an	  A-­‐G	  
Figure	  3.3	  Box	  plots	  illustrating	  the	  types	  of	  base	  substitutions	  that	  accumulated	  during	  
growth	  of	  HIV-­1	  in	  hNSG	  mice.	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transition	  over	  all	  informative	  sequences	  from	  both	  vector-­‐treated	  and	  control	  groups,	  because	  according	  to	  our	  null	  hypothesis	  there	  is	  no	  difference	  between	  the	  two	  groups.	  	  Using	  the	  A-­‐G	  transition	  probability,	  we	  assigned	  a	  binomial	  P	  value	  to	  each	  informative	  sequence	  based	  on	  the	  number	  of	  A-­‐G	  events	  as	  a	  fraction	  of	  the	  total	  A	  positions	  examined.	  	  Thus	  we	  could	  define	  an	  A-­‐G	  enrichment	  score	  for	  each	  informative	  sequence	  as	  the	  negative	  logarithm	  (-­‐log10)	  of	  their	  P	  values.	  The	  lower	  the	  P	  value	  of	  a	  sequence,	  the	  less	  likely	  the	  observed	  frequency	  of	  A-­‐G	  transitions	  occurring	  by	  chance,	  and	  the	  higher	  the	  A-­‐G	  enrichment	  score.	  	  Sequences	  with	  statistically	  significant	  enrichment	  levels	  have	  P	  values	  of	  ≤0.05	  (A-­‐G	  enrichment	  score	  ≥1.301).	  Figure	  3.4	  depicts	  a	  representative	  portion	  of	  the	  MSA,	  showing	  only	  A	  positions	  in	  the	  region	  and	  comparing	  the	  most	  A-­‐G	  enriched	  sequences	  for	  vector-­‐treated	  and	  control	  samples	  following	  HIVBaL	  challenge.	  
	  
	  Figure	  3.4	  Comparison	  of	  the	  100	  sequences	  with	  the	  greatest	  enrichment	  of	  A-­G	  transitions	  from	  the	  VRX494-­treated	  and	  control	  mice	  challenged	  with	  HIVBaL.	  
	   73	  
The	  most	  enriched	  sequences	  from	  viruses	  grown	  in	  vector-­‐treated	  mice	  (top)	  are	  compared	  to	  the	  most	  enriched	  sequences	  from	  controls	  (bottom).	  	  The	  bases	  were	  color-­‐coded	  as	  indicated	  at	  the	  bottom	  of	  the	  figure.	  	  Only	  base	  positions	  that	  were	  A	  (in	  yellow)	  in	  the	  starting	  viral	  stock	  are	  shown,	  those	  substituted	  with	  G	  are	  shown	  in	  red.	  	  Gray	  indicates	  sequence	  gaps.	  	  As	  an	  initial	  statistical	  scan	  of	  the	  data,	  we	  performed	  a	  one-­‐sided	  Fisher’s	  exact	  test	  to	  determine	  whether	  there	  was	  a	  significant	  excess	  of	  sequences	  enriched	  in	  A-­‐G	  transitions	  in	  the	  vector-­‐treated	  versus	  the	  control	  group	  (pooled	  over	  all	  mice).	  	  For	  HIVBaL	  challenge,	  we	  obtained	  a	  highly	  significant	  trend	  that	  persisted	  at	  least	  up	  to	  A-­‐G	  enrichment	  scores	  as	  high	  as	  4	  (data	  not	  shown).	  This	  confirms	  our	  observations	  (Figures	  3.3a	  and	  3.4)	  there	  are	  sequences	  with	  significantly	  higher	  proportions	  of	  A-­‐G	  transitions	  primarily	  in	  the	  HIVBaL	  vector-­‐treated	  group.	  No	  strongly	  significant	  trend	  was	  observed	  when	  we	  repeated	  our	  analysis	  for	  other	  base	  changes.	  A	  weak	  excess	  of	  sequences	  with	  G-­‐A	  changes	  was	  seen,	  but	  this	  did	  not	  survive	  the	  more	  stringent	  test	  described	  below.	  	  For	  the	  HIVNL4-­‐3	  challenge,	  the	  A-­‐G	  effect	  was	  weak	  and	  showed	  no	  statistical	  significance	  above	  an	  enrichment	  score	  of	  1.3	  	  (data	  not	  shown).	  This	  confirms	  that	  in	  this	  case	  there	  is	  no	  preferential	  occurrence	  of	  sequences	  with	  high	  rates	  of	  A-­‐G	  changes	  in	  the	  vector-­‐treated	  group.	  No	  other	  types	  of	  base	  change	  showed	  significant	  enrichment	  following	  HIVNL4-­‐3	  challenge.	  	  	  	  As	  a	  control	  for	  the	  A-­‐G	  effect,	  we	  examined	  the	  frequency	  of	  A-­‐to-­‐G	  transitions	  outside	  the	  region	  targeted	  by	  envAS.	  	  There	  are	  20	  A	  sites	  present	  in	  the	  regions	  between	  the	  edges	  of	  the	  PCR	  primers	  used	  for	  sequence	  isolation	  and	  the	  env	  region	  complementary	  to	  envAS.	  	  These	  were	  compared	  to	  the	  243	  A	  sites	  in	  the	  env	  region	  targeted	  by	  envAS	  and	  analyzed	  in	  depth	  using	  the	  shorter	  two	  amplicons.	  	  Only	  1	  of	  20	  control	  sites	  (5%)	  was	  enriched	  in	  A-­‐to-­‐G	  transitions	  in	  the	  vector-­‐treated	  compared	  to	  the	  control	  group	  (as	  determined	  by	  Fisher’s	  exact	  test	  with	  Type	  I	  error	  of	  0.05).	  	  In	  contrast,	  70	  of	  the	  243	  envAS	  targeted	  sites	  (28%)	  were	  enriched	  in	  the	  vector-­‐treated	  group	  relative	  to	  the	  control.	  	  The	  difference	  achieved	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significance	  (P	  =	  0.01)	  by	  one-­‐sided	  Fisher's	  exact	  test.	  	  Thus	  we	  conclude	  that	  the	  region	  of	  the	  HIVBaL	  genome	  complementary	  to	  envAS	  had	  an	  elevated	  vector-­‐induced	  frequency	  of	  A-­‐to-­‐G	  changes	  compared	  to	  flanking	  non-­‐targeted	  regions	  of	  the	  viral	  genome.	  	  
Sequence	  features	  at	  A-­to-­G	  transitions	  	  We	  investigated	  whether	  A-­‐to-­‐G	  changes	  were	  associated	  with	  any	  nearby	  sequence	  motifs	  in	  the	  HIV	  RNA.	  	  We	  aligned	  sites	  of	  A-­‐to-­‐G	  transitions	  at	  the	  affected	  base,	  and	  used	  WebLogo	  to	  scan	  for	  conserved	  sequence	  features.	  	  No	  strongly	  conserved	  motifs	  were	  detected,	  though	  a	  weak	  preference	  for	  a	  5'	  A	  or	  T	  residue	  was	  seen	  (data	  not	  shown).	  	  	  
Nearest 
neighbor 
% A changed to G with 
indicated nearest neighbor 
  Earlier Study [21] This work 
     
5'U 70 38 
5'A 57 29 
5'C 22 20 
5'G 17 18 
      
     
3'U 46 25 
3'A 42 25 
3'C 52 22 
3'G 48 36 
      
	  
Table	  3.2	  Proportions	  of	  A	  residues	  converted	  to	  G	  with	  the	  indicated	  5'	  and	  3'	  nearest	  
neighbor	  nucleotides.	  Data	  from	  the	  HIVBaL	  challenge	  was	  used	  for	  the	  analysis,	  considering	  only	  sites	  that	  were	  enriched	  at	  p≤0.05	  for	  A-­‐G	  transitions	  in	  the	  vector-­‐treated	  sample.	  	  We	  then	  analyzed	  the	  proportions	  of	  bases	  changed	  as	  a	  function	  of	  nearest	  neighbors	  and	  found	  a	  bias	  (Table	  3.2).	  	  	  Previous	  studies	  have	  suggested	  that	  
	   75	  
dsRAD	  acts	  on	  A	  residues	  with	  5'	  neighbors	  in	  order	  of	  preference	  U	  and	  A	  greater	  than	  C	  and	  G	  [20,	  21].	  	  	  We	  found	  a	  relatively	  higher	  proportion	  of	  modified	  A	  residues	  3'	  of	  U	  or	  A	  compared	  to	  3'	  of	  a	  G	  or	  C	  (Table	  3.2).	  	  This	  suggests	  that	  dsRAD	  is	  responsible	  for	  modifying	  A	  to	  I	  in	  our	  experiments,	  leading	  to	  substitution	  with	  G.	  	  However,	  in	  the	  published	  study	  no	  preference	  for	  3'	  neighbors	  was	  found,	  whereas	  for	  unknown	  reasons	  we	  found	  a	  preference	  for	  G	  residues.	  	  We	  further	  asked	  whether	  there	  was	  a	  relation	  between	  the	  frequency	  of	  A-­‐to-­‐G	  substitutions	  and	  the	  extent	  of	  complementarity	  of	  the	  target	  genome	  with	  envAS.	  For	  this,	  we	  classified	  sites	  in	  the	  HIVBaL	  template	  into	  those	  that	  were	  complementary	  to	  the	  corresponding	  antisense	  position	  and	  those	  that	  were	  not.	  	  Likewise,	  we	  classified	  the	  A	  sites	  in	  HIVBaL	  as	  ones	  which	  underwent	  significant	  transition	  to	  G	  or	  not.	  We	  then	  compared	  the	  extent	  of	  sequence	  complementarity	  and	  fraction	  of	  sites	  with	  A-­‐to-­‐G	  transitions	  (using	  a	  sliding	  window	  of	  25	  bases).	  These	  were	  positively	  correlated	  with	  a	  highly	  significant	  P	  value	  (P	  <	  0.0001)	  for	  Spearman’s	  rank	  correlation	  coefficient.	  This	  is	  consistent	  with	  earlier	  reports	  of	  preferential	  RNA	  editing	  by	  dsRAD	  within	  perfectly	  matched	  regions	  of	  partially	  mismatched	  templates.	  	  
Comparing	  sequences	  enriched	  in	  A-­G	  transitions	  among	  the	  groups	  of	  
mice	  	  A	  more	  rigorous	  statistical	  approach	  involves	  treating	  each	  mouse	  as	  a	  single	  measurement	  instead	  of	  analyzing	  all	  sequences	  pooled	  over	  a	  cohort	  of	  mice.	  	  For	  the	  analysis	  over	  pooled	  sequences	  described	  above,	  a	  single	  anomalous	  mouse	  might	  contribute	  sequences	  that	  dominated	  the	  behavior	  of	  the	  pool,	  particularly	  in	  a	  study	  of	  rare	  sequence	  variants,	  whereas	  trends	  reproducible	  over	  many	  mice	  are	  of	  greater	  interest.	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  For	  the	  statistical	  analysis,	  each	  mouse	  was	  treated	  as	  an	  individual	  measure	  of	  proportions.	  	  (a)	  Comparison	  of	  vector-­‐treated	  and	  control	  mice	  after	  HIVBaL	  challenge.	  	  (b)	  Comparison	  of	  vector-­‐treated	  and	  control	  mice	  after	  HIVNL4-­‐3	  challenge.	  	  In	  each	  panel,	  the	  x-­‐axis	  indicates	  the	  extent	  of	  enrichment	  per	  sequence	  for	  each	  base	  substitution	  used	  in	  the	  analysis,	  so	  that	  at	  any	  indicated	  enrichment	  score,	  only	  sequences	  with	  at	  least	  that	  score	  were	  considered.	  	  Progressing	  from	  left	  to	  right	  indicates	  analysis	  of	  increasingly	  high	  levels	  of	  substitution.	  	  The	  y-­‐axis	  indicates	  the	  –log10	  p	  value	  from	  the	  Mann-­‐Whitney	  nonparametric	  comparison	  of	  means	  (one-­‐sided)	  for	  the	  excess	  in	  vector-­‐treated	  cohort	  compared	  to	  control	  cohort.	  	  The	  analysis	  was	  carried	  out	  for	  each	  of	  the	  12	  base	  substitutions.	  	  The	  horizontal	  red	  line	  indicates	  the	  threshold	  for	  achieving	  statistical	  significance	  at	  P	  values	  ≤0.05	  (above	  is	  significant).	  	  (c)	  Scatter	  plot	  showing	  the	  proportions	  of	  sequences	  with	  enrichment	  scores	  >1.3	  (P	  values	  <0.05)	  of	  A-­‐G	  transitions	  for	  each	  mouse	  in	  the	  HIVBaL	  group.	  	  Figure	  3.5a	  shows	  a	  comparison	  of	  the	  enrichment	  scores	  for	  base	  substitutions	  in	  the	  sequence	  reads,	  comparing	  vector-­‐treated	  and	  control	  mice	  after	  challenge	  with	  the	  HIVBaL	  virus	  (one	  sided	  Mann-­‐Whitney	  comparison	  of	  means).	  	  The	  x-­‐axis	  shows	  the	  enrichment	  score,	  and	  the	  y-­‐axis	  shows	  the	  P	  value	  for	  the	  mean	  sequence	  excess	  comparing	  the	  vector-­‐treated	  mice	  to	  control	  mice	  at	  the	  indicated	  enrichment	  score.	  	  For	  A-­‐G	  substitutions	  (Figure	  3.5a,	  black	  line),	  there	  is	  a	  significant	  excess	  of	  enriched	  sequences	  (above	  the	  horizontal	  red	  line)	  regardless	  of	  whether	  only	  high	  levels	  of	  enrichment	  (right	  side)	  or	  both	  low	  and	  high	  levels	  (left	  side)	  are	  used	  in	  the	  statistical	  analysis.	  	  The	  remaining	  11	  transitions	  and	  transversions	  were	  also	  compared.	  	  None	  showed	  a	  consistently	  significant	  trend	  for	  sequences	  enriched	  for	  substitutions	  in	  the	  vector-­‐treated	  cohort.	  	  Only	  T-­‐A	  and	  G-­‐A	  substitutions	  achieved	  a	  low	  level	  of	  significance	  at	  specific	  enrichment	  scores	  but	  were	  non-­‐significant	  at	  most	  x-­‐values	  and	  are	  of	  questionable	  biological	  importance.	  	  
Figure	  3.5	  Statistical	  analysis	  of	  base	  substitution	  frequencies	  in	  vector-­treated	  and	  control	  
mice.	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The	  analysis	  was	  repeated	  for	  the	  experiment	  with	  the	  HIVNL4-­‐3	  challenge	  virus	  (Figure	  3.5b).	  	  None	  of	  the	  12	  substitutions	  achieved	  significance.	  	  Thus,	  the	  low	  level	  of	  significance	  seen	  for	  A-­‐G	  transitions	  when	  all	  HIVNL4-­‐3	  sequences	  were	  pooled	  was	  not	  confirmed	  in	  the	  more	  rigorous	  analysis	  in	  which	  each	  mouse	  was	  treated	  as	  a	  single	  measurement.	  	  A	  representation	  of	  the	  excess	  of	  sequences	  with	  A-­‐G	  enrichment	  among	  vector-­‐treated	  mice	  in	  the	  HIVBaL	  challenge	  group	  is	  depicted	  in	  Figure	  3.5c,	  using	  the	  enrichment	  level	  of	  P	  <	  0.05	  (score	  of	  >1.301)	  as	  an	  example.	  	  Most	  of	  the	  control	  mice	  had	  few	  or	  no	  sequences	  passing	  this	  A-­‐G	  enrichment	  threshold,	  whereas	  the	  vector-­‐treated	  mice	  had	  an	  average	  of	  ~4.5%	  passing	  the	  threshold	  (P	  =	  0.005).	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(a)	  Illustration	  of	  the	  numbers	  and	  locations	  of	  deletions	  in	  HIVBaL	  from	  the	  vector-­‐treated	  and	  control	  groups	  corresponding	  to	  the	  5’	  end	  of	  amplicon	  2.	  	  Gray	  indicates	  sequence	  gaps.	  	  Deletions	  of	  
≥70	  bases	  were	  plotted.	  	  (b)	  Analysis	  of	  the	  significance	  of	  the	  difference	  in	  deletion	  frequencies	  between	  vector-­‐treated	  and	  control	  mice	  after	  HIVBaL	  challenge.	  	  The	  x-­‐axis	  shows	  the	  length	  of	  deletions	  included	  in	  the	  analysis,	  so	  that	  at	  any	  indicated	  value	  only	  deletions	  of	  that	  length	  or	  greater	  were	  included	  in	  the	  analysis.	  	  The	  y-­‐axis	  shows	  the	  P	  value	  for	  the	  comparison	  of	  means	  between	  vector-­‐treated	  and	  control	  groups	  calculated	  using	  the	  nonparametric	  Mann-­‐Whitney	  test	  (one-­‐sided).	  	  Each	  mouse	  was	  treated	  as	  a	  single	  measurement	  of	  proportions.	  	  (c)	  As	  in	  (b),	  but	  analysis	  of	  the	  HIVNL4-­‐3	  challenge	  group.	  	  (d)	  Comparison	  of	  proportions	  for	  deletions	  ≥70	  bases,	  for	  the	  control	  and	  vector-­‐treated	  mice.	  	  Each	  mouse	  is	  shown	  as	  a	  point.	  	  Studies	  of	  antisense	  inhibition	  of	  HIV	  in	  tissue	  culture,	  where	  most	  cells	  contained	  the	  VRX494	  vector,	  indicated	  that	  deletions	  also	  accumulated	  [4],	  so	  we	  analyzed	  the	  frequencies	  of	  deletions	  here.	  	  The	  distribution	  of	  sequences	  with	  deletions	  of	  at	  least	  70	  bases	  is	  shown	  in	  Figure	  3.6a	  for	  one	  of	  the	  HIVBaL	  amplicons.	  	  Inspections	  suggested	  that	  the	  number	  of	  sequences	  with	  deletions	  is	  greater	  in	  the	  vector-­‐treated	  mice	  than	  in	  the	  controls.	  	  We	  thus	  calculated	  the	  significance,	  again	  treating	  each	  mouse	  as	  a	  single	  measure,	  of	  the	  proportion	  of	  deleted	  viruses	  (Figures	  3.6b,c).	  	  	  The	  x-­‐axis	  indicates	  the	  length	  of	  deletion	  used	  in	  the	  analysis	  –	  progressing	  to	  the	  right	  indicates	  restricting	  the	  analysis	  to	  incrementally	  longer	  deletions.	  	  The	  y-­‐axis	  shows	  the	  statistical	  significance	  of	  testing	  for	  the	  excess	  of	  sequences	  in	  vector-­‐treated	  mice	  versus	  controls	  at	  the	  indicated	  deletion	  length.	  	  Segments	  of	  the	  curve	  above	  the	  horizontal	  blue	  line	  indicate	  statistical	  significance.	  	  For	  HIVBaL	  challenge,	  some	  data	  sets	  with	  deletions	  in	  the	  range	  of	  ~10-­‐100	  bases	  showed	  significant	  enrichment	  in	  the	  vector-­‐treated	  group,	  though	  others	  did	  not,	  indicating	  that	  the	  enrichment	  of	  deletions	  achieved	  marginal	  significance	  (Figure	  3.6b).	  	  No	  such	  significant	  enrichment	  in	  deletions	  was	  seen	  with	  HIVNL4-­‐3	  challenge	  (Figure	  3.6c).	  	  The	  enrichment	  in	  deletions	  for	  HIVBaL	  sequences,	  using	  deletions	  of	  ≥70	  bases	  for	  
Figure	  3.6	  Frequency	  of	  deletions	  in	  HIV-­1	  challenge	  viruses	  grown	  in	  the	  presence	  of	  vector-­
treated	  cells	  or	  controls.	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analysis,	  is	  shown	  in	  Figure	  3.6d,	  where	  each	  mouse	  is	  plotted	  individually.	  	  As	  can	  be	  seen,	  the	  difference	  in	  means	  is	  significant	  (P	  =	  0.04),	  but	  the	  effect	  slight.	  	  We	  conclude	  that	  there	  is	  a	  significant	  though	  modest	  increase	  in	  the	  frequency	  of	  deletions	  in	  the	  HIVBaL	  but	  not	  the	  HIVNL4-­‐3	  challenged	  vector-­‐treated	  mice.	  	  We	  next	  checked	  whether	  variants	  with	  deletions	  ≥70	  bases	  were	  also	  enriched	  for	  A-­‐G	  transitions,	  as	  both	  features	  potentially	  arise	  from	  envAS	  pressure.	  	  We	  performed	  Fisher’s	  exact	  test	  to	  establish	  whether	  there	  was	  an	  excess	  of	  deletion-­‐harboring	  variants	  among	  the	  population	  of	  sequences	  significantly	  enriched	  for	  A-­‐G.	  	  We	  did	  not	  observe	  any	  significant	  enrichment	  or	  depletion.	  Thus	  the	  A-­‐G	  transitions	  and	  deletions	  appear	  to	  accumulate	  independently.	  	  
Correlation	  between	  extent	  of	  T	  cell	  modification	  and	  effects	  of	  VRX494	  
envAS	  treatment	  	  Each	  cohort	  of	  mice	  showed	  variation	  in	  the	  final	  extent	  of	  T	  cell	  modification	  by	  the	  VRX494	  vector	  following	  engraftment,	  allowing	  us	  to	  investigate	  possible	  correlations	  with	  the	  frequency	  of	  A-­‐to-­‐G	  transitions	  or	  deletions.	  	  	  No	  significant	  correlation	  was	  observed	  between	  modification	  frequencies	  and	  enrichment	  of	  sequences	  with	  high	  frequencies	  of	  A-­‐G	  transitions	  (for	  Spearman’s	  rank	  correlation	  coefficient).	  However	  a	  modest	  but	  significant	  correlation	  (P	  =	  0.04)	  was	  seen	  for	  vector	  modification	  (measured	  at	  day	  48)	  and	  deletion	  frequency	  for	  HIVBaL	  challenged	  mice.	  	  Significance	  was	  achieved	  when	  deletions	  of	  about	  70	  bp	  or	  larger	  were	  studied,	  which	  we	  know	  are	  enriched	  in	  vector-­‐treated	  mice,	  but	  not	  with	  shorter	  lengths	  (data	  not	  shown).	  	  We	  thus	  conclude	  that	  a	  possible	  modest	  positive	  correlation	  could	  be	  seen	  where	  increased	  vector	  modification	  was	  associated	  with	  increased	  deletion	  frequency.	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Discussion	  
	  Here	  we	  report	  modeling	  the	  effects	  of	  an	  HIV	  envAS	  vector	  on	  HIV	  challenge	  virus	  under	  conditions	  where	  cells	  harboring	  the	  envAS	  construct	  were	  a	  minor	  component	  of	  the	  cell	  population.	  	  This	  setting	  is	  of	  interest	  because	  studies	  of	  cells	  in	  culture,	  where	  all	  cells	  contain	  the	  envAS,	  show	  strong	  inhibition	  of	  HIV	  replication	  by	  the	  envAS	  [4],	  but	  trials	  to	  date	  in	  human	  subjects	  have	  achieved	  vector	  marking	  in	  only	  a	  minority	  of	  circulating	  T	  cells.	  	  Despite	  this,	  some	  patients	  showed	  intriguing	  alterations	  in	  disease	  parameters	  [5].	  	  We	  thus	  sought	  to	  study	  in	  detail	  the	  effects	  on	  HIV	  populations	  when	  only	  a	  minority	  of	  cells	  contained	  the	  
envAS	  using	  hNSG	  mice.	  	  We	  found	  a	  significant	  enrichment	  compared	  to	  controls	  for	  sequences	  enriched	  for	  A-­‐G	  transitions	  and	  deletions	  in	  mice	  harboring	  the	  
envAS	  in	  the	  experimental	  infections	  with	  the	  HIVBaL	  challenge	  virus.	  	  	  
	  However,	  unexpectedly,	  we	  also	  found	  that	  A-­‐G	  transitions	  were	  only	  enriched	  in	  samples	  from	  the	  HIVBaL	  infections,	  and	  not	  HIVNL4-­‐3	  infections.	  	  The	  origin	  of	  the	  difference	  is	  unknown.	  	  According	  to	  one	  idea,	  the	  different	  co-­‐receptor	  usage	  of	  the	  two	  challenge	  viruses	  might	  have	  resulted	  in	  infection	  of	  two	  different	  cell	  types	  possibly	  resulting	  in	  different	  treatment	  of	  double-­‐stranded	  RNA,	  but	  at	  present	  we	  have	  no	  evidence	  in	  favor	  of	  this	  view.	  	  A	  more	  attractive	  model	  is	  that	  double-­‐stranded	  RNA	  is	  processed	  differently	  depending	  on	  whether	  the	  duplexes	  were	  perfectly	  matched	  or	  contained	  mismatches.	  	  The	  envAS	  was	  derived	  from	  HIVNL4-­‐3,	  so	  RNA	  duplexes	  formed	  with	  HIVNL4-­‐3	  RNA	  would	  be	  perfectly	  paired,	  while	  those	  with	  HIVBa	  would	  contain	  a	  mixture	  of	  paired	  and	  mismatched	  regions.	  	  Favored	  action	  at	  duplex	  regions	  near	  mismatches,	  and	  the	  observed	  RNA	  nearest	  neighbor	  preferences,	  are	  consistent	  with	  action	  of	  the	  dsRAD	  enzyme	  [20,	  21].	  	  However,	  dsRAD	  is	  also	  able	  to	  act	  on	  perfectly	  matched	  duplexes,	  so	  it	  is	  unclear	  why	  no	  A-­‐to-­‐G	  transitions	  accumulated	  in	  the	  HIVNL4-­‐3	  infection.	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The	  difference	  in	  processing	  could	  be	  a	  consequence	  of	  differential	  initial	  attack,	  in	  which	  only	  RNA	  duplexes	  containing	  mismatches	  are	  substrates	  for	  the	  duplex-­‐processing	  enzyme.	  	  However,	  another	  possibility	  is	  that	  the	  perfect	  duplexes	  are	  attacked	  but	  degraded	  more	  quickly,	  so	  that	  no	  HIV	  sequences	  with	  perfect	  matches	  survive	  to	  allow	  detection	  even	  by	  deep	  sequencing.	  	  We	  presently	  have	  no	  basis	  for	  favoring	  either	  model.	  	  	  The	  origins	  of	  the	  deletions	  in	  the	  HIVBaL	  challenge	  virus	  seen	  here	  and	  in	  a	  previous	  study	  [4]	  are	  unclear.	  	  Not	  only	  must	  the	  RNA	  duplex	  be	  cleaved,	  it	  must	  be	  rejoined	  to	  form	  the	  internal	  deletion	  detected	  by	  sequencing.	  	  One	  candidate	  mechanism	  involves	  cleavage	  by	  a	  double-­‐strand	  specific	  ribonuclease	  (RNAse	  III)	  such	  as	  Drosha,	  followed	  by	  copy-­‐choice	  polymerization	  by	  reverse	  transcriptase,	  so	  that	  template	  switching	  from	  a	  broken	  RNA	  template	  to	  a	  site	  elsewhere	  on	  a	  second	  HIV	  RNA	  would	  yield	  the	  observed	  internal	  deletion.	  	  We	  did	  not	  observe	  enrichment	  for	  deletions	  following	  HIVNL4-­‐3	  challenge,	  so	  one	  model	  would	  hold	  that	  the	  RNAse	  III	  involved	  acts	  preferentially	  on	  mismatched	  dsRNA.	  	  However,	  we	  note	  that	  the	  same	  results	  would	  be	  obtained	  if	  products	  of	  cleavage	  of	  perfectly	  matched	  RNA	  were	  rapidly	  degraded.	  	  No	  positive	  correlation	  was	  seen	  between	  the	  deletions	  and	  A-­‐G	  transitions,	  indicating	  that	  the	  enzyme	  systems	  responsible	  for	  RNA	  cleavage	  and	  RNA	  editing	  are	  likely	  acting	  independently.	  	  It	  is	  surprising	  that	  modification	  of	  only	  4-­‐11%	  of	  cells	  in	  the	  mice	  could	  have	  caused	  detectable	  alterations	  in	  the	  HIVBaL	  population,	  and	  similarly	  surprising	  to	  observe	  possible	  alterations	  in	  disease	  parameters	  in	  human	  subjects	  after	  gene	  therapy	  with	  a	  similar	  envAS	  vector	  [5].	  	  However,	  it	  is	  possible	  that	  mobilization	  of	  the	  VRX494	  envAS	  vector	  augmented	  the	  effect.	  	  The	  VRX494	  vector	  contains	  intact	  LTRs,	  the	  cis	  sites	  needed	  for	  RNA	  packaging,	  reverse	  transcription,	  and	  integration,	  and	  also	  sites	  needed	  for	  response	  to	  Tat	  and	  Rev.	  Thus,	  if	  a	  cell	  harboring	  the	  integrated	  VRX494	  provirus	  were	  infected	  by	  HIV,	  the	  VRX494	  provirus	  could	  be	  transcribed,	  then	  the	  RNA	  exported	  from	  the	  nucleus,	  packaged	  and	  released.	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Infection	  into	  a	  naïve	  cell,	  followed	  by	  reverse	  transcription	  and	  integration,	  would	  achieve	  spread	  of	  the	  VRX494	  envAS	  vector	  between	  cells.	  	  Such	  conditional	  replication	  of	  the	  vector	  could	  expand	  the	  proportion	  of	  vector-­‐containing	  cells	  and	  increase	  the	  likelihood	  of	  accumulating	  the	  observed	  mutations	  in	  the	  challenge	  viruses.	  	  	  	  Are	  the	  A-­‐to-­‐G	  transitions	  and	  deletions	  viral	  escape	  mutations?	  	  This	  is	  an	  important	  question	  and	  the	  answer	  is	  not	  fully	  clarified	  here,	  but	  at	  present	  it	  seems	  unlikely	  that	  they	  confer	  escape.	  	  The	  large	  deletions	  in	  HIV	  envelope	  are	  sure	  to	  be	  
env-­‐minus,	  and	  a	  few	  A-­‐to-­‐G	  transitions	  in	  an	  ~900	  bp	  duplex	  are	  not	  likely	  to	  destabilize	  RNA	  pairing	  significantly.	  	  More	  likely	  the	  mutations	  that	  accumulate	  in	  HIVBaL	  are	  by-­‐products	  of	  the	  action	  of	  cellular	  RNA-­‐modifying	  enzymes	  that	  inhibit	  viral	  replication.	  The	  modified	  RNAs	  with	  deletions	  could	  persist	  in	  the	  population	  by	  complementation	  during	  co-­‐infection	  with	  wild-­‐type	  viruses,	  as	  they	  were	  found	  in	  viral	  particles	  in	  serum.	  	  They	  may	  also	  be	  continually	  arising	  de	  novo	  in	  the	  infected	  cell	  populations	  during	  ongoing	  viral	  replication,	  or	  else	  complementation	  may	  be	  efficient	  enough	  to	  maintain	  modified	  RNAs	  in	  the	  population	  for	  multiple	  generations.	  	  The	  experimental	  protocol	  used	  here	  differed	  from	  the	  clinical	  trial	  in	  the	  order	  of	  gene	  modification	  versus	  HIV	  infection.	  In	  the	  clinical	  trial,	  gene-­‐modified	  cells	  were	  re-­‐infused	  into	  patients	  with	  pre-­‐existing	  HIV	  infection.	  In	  our	  hNSG	  mouse	  model,	  the	  cells	  were	  first	  gene-­‐modified	  and	  mice	  were	  infected	  afterward.	  The	  composition	  of	  pre-­‐existing	  viral	  populations	  can	  affect	  disease	  course	  [22],	  and	  this	  may	  be	  modified	  by	  prior	  treatment	  history.	  Thus,	  it	  would	  be	  of	  potential	  interest	  to	  compare	  effects	  of	  infection	  first	  followed	  by	  envAS	  modification	  in	  the	  hNSG	  model.	  	  To	  summarize,	  we	  observe	  significant	  effects	  of	  envAS	  pressure	  in	  vivo	  when	  only	  4-­‐11%	  of	  HIV-­‐1	  target	  CD4+	  T	  cells	  are	  gene-­‐modified.	  	  The	  effects	  were	  only	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detectable	  with	  divergent	  env	  target	  sequence,	  suggesting	  action	  of	  dsRNA-­‐modifying	  enzymes	  acting	  on	  imperfectly	  matched	  sequences.	  	  As	  envAS	  has	  been	  shown	  to	  control	  HIV-­‐1	  replication	  and	  has	  also	  been	  deemed	  safe	  in	  gene	  therapeutic	  clinical	  trails,	  this	  represents	  a	  promising	  antiviral	  agent.	  	  	  
Materials	  and	  Methods	  
	  
Transduction	  and	  culture	  of	  primary	  human	  CD4	  T	  cells	  	  All	  human-­‐related	  studies	  were	  done	  per	  Declaration	  of	  Helsinki	  Protocols.	  Primary	  human	  CD4+	  T	  cells	  were	  obtained	  from	  the	  University	  of	  Pennsylvania	  CFAR	  Immunology	  Core	  under	  an	  institutional	  review	  board	  (IRB)	  approved	  protocol	  and	  stimulated	  with	  anti-­‐CD3	  and	  anti-­‐CD28	  antibody-­‐coated	  beads	  as	  previously	  described	  [23].	  The	  following	  day	  the	  activated	  T	  cells	  were	  either	  left	  alone	  (untransduced),	  or	  transduced	  with	  VRX494	  [24],	  expanded	  and	  frozen.	  This	  work	  was	  done	  in	  the	  Riley	  lab.	  	  
Infection	  of	  humanized	  NOD/SCID	  IL-­2Rγnull	  (hNSG)	  mice	  	  NSG	  mice	  (NOD.Cg-­‐Prkdcscid	  Il2rgtm1Wjl/SzJ	  stock)	  were	  obtained	  from	  the	  Jackson	  Laboratory	  (Bar	  Harbor,	  ME)	  and	  bred	  and	  housed	  in	  the	  University	  of	  Pennsylvania	  Xenograft	  and	  Stem	  Core	  Lab.	  	  Before	  injection,	  each	  expanded	  cell	  population	  was	  thawed	  and	  transduced	  cells	  were	  mixed	  with	  untransduced	  T	  cells	  so	  that	  the	  final	  concentration	  of	  transduced	  T	  cells	  was	  approximately	  10%.	  	  The	  mixed	  cells	  were	  washed	  in	  phosphate-­‐buffered	  saline	  (PBS)	  and	  10	  million	  cells	  were	  injected	  intravenously	  into	  each	  mouse.	  A	  total	  of	  20	  animals	  received	  cells	  containing	  10%	  transduced	  cells	  with	  VRX494,	  whereas	  20	  animals	  received	  only	  the	  untransduced	  cells.	  	  The	  HIV-­‐1	  based	  vector	  VRX494	  used	  in	  this	  study	  encodes	  an	  envAS	  complementary	  to	  the	  HIVNL4-­‐3	  	  env	  gene.	  After	  20	  days,	  the	  number	  and	  percentage	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of	  GFP-­‐positive,	  CD4+	  T	  cells	  within	  the	  NSG	  mouse	  peripheral	  blood	  was	  measured	  using	  TruCount	  beads	  as	  per	  the	  manufacturer’s	  recommendation	  (BD	  Biosciences,	  San	  Jose,	  CA).	  One	  mouse	  in	  the	  control	  group	  showed	  poor	  engraftment	  and	  was	  excluded	  from	  further	  studies.	  For	  both	  control	  and	  VRX494-­‐treated	  groups,	  the	  engraftment	  data	  (and	  additionally	  the	  engrafted	  proportions	  of	  VRX494-­‐modified	  cells	  for	  the	  treated	  group)	  were	  used	  to	  randomize	  mice	  between	  the	  HIVNL4-­‐3	  and	  HIVBaL	  challenge	  cohorts.	  Each	  group	  of	  mice	  was	  then	  challenged	  with	  the	  supernatants	  of	  293	  T	  cells	  transfected	  with	  molecular	  clones	  of	  HIV-­‐1	  expressing	  either	  the	  HIVNL4-­‐3	  or	  HIVBaL	  env	  sequence	  [pNL4-­‐3,	  a	  gift	  of	  VIRxSYS	  (Gaithersburg,	  MD)	  and	  pWT/BaL,	  obtained	  from	  the	  NIH	  AIDS	  Research	  &	  Reference	  Reagent	  Program	  (Germantown,	  MD),	  respectively].	  	  HIV-­‐1	  infection	  of	  reconstituted	  mice	  was	  performed	  at	  Bioqual	  (Rockville,	  MD)	  under	  an	  approved	  animal	  protocol.	  	  
Amplification	  and	  deep	  sequencing	  of	  HIV	  quasispecies	  	  Total	  RNA	  was	  extracted	  from	  mouse	  plasma	  samples	  using	  the	  Illustra	  RNAspin	  kit	  (GE	  Healthcare,	  Buckinghamshire,	  UK)	  with	  RNA	  carrier	  added	  to	  improve	  extraction	  efficiency.	  Composite	  primers	  (Table	  3.3)	  made	  of	  454	  sequencing	  adapters,	  barcodes	  and	  HIVenv	  primers,	  5’	  to	  3’	  in	  that	  order,	  were	  used	  to	  amplify	  HIV-­‐1	  RNA	  by	  One-­step	  RT-­‐PCR	  (Qiagen,	  Valencia,	  CA)	  using	  RNasin	  RNase	  inhibitor	  (Promega,	  Madison,	  WI)	  and	  a	  touch-­‐down	  protocol	  (with	  a	  total	  of	  30	  cycles	  of	  amplification)	  as	  follows:	  	  1	  x	  (30	  min	  at	  50°C),	  1	  x	  (15	  min	  at	  95°C),	  10	  x	  (1	  min	  at	  94°C;	  1	  min	  at	  58°C-­‐53°C,	  0.5°C	  iterative	  decrement;	  1	  min	  at	  72°C)	  (starting	  with	  a	  temperature	  of	  58°C	  and	  reducing	  it	  successively	  by	  0.5°C	  to	  reach	  53°C),	  20	  x	  (1	  min	  at	  94°C;	  1	  min	  at	  53°C;	  1	  min	  15	  sec	  at	  72°C),	  1	  x	  (10	  min	  at	  72°C;	  maintained	  at	  4°C).	  	  Amplified	  products	  were	  gel-­‐purified	  separately	  for	  each	  mouse-­‐amplicon	  combination	  and	  pooled	  following	  DNA	  quantitation	  by	  Quant-­iT	  PicoGreen	  dsDNA	  Assay	  kit	  (Molecular	  Probes,	  Invitrogen,	  Eugene,	  OR).	  Pooled	  sequences	  were	  pyrosequenced	  using	  the	  454/Roche	  platform	  at	  the	  University	  of	  Pennsylvania.	  A	  total	  of	  84,074	  raw	  reads	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were	  recovered.	  These	  have	  been	  deposited	  with	  the	  Sequence	  Read	  Archive	  (SRA)	  of	  National	  Center	  for	  Biotechnology	  Information	  (NCBI)	  under	  submission	  accession	  SRA010586.3.	  The	  raw	  reads	  have	  accessions	  SRR033739.1-­‐SRR033739.84074.	  	  
(a)	  
Sequence envAS 
Primer 454 Adapter Barcode envAS Primer 
for NL4-3     
EnvF6553 GCCTCCCTCGCGCCATCAG Listed  ATGGGATCAAAGCCTAAAGCC 
EnvR6954 GCCTTGCCAGCCCGCTCAG in (b) CATTGTACTGTGCTGACATTTGTAC 
EnvF7184 GCCTCCCTCGCGCCATCAG  GGAAATATGAGACAAGCACATTG 
EnvR7587 GCCTTGCCAGCCCGCTCAG  CCATCTCTTGTTAATAGCAGCCC 
for BaL     
EnvF701 GCCTCCCTCGCGCCATCAG Listed  ATGGGATCAAAGCCTAAAGCC 
EnvR1123 GCCTTGCCAGCCCGCTCAG in (b) CATTGTACTGTGCTGACATTTGAAC 
EnvF1350 GCCTCCCTCGCGCCATCAG  GGAGATATAAGACAAGCACATTG 
EnvR1738 GCCTTGCCAGCCCGCTCAG  CCATCTCTTGTTAATAGCAGCCC 
        
	  
(b)	  
Barcode Sequence Mice Barcode Sequence Mice 
         
bc1 CAGTCAGT 1050 bc18 TCACTGTC 985 
bc2 ACACACTG 1090 bc19 TCTGTGAG 1037 
bc3 ACGACATC 1044 bc20 TGAGTCAC 1089 
bc4 AGACACTC 1046 bc21 ACAGACTC 1093 
bc5 ATATCGCG 1048 bc22 ACTGCTGA 946 
bc6 ATCGATGC 1051 bc23 AGCACTAC 948 
bc7 CACTACAG 1055 bc24 AGTCGTCA 1038 
bc8 CGATATGC 1086 bc25 AGTGTCAC 1040 
bc9 CGTACGAT 1087 bc26 CACTGTGA 1094 
bc10 CTACGATG 1092 bc27 CATCGTAG 1136 
bc11 GACACTCA 1042 bc28 CGATGCTA 1137 
bc12 GAGTACAG 1045 bc29 CTAGTGCA 1139 
bc13 GCATATCG 1047 bc30 GAGTGACA 1091 
bc14 GCTACGTA 1052 bc31 TCACGAGT 1095 
bc15 GTACACGT 1053 bc32 TCGACATG 1138 
bc16 TACGATCG 1085 bc33 TGAGCACT 1140 
bc17 TAGCGCAT 947      
            
	  
Table	  3.3	  Sequences	  of	  oligonucleotides	  and	  barcodes	  used	  in	  this	  study.	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(a)	  Composite	  primers.	  There	  are	  4	  primers	  each	  for	  the	  HIVNL4-­‐3	  and	  HIVBaL	  template	  corresponding	  to	  the	  ones	  depicted	  in	  Figure	  3.2.	  For	  envAS	  primer,	  ‘EnvF’	  and	  ‘EnvR’	  refer	  to	  the	  forward	  and	  reverse	  primers	  respectively	  whereas	  the	  following	  numbers	  refer	  to	  the	  starting	  genomic	  coordinates	  on	  the	  HIVNL4-­‐3	  and	  HIVBaL	  templates.	  The	  composite	  primer	  sequence	  is	  made	  up	  of	  454	  adapter,	  barcode	  and	  the	  actual	  envAS	  primer	  (from	  5’	  to	  3’).	  (b)	  List	  of	  unique	  barcodes	  with	  their	  8	  bp	  sequence	  and	  tagged	  mouse.	  Barcodes	  1-­‐10	  and	  21-­‐29	  were	  used	  to	  tag	  mice	  challenged	  with	  HIVNL4-­‐3	  while	  barcodes	  11-­‐20	  and	  30-­‐33	  were	  used	  for	  mice	  challenged	  with	  HIVBaL.	  
	  
Bioinformatics	  	  Pyrosequence	  reads	  were	  barcode-­‐decoded	  for	  assignment	  to	  source	  mouse	  samples.	  	  Sequence	  reads	  were	  filtered	  for	  exact	  match	  to	  primers.	  To	  remove	  sequences	  shorter	  than	  the	  read	  length	  distribution	  peak,	  that	  are	  known	  to	  have	  high	  454	  error	  rates,	  additional	  filtering	  was	  carried	  out	  to	  select	  only	  sequences	  
≥220	  bases	  long.	  Reference	  genomes	  corresponding	  to	  the	  HIVNL4-­‐3	  and	  HIVBaL	  infection	  stocks	  were	  obtained	  from	  NCBI’s	  nucleotide	  database	  (http://www.ncbi.nlm.nih.gov/nuccore/),	  accession	  IDs	  M19921	  (Version:	  M19921.1,	  GI:	  328415)	  and	  M63929	  (Version:	  M63929.1,	  GI:	  326765).	  Viral	  infection	  stocks	  were	  Sanger-­‐sequenced	  and	  verified	  that	  they	  matched	  the	  respective	  NCBI	  sequences	  for	  the	  genomic	  region	  analyzed.	  Sequences	  were	  then	  aligned	  to	  the	  reference	  HIV-­‐1	  genome	  using	  the	  Needleman-­‐Wunsch	  pair-­‐wise	  global	  alignment	  (PWA)	  algorithm	  with	  a	  match	  score	  of	  5,	  and	  gap	  opening	  and	  extension	  penalties	  of	  20	  and	  0.5.	  A	  few	  sequences	  from	  HIVNL4-­‐3	  challenge	  group	  had	  a	  higher	  alignment	  score	  to	  the	  HIVBaL	  reference	  and	  vice-­‐versa;	  these	  were	  classified	  as	  apparent	  sequence	  crossovers	  and	  were	  excluded	  from	  further	  analysis.	  	  For	  remaining	  sequences	  in	  HIVNL4-­‐3	  and	  HIVBaL	  group,	  two	  multiple	  sequence	  alignments	  (MSAs)	  were	  created,	  one	  for	  each	  group,	  by	  parsing	  the	  individual	  PWAs	  within	  each	  group.	  Finally,	  primer	  sequences	  were	  trimmed	  from	  each	  sequence	  because	  these	  are	  not	  part	  of	  the	  viral	  genome	  actually	  sampled.	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All	  statistical	  programming	  and	  tests	  were	  performed	  in	  the	  R	  computing	  framework	  (http://www.r-­‐project.org/).	  One	  sided	  statistical	  tests	  were	  used	  for	  analysis	  of	  the	  A-­‐G	  substitutions	  and	  deletions	  because	  a	  previous	  report	  established	  a	  directional	  hypothesis	  (increased	  frequency	  after	  treatment)	  [4].	  	  
A-­G	  analysis:	  For	  each	  MSA,	  base	  positions	  having	  more	  than	  50%	  change	  from	  the	  reference	  sequence	  base	  over	  all	  other	  sequences	  (discounting	  MSA	  gaps)	  were	  excluded,	  by	  reasoning	  that	  the	  preferred	  base	  reported	  by	  pyrosequencing	  could	  likely	  be	  the	  correct	  base	  at	  these	  positions.	  For	  the	  HIVBaL	  MSA,	  of	  the	  994	  positions	  sampled	  by	  our	  amplification	  scheme,	  22	  positions	  were	  excluded,	  of	  which	  17	  were	  in	  regions	  of	  high	  coverage	  (>1000	  reads	  per	  position)	  corresponding	  to	  the	  shorter	  two	  amplicons.	  For	  HIVNL4-­‐3,	  all	  40	  positions	  excluded	  (out	  of	  991)	  were	  in	  the	  low	  coverage	  region	  between	  the	  shorter	  two	  amplicons	  (<30	  reads	  per	  position).	  For	  each	  base-­‐change,	  overall	  probability	  of	  the	  event	  was	  obtained	  from	  the	  pool	  of	  all	  informative	  sequences	  (see	  Results).	  Using	  this,	  a	  binomial	  distribution	  based	  P	  value	  was	  assigned	  per	  sequence	  based	  on	  the	  observed	  proportion	  of	  base-­‐change	  in	  a	  sequence.	  This	  P	  value	  was	  termed	  the	  enrichment	  level	  and	  the	  –log10	  of	  this	  was	  called	  the	  enrichment	  score.	  For	  each	  base-­‐change,	  excess	  within	  the	  vector-­‐treated	  cohort,	  of	  sequences	  with	  a	  minimum	  enrichment	  was	  statistically	  inferred.	  	  For	  the	  pooled	  analysis,	  i.e.,	  taking	  vector-­‐treated	  group	  as	  a	  whole,	  this	  was	  done	  by	  Fisher’s	  exact	  test.	  For	  un-­‐pooled	  analysis	  Mann-­‐Whitney	  test	  was	  done.	  In	  each	  case,	  statistical	  significance	  was	  tested	  with	  enrichment	  scores	  up	  to	  4	  (P	  value	  of	  0.0001)	  and	  displayed	  as	  –log10	  of	  the	  P	  value	  (Figure	  3.5a,b).	  	  
Investigating	  Sequence	  Features	  for	  A-­G	  modifications:	  	  (a)	  Conserved	  Motifs.	  To	  research	  sequence	  motifs	  on	  the	  HIV-­‐1	  genome	  associated	  with	  A-­‐G	  transitions,	  for	  informative	  sequences,	  sites	  with	  enriched	  changes	  in	  the	  vector-­‐treated	  group	  were	  chosen.	  Sites	  were	  selected	  at	  an	  enrichment	  corresponding	  to	  P	  value	  ≤0.05	  by	  Fisher’s	  exact	  test.	  Reference	  genome	  positions	  10	  bases	  upstream	  and	  downstream	  of	  each	  site	  were	  aligned	  and	  WebLogo	  was	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used	  for	  information	  content	  analysis	  (http://weblogo.berkeley.edu/)	  to	  detect	  conserved	  motifs.	  	  (b)	  Neighbor	  Base	  Rules.	  All	  instances	  of	  XA	  and	  AX	  dinucleotides	  in	  the	  envAS	  target	  region	  were	  tabulated,	  X	  ∈	  {A,T,G,C}.	  Then	  for	  each	  X,	  in	  both	  cases	  of	  X	  being	  5’	  or	  3’	  to	  A,	  the	  proportion	  of	  instances	  the	  A	  was	  a	  statistically	  preferred	  site	  for	  transitioning	  to	  G	  (as	  determined	  in	  (a)	  above	  with	  Fisher’s	  exact	  test)	  was	  calculated.	  (c)	  Genomic	  Distribution	  in	  Relation	  to	  Complementarity.	  The	  fraction	  of	  sites	  in	  the	  HIVBaL	  template	  that	  were	  complementary	  to	  envAS	  was	  calculated	  across	  the	  envAS	  targeted	  region	  with	  a	  sliding	  window	  of	  25	  bases.	  Similarly,	  of	  all	  A	  sites,	  the	  fraction	  of	  A	  sites	  statistically	  preferred	  for	  transitioning	  to	  G	  (as	  determined	  in	  (a)	  above	  with	  Fisher’s	  exact	  test)	  was	  calculated.	  The	  correlation	  between	  the	  two	  quantities	  was	  estimated	  by	  Spearman’s	  rank	  correlation	  coefficient.	  	  
Deletion	  Analysis:	  Small	  deletions	  can	  arise	  by	  chance	  among	  viral	  quasi-­‐species	  or	  during	  sample	  work	  up,	  so	  meaningful	  deletions	  were	  qualified	  as	  only	  those	  which	  had	  a	  length	  >10	  bases.	  	  Additionally	  deletions	  were	  required	  to	  have	  a	  ≥10	  base	  long	  gapless	  aligned	  region	  at	  both	  ends.	  With	  this	  constraint,	  the	  hope	  was	  to	  select	  deletions	  that	  are	  biological	  while	  weeding	  out	  those	  that	  could	  be	  generated	  as	  alignment	  artifacts	  through	  gapped	  matching	  of	  a	  few	  error-­‐prone	  bases.	  Two	  deletion-­‐related	  quantities	  were	  defined	  for	  each	  sequence:	  1)	  Total	  deletion	  length,	  representing	  the	  cumulative	  length	  of	  all	  qualifying	  deletions,	  and	  2)	  Maximum	  
deletion	  length,	  representing	  the	  length	  of	  the	  longest	  qualifying	  deletion.	  Then	  the	  spectrum	  of	  total	  deletion	  lengths	  that	  can	  be	  assayed	  by	  our	  study	  ranges	  from	  11	  to	  ~900	  bases,	  the	  upper	  limit	  being	  imposed	  by	  the	  longest	  amplicon.	  For	  each	  possible	  deletion	  length	  in	  this	  range,	  sequences	  with	  cumulative	  deletions	  of	  at	  least	  that	  size	  were	  selected	  and	  tested	  for	  excess	  in	  vector-­‐treated	  mice	  (un-­‐pooled	  analysis).	  Statistical	  significance	  was	  inferred	  by	  Mann-­‐Whitney	  test	  and	  displayed	  as	  –log10	  of	  the	  p-­‐value	  (Figure	  3.6b,c).	  Repeating	  analysis	  with	  maximum	  deletion	  length	  did	  not	  alter	  results	  significantly.	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Chapter	  4 EFFECTS	  OF	  ENV	  ANTISENSE	  VISIBLE	  IN	  PATIENTS	  IN	  A	  CLINICAL	  TRIAL	  	  This	  work	  is	  being	  prepared	  for	  publication.	  
	  
Abstract	  
	  Antisense	  sequences	  targeting	  HIV	  genomic	  RNA	  provide	  a	  mechanism	  to	  control	  the	  virus.	  These	  inhibited	  HIV	  in	  tissue	  culture	  studies	  and	  mice	  offering	  an	  attractive	  choice	  for	  anti-­‐HIV	  gene	  therapy	  strategies.	  T	  cells	  modified	  with	  an	  antisense	  directed	  against	  HIV	  env	  were	  shown	  to	  control	  heterogeneous	  viral	  strains	  in	  vitro.	  Subsequently,	  this	  env	  antisense	  or	  envAS	  became	  the	  first	  of	  its	  kind	  to	  be	  used	  in	  a	  clinical	  trial.	  Antisense	  was	  delivered	  to	  patient	  T	  cells	  by	  lentiviral	  vectors.	  This	  was	  also	  the	  first	  use	  of	  a	  lentiviral	  vector	  in	  a	  clinical	  setting.	  A	  few	  participants	  exhibited	  reduction	  in	  viral	  loads	  and	  improvements	  in	  immune	  function.	  To	  assess	  envAS	  pressure	  on	  evolving	  virus,	  we	  simulated	  the	  clinical	  trial	  
in	  vivo	  in	  a	  mouse	  model.	  Consistent	  with	  previous	  work	  that	  studied	  envAS	  in	  vitro,	  we	  observed	  enrichment	  of	  molecular	  signatures	  on	  virus	  impacted	  by	  envAS	  –	  in	  the	  form	  of	  A-­‐G	  changes	  and	  deletions.	  Here	  we	  investigated	  8	  patients	  participating	  in	  a	  follow-­‐up	  phase	  I/II	  trial	  for	  evidence	  of	  such	  signatures	  in	  virus	  rebounding	  during	  structured	  treatment	  interruption	  (STI).	  We	  included	  9	  patients	  from	  an	  unrelated	  trial	  STI	  as	  a	  control	  group.	  All	  patients	  were	  studied	  longitudinally	  over	  2-­‐5	  time-­‐points.	  A	  total	  of	  218,756	  reads	  obtained	  by	  454/Roche	  pyrosequencing	  were	  condensed	  into	  127,290	  viral	  variants	  following	  quality	  filtering	  and	  error	  control	  by	  Pyronoise.	  There	  was	  an	  indication	  of	  a	  higher	  rate	  for	  A-­‐G	  transitions	  within	  the	  envAS-­‐target	  region	  for	  treated	  patients	  as	  compared	  to	  controls.	  This	  recapitulates	  findings	  in	  the	  mouse	  study,	  although	  the	  signal	  is	  weaker.	  Interestingly,	  the	  A-­‐G	  effect	  is	  detectable	  only	  in	  the	  initial	  time-­‐point	  in	  the	  treated	  patients.	  We	  did	  not	  find	  a	  similar	  trend	  for	  deletions,	  although	  in	  a	  pooled	  analysis	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over	  groups,	  there	  were	  more	  deletions	  in	  the	  treated.	  This	  analysis	  illustrates	  that	  
envAS	  exerts	  pressure	  on	  circulating	  virus	  in	  patients.	  The	  signal	  is	  faint	  but	  this	  is	  likely	  a	  consequence	  of	  the	  low	  levels	  and	  persistence	  of	  envAS-­‐modified	  cells	  in	  the	  clinical	  trial.	  	  
Introduction	  	  Survival	  rates	  for	  HIV-­‐infected	  patients	  have	  improved	  dramatically	  with	  the	  advent	  of	  HAART	  or	  combination	  anti-­‐retroviral	  drug	  therapy.	  HAART	  suppresses	  virus	  replication,	  however,	  it	  has	  failed	  to	  cure	  patients	  of	  HIV	  completely.	  Latent	  reservoirs	  of	  HIV	  [1-­‐3]	  persist	  in	  the	  patients	  undergoing	  HAART,	  contributing	  to	  residual	  levels	  of	  viremia	  [4-­‐6].	  Treated	  patients	  still	  suffer	  from	  reduced	  life	  expectancy	  and	  increased	  risk	  of	  complications	  such	  as	  cardiovascular,	  hepatic	  or	  renal	  diseases,	  and	  cancer	  [7].	  Further,	  HAART	  often	  does	  not	  restore	  CD4	  T	  cells	  to	  normal	  pre-­‐infection	  levels	  [8].	  Drug-­‐related	  toxicities	  and	  persistent	  immune	  deficiencies	  likely	  contribute	  to	  premature	  ageing-­‐related	  deficiencies.	  To	  develop	  alternatives,	  research	  on	  anti-­‐HIV	  gene	  and	  cell	  therapy	  has	  been	  conducted	  for	  many	  years.	  The	  recent	  case	  of	  the	  Berlin	  patient,	  who	  reportedly	  is	  cured	  of	  HIV	  following	  chemotherapy	  and	  transplantation	  of	  HIV-­‐resistant	  cells	  [9,	  10],	  holds	  promise	  for	  such	  approaches.	  	  Inhibition	  of	  HIV	  in	  vitro	  by	  antisense	  oligonucleotides	  was	  among	  the	  first	  anti-­‐HIV	  strategies	  reported	  in	  the	  beginning	  years	  of	  the	  AIDS	  pandemic	  [11,	  12].	  By	  the	  early	  1990s	  researchers	  had	  described	  HIV	  suppression	  in	  vitro	  by	  T	  cells	  modified	  with	  antisense	  that	  targeted	  HIV	  gag	  [13,	  14]	  or	  tat,	  env	  and	  rev	  in	  conjunction	  [15].	  The	  first	  antisense-­‐based	  gene	  therapy	  clinical	  trial	  was	  conducted	  in	  2006	  at	  the	  University	  of	  Pennsylvania	  [16].	  This	  was	  also	  the	  first	  time	  a	  lentiviral	  vector	  was	  used	  in	  the	  clinic,	  to	  modify	  autologous	  human	  CD4	  T	  cells	  before	  their	  reinfusion	  into	  HIV	  infected	  patients	  who	  were	  failing	  their	  HAART	  regimens.	  The	  outline	  of	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this	  procedure	  is	  illustrated	  in	  Figure	  4.1.	  The	  vector	  was	  called	  VRX496	  and	  its	  payload	  was	  an	  antisense	  targeting	  HIV	  env,	  which	  had	  been	  shown	  to	  control	  HIV	  replication	  in	  vitro	  [17,	  18].	  The	  results	  of	  this	  phase	  I	  trial	  was	  encouraging	  –	  there	  were	  no	  safety	  concerns	  and	  therapeutic	  benefits	  in	  terms	  of	  lowering	  of	  viral	  load	  and	  increase	  in	  CD4	  cell	  counts	  were	  observed	  in	  some	  participants.	  This	  motivated	  the	  design	  of	  a	  subsequent	  clinical	  trial	  to	  study	  if	  VRX496	  could	  suppress	  HIV	  in	  the	  absence	  of	  HAART.	  
Accordingly	  a	  phase	  I/II	  trial	  was	  set	  up	  also	  at	  University	  of	  Pennsylvania	  (clinicaltrials.gov	  Id	  NCT00295477).	  This	  enrolled	  HIV-­‐positive	  patients	  who	  were	  on	  HAART	  with	  no	  detectable	  virus	  (<50	  copies/ml).	  As	  earlier	  [16],	  clinicians	  infused	  participants	  with	  10	  billion	  VRX496-­‐modified	  autologous	  CD4	  T	  cells	  –	  either	  3	  or	  6	  such	  doses	  were	  administered.	  This	  was	  followed	  by	  a	  structured	  
Figure	  4.1	  Steps	  in	  the	  anti-­HIV	  antisense-­based	  gene	  therapy	  of	  HIV	  infected	  patients	  with	  
VRX496	  vector.	  Permission	  to	  reuse	  this	  figure	  was	  granted	  by	  the	  publisher,	  ©	  2009	  VIRxSYS	  Corporation,	  Gaithersburg,	  MD.	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treatment	  interruption	  (STI)	  wherein	  HAART	  was	  suspended.	  Of	  13	  patients	  who	  underwent	  STI,	  8	  could	  be	  considered	  for	  evaluation	  of	  study	  endpoints	  [19].	  The	  primary	  efficacy	  parameters	  involved	  post-­‐STI	  measurements	  of	  time	  to	  viral	  recrudescence,	  viral	  load	  and	  CD4	  counts	  in	  relation	  to	  that	  at	  baseline,	  persistence	  of	  modified	  cells,	  and	  safety.	  	  	  The	  study	  is	  ongoing	  but	  important	  observations	  have	  already	  been	  made	  [19].	  VRX496-­‐modified	  cells	  persisted	  long-­‐term	  in	  participants.	  Although	  levels	  of	  modified	  cells	  reduced	  over	  time,	  they	  were	  detectable	  in	  all	  patients	  for	  30	  weeks	  post-­‐infusion	  to	  beyond	  a	  year	  in	  some.	  No	  serious	  adverse	  events	  have	  been	  reported	  and	  CD4	  counts	  have	  remained	  stable	  post-­‐STI	  compared	  to	  baseline.	  Interestingly	  two	  patients	  exhibited	  delayed	  viral	  recrudescence	  –	  viral	  breakthrough	  was	  observed	  respectively	  at	  1	  and	  4	  months	  post-­‐STI.	  Return	  of	  viremia	  following	  treatment	  interruption	  of	  HAART	  normally	  occurs	  within	  2	  months	  [20-­‐22]	  so	  viral	  suppression	  in	  the	  absence	  of	  HAART	  for	  4	  months	  was	  unusual.	  Further,	  the	  viral	  load	  set	  point	  following	  recrudescence	  was	  below	  the	  pre-­‐HAART	  baseline	  value	  except	  in	  one	  patient.	  This	  amounted	  to	  a	  significant	  increase	  in	  the	  numbers	  of	  patients	  experiencing	  such	  a	  lowering	  of	  viral	  loads	  post-­‐STI	  compared	  to	  observations	  made	  before	  in	  a	  similar	  setting	  of	  HAART	  interruption	  [23].	  	  	  Given	  these	  promising	  results,	  it	  was	  important	  to	  investigate	  if	  effects	  of	  antisense	  on	  the	  post-­‐STI	  evolving	  viral	  populations	  in	  the	  patients	  could	  be	  measured.	  Molecular	  effects	  of	  antisense	  on	  virus	  such	  as	  A-­‐to-­‐G	  mutations	  and	  deletions	  in	  the	  antisense-­‐target	  region	  have	  been	  documented	  previously	  in	  cell	  culture	  experiments	  [17].	  These	  findings	  were	  recapitulated	  in	  vivo	  in	  a	  mouse	  model	  of	  HIV	  [24]	  and	  is	  presented	  in	  Chapter	  3	  of	  this	  dissertation.	  This	  study	  modeled	  the	  clinical	  trial	  in	  that	  modified	  T	  cells	  were	  present	  as	  a	  minority	  of	  cells,	  similar	  to	  levels	  in	  patients	  following	  reinfusion	  of	  these	  cells.	  In	  such	  a	  scenario,	  antisense-­‐induced	  viral	  sequence	  signatures	  in	  vivo,	  if	  present,	  are	  likely	  to	  occur	  in	  a	  minority	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of	  HIV	  variants	  [24].	  Therefore	  deep	  sequencing	  was	  used	  to	  analyze	  virus	  from	  patient	  plasma	  samples,	  the	  results	  of	  which	  are	  detailed	  in	  this	  chapter.	  	  
Results	  
	  
Description	  of	  clinical	  samples	  	  All	  8	  patients	  evaluated	  in	  the	  phase	  I/II	  VRX496	  clinical	  trial	  [19]	  were	  analyzed	  longitudinally	  	  (Table	  4.1)	  (referred	  to	  as	  the	  VRX	  group).	  Patient	  218	  was	  the	  only	  participant	  to	  exhibit	  a	  rise	  in	  viral	  set	  point	  post-­‐STI	  relative	  to	  baseline.	  To	  investigate	  antisense	  pressure,	  we	  considered	  only	  those	  post-­‐STI	  time-­‐points	  after	  viral	  recrudescence	  and	  before	  patients	  restarted	  on	  HAART.	  Successive	  time	  points	  assayed	  were	  separated	  by	  4-­‐8	  weeks	  in	  an	  effort	  to	  capture	  possible	  viral	  signatures	  at	  any	  point	  during	  STI.	  	  	  For	  each	  patient	  we	  included	  the	  earliest	  time-­‐point	  post-­‐recrudescence	  available	  for	  analysis,	  because	  antisense	  pressure	  might	  be	  most	  detectable	  at	  the	  point	  of	  viral	  breakthrough.	  Virus	  was	  detectable	  in	  most	  patients	  by	  week	  4	  post-­‐STI	  [19].	  The	  earliest	  sample	  analyzed	  corresponded	  to	  week	  6	  (Table	  4.1).	  Patient	  201	  was	  an	  exception	  as	  the	  earliest	  time-­‐point	  available	  was	  for	  week	  14.	  For	  patient	  215,	  recrudescence	  was	  relatively	  delayed	  at	  6	  weeks	  but	  the	  earliest	  sample	  dated	  to	  18	  weeks.	  Patient	  252	  was	  of	  particular	  interest	  having	  suppressed	  virus	  at	  undetectable	  levels	  for	  4	  months	  post-­‐STI	  and	  had	  a	  sample	  for	  week	  18,	  which	  was	  when	  virus	  rebounded.	  All	  patient	  time-­‐points	  studied,	  together	  with	  corresponding	  viral	  load	  and	  CD4	  counts,	  are	  listed	  in	  Table	  4.1.	  	  We	  included	  as	  controls	  HIV-­‐infected	  patients	  who	  participated	  in	  a	  STI	  trial	  at	  the	  Wistar	  Institute,	  Philadelphia	  [20]	  designed	  to	  evaluate	  effects	  of	  multiple	  intermittent	  treatment	  interruptions	  (TI).	  Participants	  were	  randomized	  into	  two	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201 5/31/07 29520 730 14 1500 2663 
201 6/28/07 28174 636 18 600 1815 
201 8/23/07 18684 711 26 600 3760 
201 10/18/07 33467 687 34 300 2719 
201 12/13/07 16165 600 42 100 2756 
203 8/9/07 39524 440 6 NA 4023 
203 8/28/07 26925 462 10 300 2562 
203 10/22/07 18463 463 18 200 243 
203 12/20/07 8049 542 26 100 2199 
203 2/14/08 26563 465 34 100* 2214 
203 4/8/08 30982 462 42 100* NP 
204 11/5/07 26627 318 6 NA 1494 
204 12/3/07 5993 381 10 300 2151 
204 2/4/08 22108 301 18 100* 2337 
204 3/31/08 20650 304 26 0 3901 
204 5/22/08 16940 356 34 0 2900 
215 6/11/09 3360 388 18 100 2958 
215 8/6/09 4522 947 26 100 NP 
215 10/13/09 3952 627 34 100 1744 
215 12/16/09 3619 773 42 100 2148 
218 6/18/09 97623 617 6 NA 3380 
218 7/22/09 15497 627 10 100 2252 
218 9/16/09 28061 704 18 100 249 
218 11/11/09 24588 426 26 0 641 
218 1/6/10 19508 519 34 NA NP 
250 5/12/09 414365 424 6 NA 6180 
250 6/9/09 101458 350 10 300 3972 
251 5/12/09 77545 470 6 NA 984 
251 6/9/09 10518 450 10 500 NP 
251 8/6/09 36921 400 18 300 580 
252 10/6/09 5052 1070 18 1100 696 
252 12/8/09 365196 935 26 500 4591 	  















8 2/14/02 55812 352 4 2268 
8 3/14/02 164904 228 8 1723 
8 4/11/02 140203 234 12 4167 
14 10/4/01 18961 858 4 1855 
14 11/8/01 21246 574 9 2629 
14 11/29/01 15197 694 12 1958 
22 10/9/02 44673 893 4 1279 
22 11/6/02 9943 953 8 1447 
22 12/4/02 147500 966 12 1991 
35 5/28/03 8621 464 8 1996 
35 6/25/03 5291 393 12 1557 
35 7/30/03 8921 318 17 2389 
41 5/30/02 124747 661 8 1415 
41 6/27/02 24995 467 12 1786 
41 7/25/02 15464 533 16 2920 
43 7/17/02 14424 496 14 1476 
43 8/15/02 17247 409 18 3637 
43 11/6/02 17531 488 30 2417 
44 8/29/02 23519 341 4 2012 
44 9/25/02 63255 362 8 2576 
44 10/16/02 61417 279 11 3281 
53 2/6/03 81957 531 4 2070 
53 3/6/03 6572 701 8 1010 
53 4/3/03 6152 630 12 1441 
54 4/24/03 7860 747 4 3143 
54 5/22/03 18581 644 8 2318 
54 6/19/03 25870 636 12 2417 
	  
Table	  4.1	  Patient	  time-­points	  studied.	  Sample	  characteristics	  are	  indicated	  along	  with	  Pyronoise	  OTU	  numbers	  recovered	  by	  denoising	  raw	  454/Roche	  pyrosequence	  reads	  obtained	  for	  a	  given	  sample.	  TI:	  Treatment	  interruption;	  NA:	  Not	  available;	  NP:	  Not	  pyrosequenced	  due	  to	  insufficient	  DNA;	  100*:	  Below	  limit	  of	  detection	  	  For	  matched	  controls,	  longitudinal	  samples	  were	  obtained	  from	  nine	  patients	  from	  the	  OE-­‐TI	  period.	  Similar	  to	  VRX496	  patients,	  time-­‐points	  selected	  for	  analysis	  were	  at	  least	  4	  weeks	  apart	  with	  the	  earliest	  being	  4	  or	  8	  weeks	  following	  OE-­‐TI	  –	  except	  for	  patient	  43,	  in	  which	  case	  the	  first	  available	  time-­‐point	  was	  for	  week	  14.	  Details	  for	  control	  samples	  including	  viral	  loads	  and	  CD4	  counts	  are	  mentioned	  in	  Table	  4.1.	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Patients	  35	  and	  53	  belonged	  to	  the	  group	  with	  continuous	  HAART	  before	  OE-­‐TI,	  whereas	  the	  rest	  were	  from	  the	  group	  with	  three	  TIs	  before	  OE-­‐TI.	  	  
Viral	  RNA	  amplification	  and	  pyrosequencing	  	  RNA	  was	  extracted	  from	  plasma	  samples	  for	  each	  patient/time-­‐point	  combination	  listed	  in	  Table	  4.1.	  HIV	  RNA	  was	  reverse-­‐transcribed	  and	  amplified	  following	  which	  PCR	  products	  were	  purified	  and	  pyrosequenced.	  The	  amplification	  was	  targeted	  to	  the	  region	  of	  env	  targeted	  by	  antisense	  (envAS)	  and	  involved	  a	  modification	  of	  the	  scheme	  described	  earlier	  [24].	  To	  take	  advantage	  of	  longer	  read	  lengths	  offered	  by	  the	  454/Roche	  Titanium	  platform,	  the	  length	  of	  the	  two	  shorter	  envAS	  amplicons	  was	  increased.	  This	  also	  allowed	  inclusion	  of	  more	  positions	  outside	  the	  antisense-­‐target	  region	  for	  comparison	  to	  targeted	  nucleotides.	  On	  the	  basis	  of	  earlier	  observations	  that	  antisense-­‐mediated	  deletions	  were	  small	  (<100	  bases)	  [24],	  we	  anticipated	  that	  the	  two	  new	  envAS	  amplicons	  would	  be	  sufficient	  to	  detect	  antisense	  signatures,	  if	  any.	  	  	  
	  
The	  blow-­‐up	  shows	  the	  envAS	  target	  region	  and	  the	  amplicons	  designed	  for	  this	  study.	  Both	  Figure	  4.2	  Representation	  of	  the	  amplification	  scheme	  in	  the	  context	  of	  the	  HIVNL4-­3	  genome.	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amplicons	  include	  adjacent	  non-­‐target	  bases.	  Amplicons	  were	  sequenced	  from	  both	  directions.	  The	  first	  5’	  200	  high	  quality	  bases	  for	  pyrosequence	  reads	  correspond	  to	  the	  white	  parts	  at	  either	  end	  of	  each	  amplicon.	  All	  numbering	  pertains	  to	  HIVNL4-­‐3	  genome	  positions.	  	  The	  current	  study	  required	  amplifying	  virus	  from	  different	  patients	  potentially	  with	  heterogeneous	  HIV	  sequence	  backgrounds.	  Under	  the	  assumption	  that	  patients	  harbored	  HIV	  subtype	  B,	  which	  is	  the	  predominant	  form	  in	  the	  USA,	  the	  new	  envAS	  primers	  were	  redesigned	  to	  sites	  of	  high	  conservation	  for	  HIV	  subtype	  B.	  This	  improved	  amplification	  efficiency	  for	  the	  patient	  samples	  as	  evidenced	  by	  gel	  electrophoresis.	  The	  coordinates	  of	  the	  envAS	  amplicons	  used	  in	  this	  study	  are	  illustrated	  in	  Figure	  4.2.	  For	  amplification,	  envAS	  primers	  were	  barcoded	  to	  enable	  multiplex	  pyrosequencing	  of	  samples	  [25,	  26].	  The	  454/Roche	  microtiter	  sequencing	  plate	  can	  be	  physically	  separated	  into	  quadrants,	  which	  enabled	  recycling	  of	  barcodes	  3-­‐4	  times	  over	  the	  sample	  set	  –	  barcode-­‐primer	  combinations	  that	  performed	  best	  during	  testing	  were	  used	  more	  often.	  Complete	  primer	  and	  barcode	  sequences	  are	  cataloged	  in	  Table	  4.2.	  	  Both	  envAS	  amplicons	  were	  pyrosequenced	  in	  two	  directions	  generating	  reads	  originating	  with	  either	  the	  forward	  or	  reverse	  primers	  in	  each	  case.	  After	  filtering	  for	  quality,	  a	  total	  of	  218,756	  pyrosequence	  reads	  were	  obtained	  over	  all	  patient/time-­‐point	  and	  primer	  combinations.	  To	  remove	  sequencing	  errors,	  and	  cluster	  reads	  into	  unique	  viral	  variants	  –	  termed	  operational	  taxonomic	  units	  (OTUs)	  –	  the	  denoising	  algorithm	  Pyronoise	  was	  used	  [27]	  according	  to	  specifications	  in	  Chapter	  2.	  This	  condensed	  the	  data	  into	  127,290	  OTUs	  over	  which	  further	  analysis	  was	  carried	  out.	  OTUs	  are	  enumerated	  according	  to	  sample	  in	  Table	  4.1.	  A	  few	  samples	  were	  not	  pooled	  for	  the	  pyrosequencing	  reaction	  due	  to	  undetectable	  DNA	  following	  amplification.	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(a)	  
 
Coordinates  Sequence envAS 
primer  From To 454 Adapter HIV template specific part 
        
1F 6432 6451 GCCTCCCTCGCGCCATCAG CACATGCCTGTGTACCCACA 
1R 7017 6994 GCCTTGCCAGCCCGCTCAG TCTTCTGCTAGACTGCCATTTAAC 
2F 6993 7016 GCCTCCCTCGCGCCATCAG TGTTAAATGGCAGTCTAGCAGAAG 
2R 7639 7618 GCCTTGCCAGCCCGCTCAG CATATCTCCTCCTCCAGGTCTG 




ID Visit date Amplicon 1 Amplicon 2 
201 6/1/11 TCGACATG TCGACATG 
201 6/29/11 TCGACATG TCGACATG 
201 8/24/11 TCGACATG TCGACATG 
201 10/19/11 CAGTCAGT CGTACGAT 
201 12/14/11 TCGACATG TCGACATG 
203 8/10/11 CAGTCAGT CACTGTGA 
203 8/29/11 GCATATCG GCATATCG 
203 10/23/11 GCATATCG GCATATCG 
203 12/21/11 CAGTCAGT CACTGTGA 
203 2/15/12 GCATATCG GCATATCG 
203 4/9/12 GCATATCG GCATATCG 
204 11/6/11 ACACACTG TGAGCACT 
204 12/4/11 ACGACATC CACTGTGA 
204 2/5/12 ACACACTG TGAGCACT 
204 4/1/12 ACACACTG TGAGCACT 
204 5/23/12 ACACACTG TGAGCACT 
215 6/12/13 CATCGTAG CATCGTAG 
215 8/7/13 CATCGTAG CATCGTAG 
215 10/14/13 CATCGTAG CATCGTAG 
215 12/17/13 CATCGTAG CATCGTAG 
218 6/19/13 ATATCGCG CGTACGAT 
218 7/23/13 GCTACGTA GCTACGTA 
218 9/17/13 GCTACGTA GCTACGTA 
218 11/12/13 GCTACGTA GCTACGTA 
218 1/7/14 GCTACGTA GCTACGTA 
250 5/13/13 ACGACATC GAGTACAG 
250 6/10/13 ACGACATC GAGTACAG 
251 5/13/13 ATCGATGC CGTACGAT 
251 6/10/13 ATCGATGC CGATGCTA 
251 8/7/13 ATCGATGC CGTACGAT 
252 10/7/13 CGATATGC CTAGTGCA 
252 12/9/13 CGATATGC TGAGTCAC 
	   104	  
	  
Barcode Sample 
ID Visit date Amplicon 1 Amplicon 2 
8 2/15/06 CACTACAG CAGTCAGT 
8 3/15/06 CACTACAG AGTCGTCA 
8 4/12/06 CACTACAG CAGTCAGT 
14 10/5/05 CGTACGAT GTACACGT 
14 11/9/05 CGTACGAT GTACACGT 
14 11/30/05 CGTACGAT GTACACGT 
22 10/10/06 TAGCGCAT CAGTCAGT 
22 11/7/06 TAGCGCAT GAGTGACA 
22 12/5/06 TAGCGCAT CAGTCAGT 
35 5/29/07 GAGTGACA GAGTGACA 
35 6/26/07 GAGTGACA GAGTGACA 
35 7/31/07 GAGTGACA GAGTGACA 
41 5/31/06 TCACTGTC CTACGATG 
41 6/28/06 TCACTGTC CTACGATG 
41 7/26/06 TCACTGTC CTACGATG 
43 7/18/06 TGAGTCAC TCTGTGAG 
43 8/16/06 TGAGTCAC TCTGTGAG 
43 11/7/06 TGAGTCAC TCTGTGAG 
44 8/30/06 CACTGTGA TCTGTGAG 
44 9/26/06 CACTGTGA AGTCGTCA 
44 10/17/06 CACTGTGA AGTCGTCA 
53 2/7/07 CGATGCTA AGTCGTCA 
53 3/7/07 CGATGCTA TCACGAGT 
53 4/4/07 CGATGCTA TCACGAGT 
54 4/25/07 CTAGTGCA TCACGAGT 
54 5/23/07 CTAGTGCA TCACGAGT 
54 6/20/07 CTAGTGCA GTACACGT 
	  
Table	  4.2	  Oligonucleotide	  sequences	  used	  for	  amplification.	  
(a)	  Complete	  sequences	  for	  primers	  including	  the	  454	  adapters,	  barcodes	  and	  HIV-­‐specific	  parts	  are	  indicated.	  Primer	  coordinates	  are	  based	  on	  numbering	  for	  the	  HIV-­‐1NL4-­‐3	  genome.	  Barcodes	  are	  placed	  between	  454	  adapter	  and	  HIV	  template-­‐specific	  sequence.	  (b)	  Barcodes	  assigned	  to	  patient	  time-­‐point	  combinations	  are	  listed	  for	  each	  sample.	  	  
Framework	  to	  estimate	  A-­G	  error	  rates	  and	  deletions	  	  To	  determine	  enrichment	  for	  A-­‐G	  transitions	  and	  deletions	  within	  the	  envAS	  target	  region,	  if	  any,	  it	  was	  important	  to	  carefully	  interpret	  base	  changes	  in	  the	  OTUs.	  For	  this,	  two	  things	  were	  necessary:	  1)	  a	  reasonable	  multiple	  sequence	  alignment	  (MSA)	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wherein	  all	  OTUs	  would	  be	  lined	  up	  base-­‐by-­‐base,	  and	  2)	  an	  appropriate	  reference	  sequence	  against	  which	  to	  measure	  base	  substitutions	  and	  deletions.	  	  	  MSA	  for	  OTUs	  corresponding	  to	  each	  envAS	  primer	  was	  generated	  on	  the	  same	  principles	  as	  described	  in	  earlier	  chapters	  (also	  see	  Methods).	  One	  important	  difference	  was	  that	  to	  account	  for	  patient	  viral	  background	  heterogeneity	  in	  the	  
envAS	  region,	  individual	  MSAs	  were	  first	  constructed	  for	  each	  patient.	  Also	  for	  the	  same	  reason,	  the	  majority	  OTU	  identified	  within	  a	  given	  patient	  was	  used	  to	  guide	  creation	  of	  these	  MSAs,	  rather	  than	  any	  standard	  reference.	  Next,	  all	  MSAs	  were	  brought	  in	  the	  context	  of	  HIV-­‐1NL4-­‐3,	  which	  is	  the	  reference	  genome	  on	  which	  envAS	  is	  based.	  Subsequently,	  the	  envAS	  sequence	  was	  used	  to	  demarcate	  non-­‐target	  and	  target	  bases	  for	  each	  read	  for	  each	  patient.	  A	  consensus	  was	  generated	  for	  each	  patient	  and	  used	  as	  the	  reference	  to	  help	  interpret	  changes	  in	  HIV	  sequences	  within	  a	  given	  patient.	  This	  was	  a	  reasonable	  approach	  to	  detect	  envAS-­‐mediated	  effects,	  which	  were	  expected	  to	  be	  in	  a	  minority	  and	  thus	  potentially	  different	  from	  the	  consensus.	  	  
Preliminary	  assessment	  of	  A-­G	  enrichment	  	  As	  a	  first	  approach,	  an	  overall	  consensus	  sequence	  was	  created	  for	  each	  patient	  and	  for	  each	  envAS	  primer	  set	  from	  OTUs	  sampled	  over	  all	  time-­‐points.	  The	  consensus	  was	  created	  two	  ways	  –	  by	  considering	  the	  frequency	  of	  isolation	  (or	  “weight”)	  of	  the	  OTUs,	  or	  not.	  We	  call	  this	  the	  weighted	  or	  un-­‐weighted	  consensus	  respectively.	  Accordingly	  two	  modes	  of	  analysis	  were	  carried	  out:	  1)	  weighted,	  at	  the	  level	  of	  total	  reads,	  by	  replicating	  each	  OTU	  as	  many	  times	  as	  its	  weight,	  and	  2)	  un-­‐weighted,	  at	  the	  level	  of	  OTUs,	  treating	  each	  OTU	  equally	  as	  if	  they	  had	  the	  same	  weight.	  The	  “de-­‐replication”	  step	  condensing	  reads	  into	  unique	  viral	  variants	  corresponds	  to	  denoising	  and	  clustering	  of	  reads	  by	  Pyronoise.	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Since	  we	  expect	  envAS	  effects	  to	  be	  in	  the	  minority,	  our	  anticipation	  was	  that	  these	  would	  show	  up	  better	  in	  the	  un-­‐weighted	  analysis.	  For	  a	  given	  OTU,	  any	  base	  that	  was	  different	  from	  the	  consensus	  base	  at	  that	  position	  was	  characterized	  to	  be	  a	  base	  change.	  Proceeding	  as	  in	  chapter	  3,	  base-­‐change	  proportions	  per	  OTU	  were	  plotted	  for	  both	  VRX	  and	  control	  for	  all	  possible	  nucleotide	  substitutions.	  This	  was	  first	  done	  for	  the	  envAS-­‐target	  region.	  Unlike	  that	  following	  HIV-­‐1BaL	  challenge	  in	  
envAS-­‐treated	  mice	  [24],	  we	  did	  not	  find	  outliers	  that	  were	  more	  enriched	  for	  A-­‐G	  changes	  in	  the	  VRX	  patients	  compared	  to	  control	  patients	  (data	  not	  shown).	  G-­‐A,	  which	  arises	  due	  to	  APOBEC	  action	  on	  HIV-­‐1,	  was	  the	  highest	  overall	  as	  well	  as	  in	  terms	  of	  outliers	  in	  both	  groups	  –	  this	  recapitulates	  earlier	  findings	  [24]	  and	  validates	  the	  approach	  of	  using	  the	  consensus	  to	  estimate	  nucleotide	  changes.	  	  When	  pooled	  over	  groups,	  we	  found	  the	  proportion	  of	  OTUs	  enriched	  for	  A-­‐G	  was	  higher	  in	  control	  patients	  at	  levels	  requiring	  a	  minimum	  of	  5%	  or	  10%	  change.	  Only	  at	  a	  level	  needing	  15%	  or	  more	  A	  positions	  to	  change	  to	  G,	  relatively	  more	  OTUs	  were	  recorded	  in	  the	  VRX	  group.	  Closer	  inspection	  revealed	  that	  patient	  203	  alone	  contributed	  approximately	  95%	  of	  the	  numbers	  in	  the	  VRX	  group	  at	  this	  level.	  Thus,	  although	  there	  was	  some	  enrichment	  of	  OTUs	  with	  high	  A-­‐G	  rates	  in	  the	  VRX	  group,	  effects	  were	  not	  equally	  strong	  in	  all	  patients.	  This	  is	  in	  contrast	  to	  that	  observed	  in	  the	  mouse	  study	  for	  the	  treated	  cohort	  challenged	  with	  HIV-­‐1BaL	  [24].	  To	  improve	  sensitivity,	  we	  restricted	  analysis	  for	  base	  changes	  to	  informative	  OTUs,	  which	  harbor	  at	  least	  one	  change	  of	  the	  given	  type	  (as	  in	  chapter	  3).	  This	  did	  not	  lead	  to	  any	  further	  enrichment	  of	  OTUs	  in	  the	  VRX	  cohort	  at	  the	  different	  levels	  for	  A-­‐G	  changes	  examined.	  A	  weighted	  analysis	  also	  did	  not	  enrich	  for	  A-­‐G	  changes	  in	  VRX	  patients	  (data	  not	  shown).	  	  
Alternative	  approaches	  to	  evaluate	  A-­G	  changes	  	  We	  considered	  the	  possibility	  that	  over	  time	  immune	  responses	  or	  residual	  drug	  effects	  in	  both	  groups	  of	  patients	  could	  lead	  to	  outgrowth	  of	  mutations	  at	  some	  sites	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at	  a	  high	  rate.	  These	  could	  add	  significant	  noise	  to	  the	  data	  while	  attempting	  to	  interpret	  the	  potentially	  more	  subtle	  changes	  due	  to	  envAS,	  making	  detection	  of	  such	  minority	  signatures	  difficult.	  Indeed,	  repeated	  base	  substitutions	  were	  observed	  longitudinally	  at	  a	  few	  sites	  while	  inspecting	  the	  MSAs.	  To	  account	  for	  this,	  we	  modified	  our	  analysis.	  A	  consensus	  was	  determined	  for	  each	  time-­‐point,	  instead	  of	  a	  single	  consensus	  over	  all,	  and	  MSA	  positions	  where	  the	  majority	  base	  changed	  between	  time-­‐points	  were	  discarded.	  As	  determined	  by	  Fisher’s	  exact	  test	  (one-­‐sided),	  this	  showed	  significant	  enrichment	  of	  OTUs	  in	  VRX	  patients	  at	  A-­‐G	  change	  levels	  of	  10%	  and	  15%	  (P	  <	  10-­‐12	  and	  P	  <	  10-­‐14	  respectively)	  but	  not	  at	  5%	  (data	  not	  shown).	  Statistical	  test	  was	  based	  on	  pooling	  of	  OTUs	  over	  all	  patients	  within	  each	  group	  and	  results	  were	  similar	  whether	  we	  considered	  all	  sequences	  or	  just	  informative	  ones.	  As	  earlier,	  patient	  203	  alone	  contributed	  a	  vast	  majority	  of	  the	  OTUs	  with	  high	  rates	  of	  A-­‐G.	  As	  before,	  performing	  a	  weighted	  analysis	  did	  not	  improve	  signal	  detection	  and	  on	  the	  contrary,	  the	  enrichment	  observed	  at	  the	  10%	  level	  was	  lost.	  For	  all	  further	  analysis,	  only	  the	  un-­‐weighted	  approach	  was	  considered.	  	  The	  earlier	  time-­‐points	  sampled	  in	  VRX	  patients	  have	  the	  highest	  counts	  for	  VRX496-­‐modified	  cells	  [19]	  (also	  see	  Table	  4.2).	  Modified	  cell	  levels	  fall	  over	  time	  in	  all	  patients.	  Also,	  once	  there	  is	  viral	  breakthrough,	  the	  expectation	  is	  that	  the	  fittest	  forms	  will	  gradually	  dominate	  the	  HIV	  quasi-­‐species	  with	  time	  under	  given	  conditions.	  For	  these	  reasons,	  it	  is	  reasonable	  to	  expect	  envAS	  effects	  to	  be	  present	  and	  most	  readily	  detectable	  only	  toward	  the	  beginning	  of	  the	  post-­‐STI	  period	  at	  the	  point	  of	  recrudescence.	  We	  therefore	  repeated	  all	  analysis	  by	  considering	  only	  the	  first	  time-­‐point	  for	  all	  patients.	  To	  estimate	  changes,	  in	  addition	  to	  an	  overall	  consensus	  like	  earlier,	  we	  also	  considered	  a	  “founder”	  consensus	  built	  from	  OTUs	  detected	  in	  the	  first	  time-­‐point.	  	  	  As	  a	  consequence	  of	  custom	  filtering	  during	  the	  pyrosequence	  data	  acquisition	  step,	  error	  increases	  in	  the	  3’	  bases	  of	  reads	  (chapter	  2).	  This	  could	  confound	  estimates	  of	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true	  base	  changes,	  especially	  those	  generated	  in	  low	  frequencies.	  To	  account	  for	  this,	  we	  duplicated	  all	  analyses	  for	  the	  envAS-­‐target	  region	  as	  before	  except	  considering	  only	  the	  first	  100,	  and	  then	  the	  first	  50,	  5’	  positions	  for	  the	  MSAs	  for	  each	  primer	  set.	  This	  restricts	  analysis	  to	  increasingly	  high	  quality	  regions	  of	  the	  reads	  (Figure	  4.2;	  white	  area	  within	  amplicons).	  	  	  When	  considering	  high	  quality	  bases	  and	  constraining	  analysis	  to	  the	  first	  time-­‐point	  and	  using	  founder	  consensus	  for	  interpreting	  changes,	  we	  found	  enrichment	  of	  OTUs	  in	  the	  VRX	  group	  by	  Fisher’s	  exact	  test	  at	  all	  A-­‐G	  change	  levels	  examined	  (P	  <	  10-­‐5	  at	  15%,	  P	  <	  10-­‐67	  at	  10%,	  and	  P	  <	  10-­‐41	  at	  5%).	  This	  was	  not	  the	  case	  with	  other	  base	  changes.	  Importantly,	  we	  found	  a	  significant	  increase	  in	  numbers	  of	  OTUs	  with	  A-­‐G	  among	  the	  VRX	  patients	  as	  estimated	  by	  Mann-­‐Whitney	  test.	  (P	  =	  0.114	  at	  10%	  and	  P	  =	  0.046	  at	  5%).	  Enrichment	  of	  OTUs	  in	  VRX	  patients	  at	  the	  5%	  level	  as	  determined	  by	  Mann-­‐Whitney	  test	  for	  all	  base	  changes	  is	  given	  in	  Table	  4.3a.	  Apart	  from	  evidence	  of	  the	  A-­‐G	  effect	  in	  the	  initial	  time-­‐point,	  we	  also	  recorded	  significant	  excess	  of	  OTUs	  with	  G-­‐C	  substitutions	  for	  the	  third	  time-­‐point.	  The	  G-­‐C	  enrichment,	  however,	  did	  not	  survive	  the	  correction	  with	  non-­‐target	  region	  substitution	  rates	  as	  described	  below.	  	  	  
(a)	  
Within Antisense         
  To   To 
1 A T G C  3 A T G C 
A   0.760 0.046 0.405  A   0.523 0.697 0.703 
T 0.977  0.240 0.629  T 0.772  0.864 0.772 




C 0.519 0.593 0.407    C 0.994 0.568 0.736   
                    
 2 A T G C  All A T G C 
A   0.568 0.568 0.303  A   0.593 0.336 0.371 
T 0.568  0.967 0.612  T 0.970  0.882 0.593 
G 0.836 0.164  0.612  G 0.697 0.407  0.100 Fr
om
 
C 0.772 0.656 0.736    C 0.815 0.444 0.629   
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(b)	  
Rate Differentials         
  To   To 
1 A T G C  3 A T G C 
A   0.556 0.057 0.084  A   0.344 0.264 0.388 
T 0.271  0.729 0.336  T 0.344  0.772 0.523 




C 0.444 0.729 0.118    C 0.836 0.344 0.432   
                    
 2 A T G C  All A T G C 
A   0.736 0.432 0.344  A   0.371 0.212 0.185 
T 0.612  0.943 0.568  T 0.556  0.882 0.444 
G 0.523 0.388  0.697  G 0.303 0.697  0.444 Fr
om
 
C 0.836 0.982 0.112    C 0.729 0.556 0.185   
	  
Table	  4.3	  P	  values	  for	  enrichment	  of	  base	  changes	  in	  envAS	  target	  region	  among	  VRX	  patients.	  
(a)	  Enrichment	  in	  VRX	  patients	  of	  OTUs	  containing	  at	  least	  5%	  base	  changes	  within	  the	  envAS	  target	  region.	  (b)	  Significant	  excess	  of	  rate	  differentials	  in	  VRX	  patients.	  For	  each	  nucleotide	  substitution,	  the	  difference	  in	  rates	  between	  target	  and	  non-­‐target	  parts	  was	  determined	  per	  patient.	  In	  both	  a.	  and	  b.	  Mann-­‐Whitney	  P	  values	  are	  listed.	  Analysis	  was	  performed	  separately	  for	  time-­‐points	  1-­‐3	  and	  for	  all	  time-­‐points	  pooled.	  Time-­‐points	  are	  indicated	  in	  a	  shaded	  box	  to	  the	  upper	  left	  of	  each	  panel.	  Significant	  P	  values,	  or	  that	  closest	  to	  significance	  as	  in	  (b),	  are	  highlighted	  by	  white	  lettering.	  	  
Base	  change	  comparisons	  between	  envAS	  target	  and	  non-­target	  regions	  	  Given	  the	  above	  trend	  for	  A-­‐G	  transitions,	  we	  investigated	  if	  normalizing	  against	  changes	  in	  the	  non-­‐target	  region	  could	  reinforce	  this	  signal.	  Earlier	  work	  had	  reported	  preferential	  envAS-­‐mediated	  A-­‐G	  transitions	  in	  the	  envAS-­‐target	  as	  opposed	  to	  the	  adjoining	  non-­‐target	  region	  [17,	  24].	  For	  the	  current	  study	  we	  designed	  our	  amplicons	  to	  include	  240	  adjacent	  non-­‐target	  bases	  (with	  a	  variation	  of	  a	  few	  bases	  across	  patients)	  –	  150	  to	  the	  left	  and	  90	  to	  the	  right	  of	  the	  937	  base	  long	  envAS-­‐target	  region	  (Figure	  4.2).	  This	  made	  it	  feasible	  to	  interrogate	  whether	  comparisons	  of	  nucleotide	  substitution	  rates	  within	  patients	  between	  target	  and	  non-­‐target	  parts	  might	  bolster	  the	  A-­‐G	  signal	  in	  the	  VRX	  group.	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We	  repeated	  the	  analysis	  described	  in	  previous	  sections	  for	  the	  non-­‐target	  regions.	  Although	  A-­‐G	  rates	  varied	  across	  patients,	  there	  was	  no	  evidence	  of	  any	  difference	  between	  the	  control	  and	  VRX	  groups	  by	  Mann-­‐Whitney	  test.	  We	  proceeded	  to	  calculate	  differences	  in	  target	  and	  non-­‐target	  region	  base	  change	  rates.	  First,	  we	  identified	  appropriate	  nucleotide	  positions	  for	  this	  analysis	  such	  that	  non-­‐target	  and	  target	  bases	  would	  be	  matched	  for	  quality.	  This	  was	  relevant	  as	  the	  A-­‐G	  effect	  best	  showed	  up	  when	  restricting	  analysis	  to	  higher	  quality	  bases	  in	  the	  target	  region.	  The	  custom	  filtering	  performed	  during	  sequence	  data	  recovery	  from	  the	  454/Roche	  sequencer	  yields	  high	  quality	  bases	  for	  the	  first	  ~175-­‐200	  5’	  positions	  in	  the	  direction	  of	  sequencing	  with	  errors	  increasing	  further	  3’	  (chapter	  2).	  For	  each	  envAS	  primer	  set,	  we	  selected	  the	  first	  200	  5’	  positions	  –	  indicated	  by	  the	  white	  parts	  inside	  the	  amplicon	  boxes	  in	  Figure	  4.2.	  	  Over	  all	  4	  envAS	  primer	  sets,	  we	  thus	  considered	  800	  nucleotide	  positions.	  These	  included	  all	  240	  non-­‐target	  positions	  amplified	  and	  560	  target	  positions.	  We	  compared	  to	  the	  founder	  consensus	  to	  determine	  base	  changes.	  Base	  change	  rates	  were	  calculated	  separately	  for	  target	  and	  non-­‐target	  parts	  for	  each	  patient.	  By	  taking	  the	  difference	  in	  rates	  between	  the	  two	  parts,	  we	  estimated	  relative	  base	  changes	  in	  the	  target	  region.	  This	  was	  done	  over	  all	  possible	  base	  changes.	  	  	  Our	  hypothesis	  was	  that	  A-­‐G	  rate	  excess	  would	  be	  more	  in	  the	  VRX	  group,	  so	  we	  performed	  a	  one-­‐sided	  Mann-­‐Whitney	  test	  to	  check	  for	  higher	  A-­‐G	  rate	  differentials	  among	  VRX	  patients,	  which	  yielded	  P	  =	  0.057	  for	  the	  first	  time-­‐points	  (Table	  4.3b).	  This	  trend	  for	  A-­‐G	  was	  not	  detectable	  for	  other	  time-­‐points	  or	  when	  all	  time-­‐points	  were	  pooled.	  Notably,	  no	  other	  base	  change	  recorded	  a	  higher	  significance	  across	  any	  time-­‐points	  (Table	  4.3b).	  The	  distribution	  of	  rate	  differentials	  for	  the	  first	  time-­‐point	  for	  all	  base	  changes	  is	  shown	  in	  Figure	  4.3.	  	  We	  repeated	  our	  analysis	  by	  considering	  the	  first	  250	  5’	  positions	  for	  each	  envAS	  primer	  set.	  This	  gave	  a	  total	  of	  1000	  nucleotide	  positions	  –	  240	  of	  them	  non-­‐target	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and	  760	  target.	  Within	  the	  target	  parts,	  Fisher’s	  test	  revealed	  OTU	  enrichment	  at	  different	  levels	  of	  A-­‐G	  turnover	  for	  the	  initial	  time-­‐point	  as	  before.	  Also	  like	  previously,	  Mann-­‐Whitney	  test	  indicated	  significance	  across	  all	  patients	  at	  low	  levels	  of	  A-­‐G	  transitions	  (1-­‐2%).	  Testing	  for	  rate	  differentials	  between	  target	  and	  non-­‐target	  parts	  preserved	  the	  trend	  for	  A-­‐G	  in	  VRX	  patients	  for	  the	  initial	  time-­‐point	  (P	  =	  0.069;	  Mann-­‐Whitney	  test	  –	  data	  not	  shown).	  Again,	  this	  effect	  was	  not	  visible	  for	  any	  other	  time-­‐point.	  This	  reproduces	  observations	  recorded	  earlier	  in	  this	  section	  with	  a	  different	  selection	  for	  high	  quality	  bases.	  Thus	  we	  find	  an	  indication	  of	  possible	  envAS-­‐induced	  A-­‐G	  transitions	  in	  this	  study.	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  All	  possible	  base	  changes	  are	  shown.	  For	  A-­‐G	  changes,	  there	  is	  a	  near	  significant	  trend	  for	  higher	  rate	  differentials	  among	  VRX	  patients	  compared	  to	  controls	  (see	  the	  panel	  for	  Base	  From	  ‘A’	  and	  Base	  To	  ‘G’).	  Two	  outliers	  each	  for	  G-­‐A	  and	  C-­‐T	  panels	  have	  been	  removed	  for	  visualization	  purposes.	  	  
Distribution	  of	  deletions	  	  We	  next	  analyzed	  if	  envAS	  also	  led	  to	  higher	  numbers	  of	  target	  region	  deletions	  in	  viral	  populations	  among	  VRX	  patients.	  On	  similar	  lines	  as	  the	  A-­‐G	  analysis,	  we	  identified	  deletions	  with	  the	  help	  of	  founder	  consensus	  and	  using	  criteria	  for	  deletions	  as	  defined	  in	  the	  mouse	  study	  (Chapter	  3).	  The	  distribution	  of	  variants	  with	  deletions	  is	  shown	  in	  Figure	  4.4.	  We	  did	  detect	  enrichment	  for	  deletion-­‐bearing	  sequences	  in	  the	  VRX	  group	  (P	  <	  10-­‐6;	  Fisher’s	  exact	  test,	  one-­‐sided),	  however	  all	  VRX	  patients	  did	  not	  support	  this	  (P	  =	  0.44;	  Mann-­‐Whitney	  test,	  one-­‐sided).	  Also,	  in	  contrast	  to	  the	  A-­‐G	  effect,	  there	  was	  no	  excess	  of	  deletions	  in	  VRX	  group	  when	  only	  the	  initial	  time-­‐points	  were	  evaluated	  by	  Fisher’s	  test.	  	  Researchers	  studying	  envAS	  pressure	  in	  tissue	  culture	  reported	  high	  proportion	  of	  variants	  containing	  deletions	  in	  the	  target	  region	  while	  analyzing	  breakthrough	  virus	  [17].	  We	  considered	  the	  possibility	  that	  unlike	  A-­‐G	  effects,	  deletions	  might	  not	  be	  a	  minority	  signature.	  In	  this	  case,	  deletions	  in	  breakthrough	  variants	  could	  be	  reflected	  in	  founder	  consensus	  making	  it	  less	  useful	  in	  interpreting	  missing	  bases.	  Therefore	  all	  analysis	  was	  repeated	  using	  an	  overall	  consensus.	  This	  yielded	  significance	  over	  OTUs	  from	  all	  time-­‐points	  pooled	  as	  well	  as	  for	  the	  first	  time-­‐point	  separately	  (P	  <	  10-­‐64	  and	  P	  <	  10-­‐21	  respectively;	  Fisher’s	  test).	  Still,	  Mann-­‐Whitney	  test	  failed	  to	  support	  enrichment	  for	  deletions	  over	  all	  VRX	  patients	  in	  the	  per	  subject	  analysis.	  Performing	  a	  weighted	  analysis	  either	  with	  founder	  or	  overall	  consensus	  did	  not	  change	  findings.	  We	  thus	  conclude	  that	  evidence	  for	  deletions	  was	  not	  as	  robust	  as	  for	  A-­‐G	  transitions,	  and	  was	  likely	  anecdotal	  in	  a	  few	  VRX	  patients,	  primarily	  VRX201.	  
Figure	  4.3	  Differences	  in	  rates	  between	  envAS	  target	  and	  non-­target	  parts	  for	  each	  base	  
change	  per	  patient.	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Relative	  proportions,	  indicated	  by	  density	  along	  the	  y-­‐axis,	  are	  plotted	  for	  a	  bin	  size	  of	  10.	  Thus	  proportion	  OTUs	  in	  each	  bar	  corresponds	  to	  density*10.	  Tall	  bars	  to	  the	  left	  of	  0	  represent	  OTUs	  lacking	  deletions.	  Distributions	  shown	  are	  over	  all	  time-­‐points.	  	  
Discussion	  
	  
Figure	  4.4	  Histogram	  of	  OTUs	  binned	  by	  total	  deletion	  lengths.	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In	  previous	  work	  with	  a	  mouse	  model,	  we	  documented	  evidence	  of	  envAS	  pressure	  on	  circulating	  virus	  in	  vivo	  [24].	  Understandably,	  these	  signatures	  were	  rare	  given	  that	  envAS-­‐modified	  cells	  were	  in	  a	  minority.	  Nevertheless	  this	  highlighted	  the	  potential	  of	  envAS	  as	  an	  antiviral	  payload	  for	  gene	  therapy	  approaches.	  In	  the	  current	  study,	  we	  investigated	  patients	  receiving	  envAS-­‐modified	  cells	  for	  possible	  recapitulation	  of	  observations	  from	  the	  mouse	  model.	  We	  found	  evidence	  for	  modestly	  higher	  A-­‐G	  transitions	  in	  the	  VRX	  patients	  although	  the	  same	  was	  not	  true	  for	  deletions.	  Still,	  our	  findings	  suggest	  that	  envAS	  did	  indeed	  exert	  some	  pressure	  on	  evolving	  virus	  in	  the	  subjects	  studied.	  	  The	  A-­‐G	  effect	  in	  VRX	  patients	  was	  detectable	  only	  upon	  analysis	  of	  high	  quality	  nucleotide	  positions	  in	  the	  MSAs	  rather	  than	  all	  available	  bases	  across	  all	  reads.	  Yet,	  there	  are	  quite	  a	  few	  indicators	  that	  we	  observed	  an	  authentic	  envAS-­‐induced	  signature.	  First,	  the	  A-­‐G	  effect	  was	  only	  apparent	  for	  the	  first	  time-­‐point.	  This	  tracks	  with	  declining	  proportions	  for	  envAS-­‐modified	  cells	  in	  patients	  over	  time.	  Once	  virus	  breaks	  through,	  it	  is	  likely	  that	  any	  envAS	  effect	  would	  be	  progressively	  washed	  out	  as	  fewer	  virus	  interacts	  with	  dwindling	  numbers	  of	  modified	  cells.	  This	  would	  make	  
envAS	  signatures	  harder	  to	  detect	  at	  later	  time-­‐points.	  	  A-­‐G	  effects	  were	  most	  perceptible	  when	  interpreted	  against	  the	  founder	  consensus.	  This	  is	  consistent	  with	  the	  expectation	  that	  envAS	  pressure	  would	  be	  discernible	  at	  the	  level	  of	  breakthrough	  virus	  rather	  than	  in	  later	  forms.	  The	  founder	  consensus	  best	  represents	  the	  recrudescent	  HIV	  background	  –	  this	  is	  also	  the	  viral	  template	  that	  is	  potentially	  free	  of	  base	  changes	  due	  to	  immune	  or	  residual	  drug	  pressure	  that	  could	  confound	  A-­‐G	  measurements.	  Another	  point	  to	  note	  is	  that	  although	  effects	  were	  weak,	  our	  reporting	  of	  the	  trend	  was	  based	  on	  stringent	  criteria.	  The	  A-­‐G	  signal	  was	  replicated	  over	  the	  whole	  VRX	  group	  and	  not	  a	  consequence	  of	  one	  or	  a	  minority	  of	  patients	  exhibiting	  enhanced	  effects.	  Furthermore,	  in	  comparison	  to	  the	  mouse	  study	  where	  we	  used	  control	  animals,	  here	  we	  included	  the	  non-­‐target	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region	  in	  addition	  to	  control	  patients	  to	  assess	  the	  signal.	  Thus	  we	  can	  say	  our	  findings	  are	  robust.	  	  	  Why	  was	  the	  A-­‐G	  signal	  not	  as	  strong	  as	  previously	  observed	  in	  the	  mouse	  model?	  In	  the	  mice,	  modified	  cells	  numbered	  4-­‐10%	  of	  all	  engrafted	  T	  cells.	  In	  the	  clinical	  trial,	  effective	  levels	  of	  envAS-­‐modified	  cells	  around	  the	  time	  of	  STI	  was	  less	  than	  1%	  in	  all	  patients.	  For	  the	  initial	  time-­‐points	  sampled	  in	  this	  study,	  corresponding	  numbers	  were	  even	  lower	  with	  some	  patients	  having	  no	  more	  than	  0.05%	  [19]	  (also	  see	  Table	  4.2).	  In	  addition,	  this	  analysis	  tabulated	  envAS	  effects	  across	  unrelated	  patients	  with	  heterogeneous	  viral	  backgrounds	  –	  magnitude	  of	  envAS	  pressure	  exerted	  is	  likely	  to	  vary	  with	  template	  making	  detection	  difficult.	  This	  is	  in	  contrast	  to	  the	  mouse	  study	  where	  all	  animals	  were	  infected	  with	  clonal	  HIV-­‐1	  populations	  resulting	  in	  straightforward	  measurements	  for	  base	  changes.	  	  	  Given	  these	  limitations,	  it	  is	  actually	  surprising	  that	  we	  recorded	  signs	  of	  envAS	  action	  reproducibly	  over	  many	  VRX	  patients.	  Presumably	  with	  more	  power	  by	  way	  of	  more	  enrolled	  participants	  in	  the	  trial,	  we	  could	  have	  detected	  a	  statistically	  robust	  signal.	  As	  concerns	  deletions,	  we	  failed	  to	  record	  convincing	  evidence	  in	  support	  of	  envAS	  activity.	  Deletions	  have	  a	  higher	  fitness	  cost	  and	  were	  barely	  enriched	  in	  the	  presence	  of	  envAS	  even	  in	  the	  mouse	  model.	  Also,	  envAS	  levels	  were	  lower	  in	  the	  clinical	  trial.	  Together,	  this	  could	  explain	  why	  it	  may	  have	  been	  difficult	  to	  identify	  envAS-­‐induced	  deletions.	  Nonetheless	  findings	  reported	  here	  are	  significant	  as	  for	  the	  first	  time	  in	  humans	  we	  show	  that	  an	  anti-­‐HIV	  gene	  therapy	  strategy	  actually	  impacts	  circulating	  virus.	  With	  improved	  persistence	  of	  modified	  cells,	  it	  may	  be	  realistic	  to	  expect	  effective	  control	  of	  virus	  by	  antisense.	  	  
Materials	  and	  Methods	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Amplicon	  design	  	  HIV-­‐1NL4-­‐3,	  which	  is	  a	  standard	  subtype	  B	  strain,	  was	  used	  as	  a	  reference	  genome.	  The	  sequence	  for	  HIV-­‐1NL4-­‐3	  was	  obtained	  from	  the	  nucleotide	  database	  at	  National	  Center	  for	  Biotechnology	  Information	  (accession	  ID	  M19921	  at	  http://www.ncbi.nlm.nih.gov/nuccore/).	  A	  multiple	  sequence	  alignment	  (MSA)	  for	  454	  HIV	  subtype	  B	  env	  sequences	  was	  downloaded	  from	  the	  HIV	  database	  at	  Los	  Alamos	  National	  Labortatory	  (http://www.hiv.lanl.gov/)	  and	  positions	  with	  high	  conservation	  determined.	  To	  this	  MSA	  were	  aligned	  sequences	  for	  the	  VRX496	  env	  antisense	  (envAS)	  payload	  and	  HIV-­‐1NL4-­‐3	  reference.	  This	  helped	  mark	  coordinates	  of	  the	  envAS	  amplicons	  designed	  earlier	  [24]	  on	  the	  MSA.	  Possible	  primer	  landing	  sites	  were	  identified	  within	  a	  region	  200	  bases	  upstream	  and	  downstream	  respectively	  of	  previously	  designed	  envAS	  forward	  and	  reverse	  primers.	  Sites	  with	  preferably	  90%	  or	  more	  conservation	  over	  all	  positions	  (with	  a	  minimum	  of	  70%)	  were	  examined	  for	  their	  potential	  to	  serve	  as	  primers	  with	  the	  help	  of	  Primer3	  program	  (http://primer3.sourceforge.net/).	  
	  
Sample	  preparation	  for	  pyrosequencing	  	  Library	  preparation	  for	  pyrosequencing	  was	  along	  similar	  lines	  as	  in	  previous	  chapters.	  For	  each	  patient	  sample,	  500µl	  of	  plasma	  was	  added	  to	  500µl	  of	  phosphate	  buffered	  saline	  (PBS)	  to	  prepare	  1ml	  aliquots	  for	  ultracentrifugation	  to	  pellet	  virus,	  under	  conditions	  specified	  in	  chapter	  2.	  Next,	  900µl	  of	  supernatant	  was	  carefully	  withdrawn	  and	  pellet	  resuspended	  in	  the	  remaining	  100µl.	  PBS	  was	  added	  to	  make	  up	  volume	  to	  100µl	  if	  there	  was	  any	  shortfall.	  RNA	  was	  purified	  from	  this	  100µl	  volume	  of	  concentrated	  virus	  as	  previously.	  HIV-­‐1	  RNA	  was	  amplified	  by	  RT-­‐PCR	  using	  composite	  primers	  with	  454	  adapters	  and	  barcodes	  (Table	  4.2).	  RT-­‐PCR	  cycling	  was	  identical	  to	  that	  in	  chapter	  3	  methods,	  except	  that	  following	  the	  touchdown	  steps,	  25	  (instead	  of	  20)	  cycles	  were	  performed	  at	  the	  annealing	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temperature	  of	  53°C	  for	  a	  total	  35	  cycles	  of	  amplification.	  RT-­‐PCR	  products	  were	  diluted	  1:1	  with	  water	  for	  a	  total	  volume	  of	  75µl	  for	  each	  sample,	  from	  which	  DNA	  was	  purified	  and	  concentrated	  using	  Agencourt	  AMPure	  XP	  (Beckman	  Coulter).	  DNA	  was	  then	  quantified,	  pooled	  and	  pyrosequenced	  as	  before.	  	  	  
Pyrosequence	  data	  processing	  	  Sequencing	  was	  performed	  on	  the	  454/Roche	  Titanium	  platform	  at	  University	  of	  Pennsylvania.	  For	  pyrosequencing	  data	  acquisition,	  to	  increase	  the	  throughput	  of	  reads,	  a	  custom	  filtering	  was	  performed	  instead	  of	  the	  default	  one	  –	  as	  previously	  stated	  in	  chapter	  2.	  According	  to	  steps	  outlined	  there,	  reads	  were	  filtered	  for	  quality,	  assigned	  to	  source	  samples	  and	  denoised	  using	  Pyronoise	  to	  remove	  pyrosequencing	  errors	  [27].	  Multiple	  sequence	  alignments	  (MSAs)	  were	  generated	  from	  pair-­‐wise	  global	  alignments	  (PWAs)	  of	  Pyronoise	  solution	  OTUs	  with	  a	  reference	  (chapter	  2).	  Also	  as	  previously,	  MSA	  positions	  that	  were	  likely	  artifactual	  were	  discarded	  based	  on	  low	  read	  coverage	  (<5%).	  For	  each	  patient,	  four	  MSAs	  was	  generated,	  one	  for	  each	  envAS	  primer,	  over	  all	  time-­‐points.	  To	  improve	  alignment	  quality,	  the	  predominant	  sequence	  isolated	  from	  a	  patient	  was	  used,	  instead	  of	  a	  pre-­‐selected	  reference,	  to	  guide	  the	  PWAs	  of	  all	  denoised	  OTUs	  for	  that	  patient.	  Additionally	  for	  quality	  purposes,	  only	  the	  first	  500	  bases	  for	  reads	  were	  considered	  for	  alignment.	  	  	  
A-­G	  and	  deletion	  analysis	  	  From	  MSA,	  patient	  consensus	  over	  all	  time-­‐pts	  was	  constructed.	  Next	  a	  modified	  consensus	  (consensus-­‐Mod)	  was	  constructed	  by	  removing	  gaps	  and	  considering	  no	  more	  than	  the	  5’	  350	  bases.	  An	  MSA	  was	  generated	  with	  consensus-­‐Mod	  sequences	  for	  all	  patients	  with	  all	  envAS	  primers	  and	  pNL4-­‐3	  reference.	  The	  reference	  was	  used	  to	  delineate	  anti-­‐sense	  target	  and	  non-­‐target	  portions	  of	  consensus-­‐Mod	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sequences.	  This	  information	  was	  in	  turn	  used	  to	  divide	  the	  patient	  MSAs	  into	  target	  and	  non-­‐target	  parts.	  	  Within-­‐patient	  consensus	  and	  founder	  sequences,	  weighted	  and	  un-­‐weighted,	  were	  used	  to	  estimate	  base	  changes	  –	  the	  proportion	  of	  A	  positions	  in	  the	  consensus	  that	  were	  G	  in	  a	  given	  OTU	  was	  used	  as	  an	  estimate	  for	  A-­‐G	  transition	  rate	  for	  that	  OTU.	  For	  each	  OTU,	  all	  possible	  base	  substitution	  rates	  were	  similarly	  determined.	  Consensus	  sequences	  were	  also	  used	  to	  identify	  deletions	  in	  OTUs	  according	  to	  qualifying	  criteria	  defined	  in	  chapter	  3.	  	  	  For	  assessing	  enrichment	  of	  OTUs	  in	  VRX	  patients	  harboring	  a	  certain	  level	  or	  more	  of	  A-­‐G	  changes	  or	  deletions,	  one-­‐sided	  statistical	  tests	  were	  performed	  following	  previous	  studies	  [17,	  24]	  which	  laid	  the	  basis	  for	  a	  directional	  null	  hypothesis.	  Fisher’s	  exact	  test	  was	  used	  to	  determine	  excess	  in	  VRX	  group	  pooled	  over	  all	  patients	  whereas	  Mann-­‐Whitney	  test	  was	  used	  to	  assess	  replication	  of	  enrichment	  over	  all	  VRX	  patients	  (more	  stringent	  un-­‐pooled	  analysis).	  In	  all	  cases,	  data	  from	  control	  helped	  evaluate	  enrichment	  in	  VRX	  patients.	  All	  statistical	  programming	  and	  tests	  were	  performed	  in	  the	  R	  computing	  framework	  (http://www.r-­‐project.org/).	  	  	  For	  paired	  analysis	  of	  base	  changes	  between	  the	  non-­‐target	  and	  target	  regions,	  high	  quality	  target	  positions	  were	  selected	  to	  match	  with	  non-­‐target	  positions	  that	  were	  all	  within	  high	  quality	  parts	  of	  pyrosequence	  reads.	  For	  each	  possible	  base	  change,	  substitution	  rates	  were	  calculated	  separately	  for	  the	  target	  and	  non-­‐target	  region	  per	  patient.	  The	  difference	  of	  rates	  between	  target	  and	  non-­‐target	  parts	  was	  then	  determined.	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Chapter	  5 CONCLUSIONS	  AND	  FUTURE	  DIRECTIONS	  	  In	  this	  dissertation,	  I	  describe	  studies	  undertaken	  to	  characterize	  evolving	  virus	  under	  different	  selection	  pressures.	  Two	  lines	  of	  therapies	  were	  investigated	  –	  1)	  treatment	  with	  the	  integrase	  inhibitor	  Raltegravir,	  and	  2)	  an	  alternative	  approach	  involving	  gene	  therapy	  with	  an	  anti-­‐HIV	  antisense	  targeting	  the	  env	  gene	  of	  the	  virus,	  which	  to	  date	  is	  the	  only	  one	  of	  its	  kind	  to	  be	  used	  in	  clinical	  trials.	  In	  each	  case,	  the	  emerging	  technology	  of	  deep	  sequencing	  (454/Roche)	  was	  used	  to	  examine	  minor	  signatures	  in	  the	  HIV	  populations	  that	  are	  indicative	  of	  how	  the	  viral	  quasi-­‐species	  responded	  to	  treatment.	  	  	  The	  power	  of	  deep	  sequencing	  needs	  to	  be	  applied	  prudently	  as	  it	  comes	  with	  the	  cost	  of	  sequencing	  errors.	  This	  dissertation	  outlines	  the	  development	  and	  implementation	  of	  computational	  and	  statistical	  approaches	  that	  rigorously	  inspects	  effects	  of	  error	  –	  this	  helped	  in	  stringent	  interpretation	  of	  rare	  patterns	  among	  viral	  variants,	  allowing	  the	  deduction	  of	  important	  clinical	  conclusions.	  This	  was	  the	  case	  whether	  in	  the	  estimation	  of	  low-­‐level	  pre-­‐treatment	  resistance	  mutations	  in	  the	  Raltegravir	  study	  or	  in	  the	  identification	  of	  subtle	  effects	  of	  env	  antisense	  in	  breakthrough	  viral	  populations.	  In	  the	  remainder	  of	  this	  section,	  I	  describe	  possible	  future	  experiments	  for	  each	  of	  the	  lines	  of	  study	  presented	  in	  the	  preceding	  chapters	  discussing	  possible	  technical	  improvements	  in	  parallel.	  I	  end	  with	  some	  observations	  on	  the	  nature	  of	  HIV	  quasi-­‐species	  and	  implications	  for	  cure.	  	  
The	  Raltegravir	  resistance	  pathway	  switch	  	  The	  drug	  Raltegravir	  (RAL)	  has	  increased	  treatment	  options	  for	  HIV	  patients	  as	  it	  inhibits	  HIV	  integrase	  (IN),	  which	  is	  a	  different	  viral	  target	  than	  that	  of	  other	  anti-­‐HIV	  drugs	  which	  have	  existed	  since	  the	  mid-­‐1990s.	  However,	  resistance	  is	  a	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problem,	  as	  with	  other	  drugs.	  The	  IN	  genotype	  Q148H	  is	  more	  resistant	  to	  RAL	  than	  others	  such	  as	  N155H	  and	  Y143R;	  Q148H	  also	  confers	  increased	  cross-­‐resistance	  to	  other	  IN-­‐inhibitors	  under	  development.	  For	  these	  reasons	  emergence	  of	  Q148H	  is	  a	  major	  challenge	  to	  treatment.	  In	  Phase	  II	  trials	  with	  RAL	  [1],	  it	  was	  observed	  that	  frequently	  the	  resistance	  profile	  of	  viruses	  in	  patients	  switched	  from	  the	  N155	  pathway	  to	  the	  Q148	  one.	  On	  occasions,	  a	  switch	  into	  Q148H	  was	  also	  recorded	  starting	  from	  a	  Y143	  mutation.	  	  	  Findings	  in	  Chapter	  2	  in	  patients	  with	  an	  N155-­‐Q148	  switch	  suggest	  that	  neither	  mutation	  existed	  detectably	  prior	  to	  RAL	  treatment.	  To	  follow-­‐up,	  more	  patients	  could	  be	  studied	  together	  with	  deeper	  sequencing	  approaches,	  such	  as	  Illumina/Solexa	  sequencing,	  or	  more	  sensitive	  detection	  methods	  for	  known	  polymorphisms	  like	  allele-­‐specific	  PCR	  [2,	  3].	  It	  would	  also	  be	  important	  to	  find	  other	  viral	  signatures,	  if	  any,	  predicting	  the	  switch.	  The	  earlier	  Phase	  II	  study	  involved	  patients	  who	  started	  out	  exhibiting	  N155H	  but	  did	  not	  shift	  to	  Q148	  [1]	  –	  including	  them	  as	  controls	  for	  a	  comparison	  of	  pre-­‐treatment	  quasi-­‐species	  structure	  could	  reveal	  such	  predictor	  patterns.	  In	  experiments	  described	  in	  Chapter	  2,	  one	  patient	  did	  have	  residual	  levels	  of	  N155H	  long	  after	  turnover	  of	  the	  resistance	  profile	  to	  Q148H.	  Interestingly,	  this	  patient	  also	  showed	  delayed	  emergence	  of	  Q148H.	  One	  could	  ask	  if	  in	  this	  case	  the	  Q148H	  mutant	  was	  less	  potent	  (or	  alternatively,	  the	  N155H	  more	  fit).	  	  	  A	  complex	  collection	  of	  intermediate	  genotypes	  was	  also	  identified,	  especially	  in	  the	  patient	  with	  residual	  long-­‐term	  N155H	  (see	  Chapter	  2).	  Some	  of	  the	  transient	  IN	  mutations	  observed	  were	  not	  known	  to	  be	  associated	  with	  major	  RAL	  resistance	  pathways.	  Future	  experiments	  could	  help	  analyze	  if	  any	  of	  these	  are	  determinants	  of	  the	  switch.	  How	  deep	  did	  we	  search	  in	  the	  viral	  populations?	  Chapter	  2	  resolves	  this	  question	  statistically.	  Better	  still,	  a	  unique	  barcode	  can	  be	  assigned	  to	  each	  viral	  template	  in	  the	  starting	  sample	  that	  is	  sequenced	  [4,	  5].	  This	  is	  made	  possible	  by	  generating	  high	  numbers	  of	  unique	  barcodes	  by	  randomizing	  a	  few	  nucleotides.	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Such	  accurate	  measurements	  of	  the	  number	  of	  viral	  variants	  sampled	  would	  help	  map	  the	  boundaries	  and	  proportions	  of	  the	  components	  of	  the	  HIV	  quasi-­‐species	  precisely.	  It	  remains	  to	  be	  seen	  if	  this	  detailed	  information	  could	  be	  used	  to	  inform	  the	  future	  course	  of	  RAL,	  and	  indeed	  integrase	  inhibitor	  treatment.	  	  
Story	  of	  the	  anti-­HIV	  env	  antisense	  	  Drugs	  can	  control	  but	  can’t	  cure	  HIV.	  Of	  alternative	  strategies,	  gene	  and	  cell	  therapy	  approaches	  have	  gained	  prominence	  with	  the	  case	  of	  the	  Berlin	  patient	  providing	  an	  example	  of	  possible	  cure	  [6].	  In	  this	  regard,	  development	  of	  T	  cells	  modified	  with	  antisense	  as	  HIV-­‐resistant	  cells	  has	  also	  shown	  promise	  with	  the	  use	  of	  antisense	  targeting	  HIV	  env	  entering	  clinical	  trials.	  Although	  anti-­‐HIV	  gene	  therapy	  has	  been	  shown	  to	  be	  safe	  in	  different	  settings,	  it	  has	  been	  difficult	  to	  demonstrate	  efficacy	  in	  terms	  of	  detectable	  pressure	  exerted	  on	  the	  HIV.	  This	  is	  largely	  due	  to	  patients	  exhibiting	  modest	  levels	  and	  low	  persistence	  of	  gene-­‐modified	  cells.	  Given	  encouraging	  clinical	  trends	  with	  env	  antisense	  (envAS),	  it	  was	  important	  to	  quantify	  possible	  envAS	  effects	  on	  virus.	  	  Once	  again,	  plumbing	  the	  depths	  of	  viral	  populations	  evolving	  in	  the	  presence	  of	  
envAS	  with	  454/Roche	  pyrosequencing	  helped	  in	  identifying	  the	  genetic	  pressure	  exerted.	  The	  effects	  were	  subtle,	  as	  one	  would	  expect	  in	  the	  presence	  of	  only	  low	  proportions	  of	  envAS-­‐modified	  cells.	  Evidence	  was	  first	  gathered	  from	  a	  mouse	  model	  simulation	  of	  the	  clinical	  trial,	  the	  results	  of	  which	  are	  presented	  in	  Chapter	  3.	  As	  a	  sequel,	  Chapter	  4	  describes	  experiments	  performed	  with	  patient	  samples.	  Encouragingly	  findings	  of	  the	  mouse	  study	  were	  recapitulated	  in	  humans.	  A-­‐G	  nucleotide	  changes,	  which	  are	  the	  major	  envAS-­‐induced	  signature,	  were	  detectable	  with	  high-­‐resolution	  deep-­‐sequenced	  data	  but	  only	  after	  judicious	  handling	  of	  noise	  generated	  during	  the	  experimental	  process.	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This	  is	  the	  first	  time	  that	  in	  a	  gene	  therapy	  clinical	  setting	  we	  have	  possible	  evidence	  of	  pressure	  applied	  on	  the	  HIV	  virus.	  Why	  were	  effects	  so	  faint?	  For	  one,	  envAS-­‐modified	  cells	  do	  not	  persist	  long	  in	  patients.	  This	  is	  a	  challenge	  for	  this	  field.	  Of	  note,	  one	  study	  has	  reported	  long-­‐term	  persistence	  of	  stable	  levels	  of	  gene-­‐modified	  cells	  in	  HIV	  infected	  patients	  [7].	  Mechanisms	  underlying	  such	  durability	  can	  be	  harnessed	  to	  potentiate	  enduring	  levels	  of	  antisense	  in	  patients.	  Dosing	  schemes	  for	  modified	  cells	  could	  also	  be	  optimized	  with	  the	  goal	  of	  improving	  persistence.	  	  	  Following	  from	  conclusions	  in	  the	  mouse	  study	  (Chapter	  3),	  it	  is	  equally	  possible	  that	  visibility	  of	  envAS	  pressure	  could	  be	  a	  function	  of	  adenosine	  deaminases	  acting	  on	  RNA	  (or	  ADAR	  enzymes),	  which	  act	  on	  the	  sense-­‐antisense	  duplex	  resulting	  in	  A-­‐I	  edits	  that	  manifest	  as	  the	  A-­‐G	  changes	  [8].	  ADAR	  effects	  on	  perfectly	  matched	  double-­‐stranded	  RNA	  templates	  has	  been	  extensively	  studied	  and	  even	  quantified	  [9].	  However	  action	  of	  ADAR	  on	  mismatched	  duplexes,	  as	  would	  arise	  if	  circulating	  virus	  were	  non-­‐complementary	  to	  envAS,	  is	  less	  understood.	  One	  study	  by	  researchers	  at	  the	  Stockholm	  University,	  Sweden,	  has	  proposed	  patterns	  of	  A-­‐I	  editing	  in	  this	  context	  [10].	  Along	  these	  lines,	  to	  help	  explain	  the	  mechanism	  of	  
envAS	  effects,	  it	  could	  be	  useful	  to	  study	  ADAR	  in	  vitro	  with	  templates	  with	  different	  degrees	  and	  quality	  of	  mismatch,	  and	  possibly	  alter	  envAS	  to	  maximize	  ADAR	  recruitment.	  	  The	  other	  concern	  is	  effectiveness	  of	  envAS	  itself	  on	  heterogeneous	  viral	  templates.	  HIV	  infection	  in	  the	  US	  is	  dominated	  by	  subtype	  B.	  In	  this	  context,	  envAS	  design	  was	  based	  on	  HIVNL4-­‐3,	  which	  is	  a	  prototype	  HIV-­‐1	  subtype	  B	  strain.	  When	  used	  therapeutically,	  as	  in	  the	  already	  HIV	  infected	  patients	  enrolled	  in	  the	  clinical	  trial,	  
envAS	  has	  to	  act	  against	  differing	  circulating	  viral	  backgrounds	  across	  patients.	  Even	  if	  all	  patients	  had	  subtype	  B	  infection,	  one	  would	  expect	  considerable	  variation	  between	  patient	  viral	  populations.	  This	  is	  true	  especially	  of	  the	  envAS	  target	  region,	  which	  is	  not	  only	  part	  of	  env	  –	  the	  most	  diverse	  HIV	  gene	  –	  but	  also	  encompasses	  3	  of	  the	  7	  hyper-­‐variable	  loops	  of	  env.	  Thus,	  it	  is	  likely	  that	  envAS	  effects	  were	  further	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diluted	  by	  the	  target	  template	  diversity.	  It	  would	  be	  interesting	  to	  examine	  if	  effects	  were	  more	  pronounced	  in	  patients	  who	  had	  baseline	  consensus	  virus	  sequence	  that	  was	  more	  complementary	  to	  envAS.	  Along	  these	  lines,	  future	  experiments	  could	  evaluate	  antisense	  directed	  against	  regions	  of	  the	  HIV	  genome	  that	  are	  more	  conserved	  across	  subtypes.	  	  
Back	  to	  the	  quasi-­species	  	  In	  the	  studies	  presented	  in	  this	  dissertation,	  viral	  populations	  were	  analyzed	  over	  the	  course	  of	  applied	  therapeutic	  pressure.	  In	  such	  situations,	  evolving	  viral	  swarms	  are	  often	  in	  a	  state	  of	  flux,	  trying	  to	  equilibrate	  with	  sudden	  modifications	  in	  selection	  forces	  in	  a	  way	  that	  best	  ensures	  survival	  of	  the	  population.	  During	  the	  process	  of	  such	  adjustment,	  however,	  HIV	  populations	  are	  in	  a	  state	  of	  instability	  –	  it	  does	  not	  conform	  to	  definitions	  of	  a	  quasi-­‐species,	  which	  alters	  the	  quantitative	  models	  one	  might	  apply	  to	  HIV	  populations.	  	  	  Thus,	  for	  example,	  until	  such	  point	  when	  resistance	  profiles	  to	  ensuing	  drug	  treatment	  have	  stabilized,	  researchers	  have	  fewer	  clues	  as	  to	  the	  effectiveness	  and	  future	  course	  of	  therapy.	  Nevertheless	  studies	  in	  this	  dissertation	  provide	  instances	  of	  minority	  signatures	  that	  are	  consistent	  over	  viral	  populations	  from	  different	  individuals	  sharing	  a	  common	  treatment	  or	  exhibiting	  similar	  outcomes	  to	  therapy.	  In	  the	  study	  investigating	  switch	  in	  RAL	  resistance	  profiles,	  all	  patients	  harbored	  low-­‐level	  Y143H	  at	  the	  pre-­‐treatment	  baseline.	  Similarly,	  all	  patients	  undergoing	  antisense	  therapy	  supported	  evidence	  for	  envAS	  effects	  at	  a	  point	  close	  to	  viral	  breakthrough	  when	  antisense	  levels	  were	  possibly	  the	  highest.	  Baseline	  or	  breakthrough	  viruses	  are	  possibly	  stable	  populations	  that	  are	  yet	  to	  react	  to	  ensuing	  therapy	  pressure.	  These	  may	  still	  exhibit	  virtues	  of	  a	  quasi-­‐species	  and	  thus	  patterns	  present	  in	  them	  could	  be	  stable	  indicators	  of	  future	  response	  such	  as	  treatment	  failure,	  as	  in	  the	  RAL	  study,	  or	  possible	  efficacy,	  as	  in	  the	  envAS	  trial.	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  The	  development	  of	  high	  fidelity	  and	  highly	  processive	  polymerases	  can	  help	  minimize	  effects	  of	  PCR-­‐related	  template	  recombination	  and	  base	  mis-­‐incorporations	  that	  often	  confound	  deep	  sequencing	  studies	  [11].	  Use	  of	  primer	  ID	  approaches,	  wherein	  genomes	  in	  the	  pre-­‐PCR	  starting	  sample	  are	  tagged	  with	  unique	  barcodes,	  permit	  derivation	  of	  consensus	  sequences	  for	  re-­‐sampled	  genomes	  that	  also	  eliminate	  PCR	  errors	  [4,	  5].	  In	  parallel,	  recent	  developments	  in	  de-­‐noising	  algorithms	  are	  promising	  a	  more	  effective	  accounting	  of	  error	  from	  various	  sources	  such	  as	  PCR	  and	  sequencing	  [12].	  With	  these	  improvements	  in	  both	  laboratory	  and	  computational	  techniques,	  we	  can	  hope	  to	  glean	  even	  finer	  details	  on	  signatures	  inherent	  of	  the	  HIV	  quasi-­‐species.	  An	  important	  goal	  is	  to	  establish	  predictors	  for	  HIV	  response	  that	  would	  suggest	  bottlenecking	  of	  HIV	  distributions	  as	  it	  adapts	  its	  quasi-­‐species	  to	  therapy	  –	  bottlenecking	  to	  a	  narrow	  region	  in	  sequence	  space	  where	  it	  is	  easily	  contained.	  I	  hope	  studies	  and	  methods	  outlined	  in	  this	  dissertation	  would	  help	  in	  this	  research.	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